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1.1 The Origin of the Tumor 
 
A tumor (from the Latin tumor, “swelling”), also defined as neoplasia (from the 
Greek néos, “new”, and plàsis, “formation”), is an abnormal mass of tissue 
growing upon a pathological proliferation of the cells in a part of the body. The 
main feature of these cells is the uncontrolled and uncoordinated growth with 
respect to the healthy ones and this behavior is due to the fact that they do not 
respond to the mechanisms of cellular control and, in turn, this is due to 
alterations of their genetic heritage. 
Although tumors are characterized by a common origin mechanism, they can 
undergo different evolution and symptoms pathways while sharing a steady and 
progressive cancerous cells increase, owing to a more rapid cellular 
reproduction. Therefore, a continuous multiplication of the majority of tumor 
cells is observed and only few cells do not survive and die. 
A neoplasia usually grows and develops obeying a geometric law: in the early 
stages, the growth is slow and then it accelerates when the tumor mass increases. 
In addition, when the tumor reaches a critical size (about 1 cm
3
), it grows more 
and more rapidly and the symptoms can be felt (Figure 1.1). 
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Figure 1.1: Scheme of the growth phases of a tumor process. 
The picture is a modification of that reported in literature [1] 
 
The term cancer (from the Latin cancer, “crab”) was introduced by observing 
neoplastic cells behavior. In fact, in the multiplication phase, they form 
ramifications that entrap and destroy the surrounding healthy cells; 
metaphorically, in the same way, a crab destroys its prey with its claws. 
The genes responsible for cellular control are located inside each cell and they 
have to prevent diseased cells to survive; the beginning of a tumoral process is 
the result of a failure of these genes. Therefore, since the mechanism responsible 
for the replication does not work anymore, the cells behave abnormally and 
multiply themselves forming daughter cells characterized by the same problems. 
Into the cells a series of changes happens, in particular as regards the genes. The 
neoplasia can have a benign or malignant biological behavior, depending on the 
features of the neoplastic cells. A benign tumor has a structure in which the cells 
mostly preserve the morphological and functional original tissue features, it has 
a growth speed usually slow and this is an expansive but not infiltrative growth. 
The tumor, indeed, is localized and enclosed in a wrapping of connective fibrous 
tissue, which allows it to distinguish itself from the other tissues, and, although 
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expanding, it does not invade the surrounding tissues but it only compresses 
them. On the contrary, a malignant tumor, commonly defined cancer, consists of 
cells which are morphologically and functionally different from the original 
tissue and this kind of neoplasia rapidly grows, also by infiltrating into the 
surrounding tissues, thus destroying them. The infiltration of these cancerous 
cells does not stop and continues its way into the human body through blood and 
lymphatic systems, giving rise to the metastasis (or secondary tumors). 
Moreover, the cancer has a high risk of reformation after surgery, unlike a 
benign tumor. 
Finally, some anomalies characterize the neoplastic cells: 
 an excess of sodium; 
 a lack of potassium; 
 an excess of water. 
In particular, water is about 90%, unlike 66% of the healthy cells: this excess is 
due, in turn, to the high sodium content in the blood, indeed sodium, being 
aggressive, attracts protective liquid around itself. 
 
The medical nomenclature of tumors provides their classification on the basis of 
the tissue where they start growing and of their biological behavior (i.e. benign 
or malignant) (Table 1.1). 
 
Tissue of origin Benign tumor Malignant tumor 
Connective tissue, 
Cartilage, Bone, 
Muscle 
Fibroma, Chondroma, 
Osteoma, Leiomyoma, 
Rhabdomyoma 
Sarcoma 
Leukocytes  Leukemia 
Glandular epithelial 
and coating 
Adenoma, Papilloma Carcinoma 
Nervous tissue  Blastoma 
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Melanocytes Melanocytic nevus Melanoma 
Lymphatic glands  Lymphoma 
Table 1.1: Classification and medical nomenclature of tumors 
Moreover, there are several methods employed to classify a neoplasia according 
to its stage. In particular, some methods consider the tumor size (T), the degree 
of regional spread or node involvement (N), or distant metastasis (M): this is the 
TNM staging method [2]. The T and N stages range from 0 to 4, e.g. T 0 means 
no cancer evidence, N 0 no nodal involvement, and T and N increase with the 
tumor size and the degree of lymph nodes involvement increasing, respectively. 
As regards metastasis, M 0 and M 1 are used and indicate no evidence or 
evidence of metastasis. 
The neoplasia formation is divided into different phases, such as hyperplasia and 
dysplasia. 
The hyperplasia is characterized by an increase of the tissue volume due to an 
abnormal multiplication of the cells that compose it: this is the expression of the 
adaptive response of a tissue to those stimuli that lead to an increase of its 
functional activity. 
An anomaly of the development of a tissue or a system is observed in the 
dysplasia and this behavior is often accompanied by deviations of the function 
and deformity. Therefore, the anomalous proliferative process involves a 
volume increase and an alteration of the affected area architecture. Thus, these 
diseases can be distinguished because the former leads to the increase of the 
cells number, while the latter to variations of their shape and organization. 
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1.2 Antitumor Therapies 
 
The immune system of the patient is not able to distinguish cancerous cells from 
healthy ones or the reaction against them is not enough. Antibiotics and antiviral 
drugs administered have no effect on tumor cells because from a structural point 
of view, they are still substantially human cells; neoplastic drugs must be highly 
selective and able to recognize a cancerous tissue respect to healthy ones. 
Therefore, a tumor needs to be cured by means of one of the following 
treatments: 
 radiotherapy; 
 surgical excision; 
 chemotherapy; 
 hormone therapies. 
The rapid reproduction of tumor cells makes them more vulnerable to radiations 
than the healthy ones and this aspect can be exploited for the treatment of some 
kinds of tumor with gamma rays (radiotherapy) to physically destroy the 
majority of malignant cells. 
By means of early diagnosis, some types of still embryonic tumors can be 
identified and therefore, in these cases, it may be necessary only surgical 
excision or the irradiation with high energy sources. 
In the case of advanced stage diseases and, in particular, when malignant cells 
have already spread in the body, giving rise to metastasis, chemotherapy is 
exploited. This treatment is based on specific chemical compounds 
(antiproliferative or antineoplastic chemotherapeutics). The antineoplastic (or 
antiblastic) drugs are substances able to stop or to slow down tumoral processes. 
Although physical therapy and surgery are the best tumor treatments, 
antineoplastic drugs, especially in particular cases, allow to obtain remarkable 
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results, even though not definitive. Among them, antimitotic and antimetabolites 
must be considered. 
Since its first administration, in half a century, the antitumor chemotherapy saw 
the study of thousands chemical compounds. However, only few reached the 
stage of trials in animals (in vivo) and a lower number showed to be tolerable 
and effective in order to allow clinical trials in patients. A small part of the 
drugs tested in patients demonstrated to be useful in cancer therapy. 
Moreover, usually, radiotherapy and chemotherapy were employed after a 
surgical excision as a preventive measure, in order to reduce the risk of a 
relapse. 
Another possible cure can be obtained by means of hormone therapies. It is 
known that the occurrence of some kinds of neoplasia (such as breast and 
prostate tumors) is stimulated by hormones (such as estrogen and androgen). 
Therefore, hormone therapy aims to limit/avoid hormone production or their 
proliferative actions on cancer. 
The requirements of an effective antitumoral treatment are numerous and some 
of them are mentioned below. In particular, the drug must be selectively sent to 
the tumor tissue and a reasonable amount of it must remain into the cells for a 
defined time, without degrading. The tumor itself must be sensitive to the drug 
treatment and the patient must tolerate the drug side effects. The employed 
strategy of administration should be specific for each case, being 
monochemotherapy, which includes the use of a single drug, or combination 
chemotherapy (or polychemotherapy), when a combination of more 
antineoplastics is exploited. It is known that a combination of antitumor drugs is 
more effective than the use of single ones because these latter, with rare 
exceptions, are not able to completely eradicate cancer. The clinical superiority 
of combination chemotherapy can be ascribed to several causes: 
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 a single drug leads to the maximum cellular destruction within the 
tolerated dose; 
 the efficacy against resistant cells is larger; 
 the development of resistant clones, from cells which initially were 
sensitive to the therapy, can be prevented or slowed down. 
Over the years, some useful principles have been identified in order to guide the 
choice of drugs to be combined for the development of new therapeutic 
combinations, even though the drugs are still combined on mainly empirical 
basis. In general, however, only singularly active drugs, which do not show 
overlapping toxicities, must be chosen. 
In today therapy, the dose is administered for a period ranging from one to five 
days per cycle and the interval between two cycles of chemotherapy is 
established according to the recovery time from the toxicity of normal tissues or 
organs, sensitive to the drug. These considerations have induced to define a two-
weeks free period between two cycles of treatment: the new cycle begins in the 
21
st
 day, if the drugs are administered on the 1
st
 and the 8
th
 days, and on the 29
th
 
day, if the administration is on the 1
st
 and the 14
th
 days. In some rapidly growing 
tumors (such as lymphomas and leukemias), however, this therapeutic scheme is 
not appropriate because the tumor can grow again during the period without 
treatment and different schedules of drugs administration must be used. 
Actually, in the clinical practice is often necessary to change the drugs dose in 
order to adapt the treatment to the tolerability of the individual patient. In doing 
so, it should be considered that a decrease of the dose intensity can result in a 
significant decrease of the treatment efficacy. For this purpose, it can be useful 
to use hematopoietic growth factors in order to maintain the dose intensity and, 
anyway, to make any modifications of dose in a standardized way, according to 
the commonly accepted guidelines, in order to avoid alterations of the 
chemotherapy regimen. 
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Another modality of therapy involves the use of combinations with variable 
drug composition, which is defined alternating or sequential polychemotherapy. 
Among the side effects that may occur, fever, nausea and vomit can be kept 
under control by means of the most modern drugs, but the most widespread 
adverse effect is myelosuppression. This medical condition occurs when the 
bone marrow produces blood components in smaller quantities: this is defined 
anemia when concerns the red blood cells, leukopenia as regards the white blood 
cells, and thrombocytopenia in the case of platelets. The effects that may occur 
are characteristic of the individual patient but, if the chemotherapy is 
accompanied by hyperthermia, the side effects can be made less pronounced and 
the positive ones for the tumor treatment are enhanced. 
 
1.3 New Generation Therapies 
 
Other therapeutic methods allow to reduce the neoplastic mass and some of 
them are mentioned below. In the radiotherapy field, a new methodology 
defined Boron Neutron Capture Therapy (BNCT) is gradually earning 
importance (Figure 1.2). This particular technique involves the penetration of a 
thermal neutrons beam in the brain tissue thus reaching the tumor mass: the low 
energy neutrons (about 0.025 eV), therefore, react with 
10
B (previously 
introduced into the neoplastic cells by means of drugs), giving origin to 
11
B, able 
to emit alpha radiations that destroy the tumor. 
 
  
       
       
         
     
     
 
Similarly to boron, in the organism there are many other elements able to 
capture neutrons, with consequent radiations emission. Their impact section (i.e. 
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the probability of capturing neutrons), however, is several orders of magnitude 
lower than the boron one (Table 1.2). 
 
Element 
Impact section 
(expressed in Barn) 
boron 3838.00 
oxygen 0.0002 
carbon 0.0037 
magnesium 0.069 
phosphorus 0.19 
hydrogen 0.332 
calcium 0.44 
sulfur 0.52 
sodium 0.536 
nitrogen 1.75 
potassium 2.07 
iron 2.62 
chlorine 33.8 
Table 1.2: Neutron capture impact section of the main elements in the organism 
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Figure 1.2: Application and advantages of Boron Neutron Capture Therapy. 
The picture is a modification of that reported in literature [3] 
 
This method is appropriate for surface tumors: indeed, the penetration of the 
thermal neutrons is limited and, therefore, this technique is ideal for cutaneous 
neoplasias, such as melanomas. Neoplastic cells, then, must be enriched with 
boron and this can be carried out by using boron compounds, bound to 
antibodies, or by using boronic acid, injected near the melanoma itself. 
Other developed techniques are Immunoscintigraphy (ISG) and 
Radioimmunotherapy (RIT), which are able to early identify neoplastic cells and 
to block the tumor, by means of a targeted action, avoiding the damage to the 
surrounding tissues. The tumoral tissues are characterized by the alteration of 
some biochemical processes, among which an increase of both cellular 
metabolism and nucleic acids synthesis must be recalled. Furthermore, the 
cancerous cells have antigens that are not expressed by normal tissues or are 
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present only in smaller amount. In this regard, the use of radiolabelled 
antibodies, specific for each antigen, allows the identification of diseased tissues 
by means of external detection; this is the purpose of Immunoscintigraphy. This 
treatment enables the detection of different types of tumor, among which 
melanoma, gastrointestinal, brain, breast, ovarian and lung tumors. 
The principle on which the previously discussed method is based can also be 
extended to Radioimmunotherapy. It directs its action towards specific targets 
(cancerous cells) by identifying them and by stopping their progress. With this 
purpose, it employs radiolabelled antibodies and specific peptides and, thanks to 
the radiations produced in situ, it makes possible the damage to the DNA of 
neoplastic cells. 
Another form of non-surgical treatment is Photodynamic Therapy (PDT), the 
principle of which is a photodynamic reaction able to selectively destroy 
tumoral cells. A photodynamic reaction involves the absortion of laser light by a 
photosensitive substance, based on metal-porphyrin groups, administered to the 
patient, and the subsequent localized formation of singlet oxygen 
1
O2, i.e. 
oxygen in its reactive form (which is one of the so-called ROS, Reactive 
Oxygen Species). The species thus formed are toxic for the cell that generated 
them and cause its death; therefore, according to the purpose of this method, 
these tissues are destroyed. Among the requirements for the choice of a 
photosensitizer, it is important that it must be a molecule which does not show 
any toxic effects in humans, with limited size in order to allow its penetration 
through the skin, and able to distinguish and, therefore, to select diseased cells 
from healthy ones. 
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1.4 Cell Proliferation 
 
The reproduction of human cells occurs by means of the duplication of their 
DNA, which is followed by the division of the parental cell into two daughter 
cells. In physiological conditions, the equilibrium of the cells number of the 
tissues is guaranteed by another equilibrium, the harmonic one among cell 
proliferation, senescence and cell death. The cell constantly receives signals of 
proliferation or death from the microenvironment, elaborates them by means of 
mechanisms of signals transduction, and, ultimately, transmits them to the 
nucleus, where the last phase of the cell cycle regulation occurs. In order to 
ensure the identity of the genetic heritage transmitted to the daughter cells, every 
individual cell includes appropriate mechanisms of DNA repair that, in the case 
of the occurrence of spontaneous mutations or induced by mutagens, provides 
for the correction. After the completion of a predefined number of mitotic 
cycles, the cells, except those stem, enter a phase of irreversible senescence. 
In contrast to normal cells homeostasis, which is regulated by a complex net of 
molecular pathways that supervise a rigid control of cell cycle, DNA repair and 
cell death, the neoplasias are characterized by specific genetic lesions which 
cause a genomic instability and alter the control of cell cycle and apoptosis. 
 
1.5 Cell Cycle 
 
The administration of cytotoxic drugs has the main purpose of preventing cell 
division and, in particular, the substances can act in a targeted way on a phase or 
indiscriminately on several cycle phases. 
The cell cycle is an event of great importance and possible mistakes could 
compromise the life of the cells themselves: for this reason, it is regulated in all 
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its phases. In particular, the cycle consists of five distinct phases [4] (Figure 1.3 
and Table 1.3): 
 
Figure 1.3: Cell division cycle of a eukaryotic cell [5] 
 
G0 phase 
resting state, in which cells have stopped dividing (temporarily or 
irreversibly) 
(not shown in Figure 1.3) 
G1 phase 
state that follows mitosis and in which it is possible to assist to the 
synthesis of proteins and RNA, necessary to duplicate 
chromosomes 
S phase chromosomes duplication occurs and, therefore, DNA synthesis 
G2 phase 
state that precedes cell division and in which proteins are 
synthesized again 
M phase 
divided into mitosis and cytodieresis (or cytokinesis), in which it is 
possible to assist to the division of chromosomes and cytoplasm of 
the cell 
Table 1.3: Main phases of the cell cycle and their biological function 
 
The points where the process control occurs in order to avoid mistakes during 
the cycle, defined as “checkpoints”, are located in correspondence with G1-S 
and G2-M transitions. 
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The genetic information must be correctly transmitted from mother to daughter 
cells (the latter are genetically identical to the progenitor cell) and, for this 
reason, at first the genome must be duplicated during the S phase and then 
chromosomes must be confined into the two daughter cells during the M phase. 
This latter phase is divided into two processes, closely related: mitosis and 
cytodieresis (or cytokinesis). During the first phase, cell chromosomes are 
divided between the two daughter cells, while in the second one it is possible to 
assist to the physical division of the cell cytoplasm. 
At the end of M phase and at the beginning of G1 phase, cells can leave the cell 
cycle and enter a quiescence phase (G0 phase), in which they can remain for an 
indefinite time, following a path that leads to the terminal differentiation, or for 
a limited period of time, returning to be a part of the cycle. At this point a strict 
genetic control exists and tumoral cells, which are less differentiated than 
healthy ones, can be induced to terminal differentiation, thus reducing the 
malignancy of the tumor. 
 
1.6 Cell Death 
 
The cytotoxicity of a molecule can be defined as the ability to kill a cell. A cell 
that starts to die modifies its structure. Below, two different types of cell death 
are described: apoptosis and necrosis (Figure 1.4). 
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Figure 1.4: Schematic representation of apoptosis and necrosis mechanisms  
 
The necrosis is an accidental cell death, which involves at the same time more or 
less large groups of cells that are part of an organ or a tissue. This pathological 
phenomenon occurs when a cell undergoes violent chemical or physical attacks 
or violent variations of the physiological conditions, due, for example, to 
hypothermia or hypoxia, which result in a irreversible damage to the cell 
membrane. 
The necrosis may occur due to considerable osmotic variations, to the stopping 
of oxygen or nutrients supply, or to the proteins denaturation. 
The necrosis is a passive process (ATP-independent) and it begins when a loss 
of the homeostatic abilities occurs. We can assist to an unregulated influx of 
water and extracellular ions, to an increase of the cellular and mitochondrial size 
until reaching the rupture (Figure 1.5). This necrotic cells explosion is followed 
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by the overflow of their content on the nearby cells and by an inflammatory 
response (phlogosis), loading to the area occupied by the debris of dead cells. 
Then this is followed by the chemotactic recall of leukocytes and this has a 
double function: the debris phagocytosis and the release of lysosomal enzymes, 
which act on the dead cells favoring their dissolution. 
 
 
Figure 1.5: Main steps which lead a healthy cell to necrosis [6] 
 
The apoptosis is an active process (ATP-dependent), which affects isolated cells 
in viable tissues, during which the cell begins a specific program which 
determines the death (it is defined, in fact, as a suicide of the cell itself). 
The term apoptosis derives from the Greek and is employed to describe the fall 
of the flowers petals or the leaves. This etymology, however, is related to the 
characteristics of the cell death process: apoptotic cells condense and detach 
from the tissue support structures on which they are growing, as well as the tree 
leaves which fall in autumn. 
It can manifest in a spontaneous way or by induction and the resulting events 
may be a cellular contraction, a change in the distribution of membrane 
phospholipids (in fact, phosphatidylserine (PS) moves from the cytoplasmic to 
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the extracellular area of the plasma membrane), and the chromatin condensation 
(due to its organization collapse), during which bubbles are formed 
(phenomenon defined Blebbing) that, separating from the cell itself, give rise to 
apoptotic bodies (which contain cytoplasm and organelles) that are subsequently 
phagocyted (Figure 1.6). 
The process begins when an alteration of the mitochondrial membrane 
permeability occurs and this is followed by the release of cytochrome c into the 
cytosol, which caused the activation of enzymatic substances (the Caspases) 
giving rise to the cutting of cytoplasmic and nuclear substrates. The DNA 
fragmentation is not random, unlike what occurs in necrosis. 
As regards the apoptotic bodies phagocytosis, it occurs very rapidly and 
efficiently so that avoids any inflammatory response because it prevents the 
release of their content outside. 
 
 
Figure 1.6: Main step which lead a healthy cell to apoptosis [7] 
 
It is a fundamental phenomenon in physiological processes because it removes 
not functional or structurally not useful cells. The apoptosis, in fact, has a 
complementary and reverse function respect to that of mitosis and cell 
proliferation in the regulation of cell populations. 
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In the embryonic phase, it proceeds to the removal of the interdigital 
membranes, to the formation of the lumen of hollow organs, to the numeric 
scaling of nerve cells and to the opening of the eyelids during the development 
of nervous and immune systems. 
In adult it is responsible for the atrophy observed in some tissues and for the 
endometrial cells destruction during the menstrual cycle, for the atresia of the 
ovarian follicles during the menopause and for the breast regression after the 
weaning. 
The apoptosis, therefore, is involved in many physiological cellular processes, 
not only in the pathological ones, unlike necrosis, which has mainly a 
pathological nature. 
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2.1 The Chemistry of Platinum Complexes 
 
Platinum was discovered in 1748 by the Spaniard Antonio de Ulloa in the gold 
mines of Colombia and the name with which it is currently known was 
disparangingly attributed to it: in fact, “platinum” is the short for “plata”, i.e. 
small silver. The explanation for this name is that, although it looked like silver, 
it had not its properties. 
It is a not very abundant metal on the Earth crust (0.015 ppm) and it can be 
found in its native state or associated with sulfur compounds of copper and 
nickel. 
Although it is noble (resistant to chemical attack), platinum can be dissolved in 
aqua regia (a mixture of nitric and hydrochloric concentrated acids in a 
volumetric ratio 1:3) and at elevated temperature it can also react with F2 to 
obtain PtF4 or PtF6, according to the reaction conditions, and with Cl2 in order to 
obtain PtCl2 or PtCl4, according to the temperature at which the process is 
carried out. 
It may form compounds in the oxidation states 0, II, IV, V and VI, and the last 
two, in particular, with oxygen and fluorine derivatives. 
The most important oxidation states in aqueous solution and, therefore, in the 
biological environments are II and IV: in the +2 oxidation state the complexes 
show a square-planar geometry (that corresponds to a coordination number of 
4), whereas in the +4 oxidation state the geometry is octahedral (the 
coordination number is 6) and this is the most stable. 
Since the platinum in the +2 oxidation state, according to the Hard Soft Acid 
Base (HSAB) classification of Pearson, is a “soft” acid, the most stable 
complexes will be realized in the presence of “soft” bases, such as S, Se, P and 
As-donor ligands and also the complexes with N-donor ligands are very 
significant. 
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The most important anionic compound of platinum(II) for the preparative 
chemistry is [PtCl4]
2-
, which is synthesized by reduction of [PtCl6]
2-
 with 
hydrazine, and, in turn, [PtCl6]
2-
 is prepared by means of the reaction of the 
metal with aqua regia. 
Among the cationic complexes, [Pt(H2O)4]
4+
 is relevant and it can be easily 
obtained by treating [PtCl4]
2-
 with a solution of AgNO3. 
Moreover, there are numerous neutral complexes with a stoichiometry 
[PtXYLL’], where X and Y are anions such as halides, hydrides and alkyls, 
whereas L and L’ are neutral ligands such as NH3, amines, nitrogen heterocycles 
and phosphines. 
In the IV oxidation state, the compounds can be prepared by means of 
substitution reaction of the halide ion in the most significant anionic complex 
[PtCl6]
2-
, by oxidative reactions of the corresponding Pt(II) compounds (by 
using oxidants such as hydrogen peroxide, N-chlorosuccinimide [1], N-
bromosuccinimide [2], iodobenzene dichloride [3, 4], etc.), by substitution of 
hydroxyl groups in axial position in neutral complexes of general formula 
[PtA2L(OH)X2] (A = amine, L = -OH, -OR, halide, -COOH, and X = -COOR, 
halide). 
 
2.2 History of Cisplatin 
 
The merit of having synthesized and, therefore, discovered one of the main 
drugs employed in antitumoral therapy, the complex cis-
diamminedichloroplatinum(II) (cisplatin), is assigned to Michele Peyrone; for 
this reason, cisplatin was originally defined “Peyrone’s chloride” (1845). After 
nearly half a century, it was possible to distinguish the compound into two 
subgroups, defined isomers. The isomers are species with the same chemical 
formula but different arrangements of the atoms in the space or different ways in 
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which the atoms are bound to each other. The isomers can be classified in many 
types and, in this regard, it is possible to introduce the cis-trans geometric 
isomerism concept, according to which the two species are defined geometric 
isomers. Alfred Werner, a theoretical of coordination chemistry, attributed the 
prefix cis to the Peyrone’s chloride to indicate the presence of two identical 
ligands on the same side of the complex. In doing this, he distinguished this 
geometric isomer from the other one (trans, Figure 2.1). 
 
Figure 2.1: Geometric isomers of the diamminedichloroplatinum(II). 
a) Cisplatin and b) Transplatin  
 
The structure of cisplatin, however, was determined by means of X-ray 
diffraction in 1966. 
In the 60s, Barnett Rosenberg, physics professor at the Biophysics Laboratory of 
the Michigan State University, by observing the similarity between the force 
lines of the electric fields and the mitotic spindles (i.e. microtubules chains that 
go from the centrioles, which are located at the poles, till the chromosomes 
located at the equator of a cell, during the mitosis), dealt with the influence of 
the electric fields on the cell growth in Escherichia coli bacteria. 
In his experiment, current was made to pass into the growth medium of the 
bacterial population (a solution also containing ammonium chloride as 
electrolyte) by means of a pair of metal electrodes (in particular, platinum, 
characterized by a high chemical inertness in normal conditions). 
One or two hours after the application of the electric field, the bacterial cells 
interrupted their normal division process, even if they continued their growth 
until they formed long filaments. After the removal of the previously applied 
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electric field, the elongation of filaments continued for about two hours, at the 
end of which the cells division began again. Therefore, Rosenberg observed that 
bacteria were not able to reproduce themselves because the division (and, 
therefore, the replication of their DNA) was impossible, but they were subject to 
a growth leading to a length of more than three orders of magnitude higher than 
in normal conditions. 
Rosenberg, therefore, focused on the possible cause of the process and, in doing 
this, he realized that it was not due to the presence of the electric field but to 
new chemical compounds generated in solution. 
Afterwards, the responsible species for this process was identified and attributed 
to a platinum complex: cis-diamminedichloroplatinum(II). 
Since the cancer is a pathology derived from the uncontrolled division process, 
that discovery allowed Rosenberg to think that the effect of the platinum 
compounds, observed on Escherichia coli, could probably occur also in tumor 
cells. 
The antitumor efficacy of cisplatin was then tested on tumors, such as sarcoma 
180 implanted in mice. The results obtained were striking: the tumor growth 
stopped and, in some cases, also the regression of the tumor itself occurred as a 
result of the administration of the platinum complex [5]. 
In the following decade (in particular, in 1972), the trials of cisplatin on humans 
began. However, its clinical use was not authorized immediately: in fact, there 
was the risk of no longer being employed because, within a short time, the 
antitumor action of the drug was accompanied by serious toxic effects 
(especially if the administration provides high doses). Among the side effects, 
alterations in renal function till the nephrotoxicity, neuropathologies, peripheral 
neuropathy and alterations in liver function may occur. Due to these negative 
aspects, its approval and clinical application occurred only after the emanation 
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of a therapeutic scheme, which can mitigate the problem by using pre- and post-
hydration of the patient and induced diuresis. 
The search for the best methods is still an active investigation field that tries to 
develop new protective agents to be administered with cisplatin, able to reduce 
its side effects but not its efficacy. 
In 1978 the clinical use of this drug was approved in the United States of 
America and, only later, in Japan and Europe. Since then, it represents the most 
employed antineoplastic drug and it shows its efficacy, in particular, in testicular 
cancer. It is successful also for other types of neoplasia, such as prostate, 
ovarian, bladder, head and neck tumors. 
The trans-diamminedichloroplatinum(II) has no significant antitumor effects. It 
is kinetically more reactive and more labile than the cis isomer and, therefore, it 
has an average life shorter than cisplatin: this explains the fact that it is not 
employed as antitumor drug. 
 
2.3 Cisplatin Mechanism of Action 
 
Cisplatin is administered intravenously. In the bloodstream, the complex does 
not dissociate due to the high concentration of chloride ions (about 0.1 M). 
In the blood plasma, cisplatin can react with human serum albumin (HSA). This 
latter is a single-chain protein of 64 kDa that contains several methionines (Met) 
and one cysteine (Cys), which can form stable N,S-chelates with cisplatin 
inactivating it. This ability is due to the high affinity of platinum(II) for sulfur. 
The cisplatin is able to cross the cell membrane by means of a passive diffusion 
mechanism of the neutral molecule, although some facilitated transport 
mechanisms (CTR1) seem to be operative [6, 7]. 
When the cisplatin molecule arrives in the cytoplasm, where the chloride ions 
concentration in very low (about 3 mM), hydrolysis processes occur in order to 
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obtain aqua- and hydroxido-complexes and, in particular, the cisplatin aqua-
complexes represent its active forms. 
The rate constant for the substitution of the first chloride ion, at 37 °C, is 7 × 10
-
3
 min
-1
, which corresponds to a half-life time of about 2 hours. The hydrolysis of 
the first chloride ligand is twice faster than the substitution of the second 
chloride ion. 
At acidic pH (< 6), about 50% of cisplatin is in the diaquacomplex form. 
At neutral and alkaline pH, the equilibrium is shifted towards the deprotonation 
of the coordinated water molecule: therefore, hydroxido and 
aquahydroxidocomplexes are obtained. 
Once into the cell, the complex is in its hydrolyzed form and its final 
pharmacological target is the DNA; moreover, it is able to interact with several 
fundamental proteins for the DNA replication itself and for the mitosis. 
The hydrated active species is a bifunctional electrophilic reagent, therefore able 
to bind a nucleophilic site present on the DNA strand. The antitumoral function 
of cisplatin depends on its activation inside the cell as diammineplatinum 
species, by the dissociation of the two chloride ions and by the formation of 
inter- and intra-strand crosslinks, respectively on the opposite strands and on the 
same strand of DNA (Figure 2.2). These crosslinks cause the DNA replication 
arrest and, as a result, the cell death, if a mechanism of repair does not occur. 
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Figure 2.2: Crosslink processes of the hydrolyzed cisplatin with the DNA 
 
The characteristics of the main DNA platination sites are (Figure 2.2): 
1. monofunctional bond with a Guanine (Figure 2.3), defined as 
monoadduct, 
2. bifunctional bond with both a Guanine and a donor atom of a protein, 
3. inter-strand crosslink by means of two Guanines, 
4. intra-strand crosslink by two adjacent Guanines, 
5. intra-strand crosslink by means of two Guanines, separated by a third 
nitrogenous base, 
6. intra-strand crosslink by a Guanine and an adjacent Adenine (Figure 
2.3). 
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Figure 2.3: The Purines Adenine and Guanine represent the nucleophilic binding sites for the 
active form of cisplatin 
 
In the case of cisplatin, the type 4 adducts represent 50-60% of metallated sites, 
the type 5 adducts 20-30%, the type 5 adducts only 10% of the coordinated 
platinum. As regards the types 1, 2 and 3 adducts, they represent a percentage 
lower than 4%. Therefore, the main coordination way of cisplatin to DNA is by 
intra-strand crosslinks with two adjacent Guanines or with a Guanine and an 
adjacent Adenine (Figure 2.4). 
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Figure 2.4: Intra-strand adduct of cisplatin with DNA, by means of the N-7 of two adjacent 
Guanines [8] 
 
The mechanism of cisplatin activation is summed below. In the first phase, it 
loses the first chloride ligand, which is replaced by a water molecule, and it 
undergoes the first aquation reaction or “hydrolysis”. Afterwards, the 
aquacomplex can bind the nitrogen in the 7
th
 position (N-7) of a Guanine. At 
this stage, the complex undergoes a second “hydrolysis” and bind a second 
adjacent Purine. 
When cisplatin binds DNA, it is possible to assist to a deformation of the 
hydrogen bonds present between the two DNA helices, which are weaker than 
the coordination bond, and this leads to a consequent distortion of the platinated 
helix. 
In the final phase, the part of the complex that does not bind to DNA is excreted, 
and therefore degraded, through the liver: only about 50% of the initially 
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administered cisplatin is eliminated from the organism within 48 hours; the 
remaining part is excreted in a period that goes from 2 to 8 weeks. 
 
2.4 Second Generation of Platinum Complexes: Features and 
Cytotoxic Activity 
 
The administered dose of an antitumoral drug is related to different factors. At 
first, it is necessary to evaluate the activity of the drug itself and, therefore, the 
maximum dose tolerated by the organism. Another very important requirement 
is the solubility of the compound: a solubility of about 1 mg/mL, as in the case 
of cisplatin, is close to the limit of chemotherapeutic agent parenterally 
administrable, i.e. by injection. 
The increase of the solubility in water of the cisplatin derivatives was the first 
target for the creation of a second generation of chemotherapeutic drugs. 
The most of the platinum complexes containing two chlorides as “leaving 
groups”, defined “leaving” because they detached before the compound reaches 
its biochemical target, is usually not much soluble in water. For this reason, it 
was decided to replace them with a carboxylate anion, preferably a chelating 
agent, i.e. a dicarboxylate, such as oxalate, glycolate, lactate or 1,1’-
cyclobutanedicarboxylate. 
The leaving groups of a complex must be coordinated to the metal by means of 
medium strength bonds. If this does not occur, the ligands weakly retained will 
lead to the formation of very toxic complexes, whereas those strongly bound 
will generate inactive compounds. For this reason, the carboxylates are the 
leaving groups preferred to make longer the half-life times of the resulting 
complexes. 
The oxidation state of the metal is another important factor: in general, the 
Pt(IV) complexes are less active than those of Pt(II) but are more soluble in 
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water and can be activated only when they are reduced to platinum(II) species 
by biological reducing agents, such as cysteine, ascorbic acid, reduced 
glutathione, cytochrome c, etc. 
Another fundamental requirement for a cytotoxic complex to be employed 
consists in being neutral so that it can more easily cross the cell membrane by 
passive diffusion. 
It is possible to summarize the SAR (Structure-Activity Relationship) rules, 
enunciated in 1973 by Cleare and Hoeschele [9], which should allow a more 
focused design of new drugs: 
 the complex must be neutral (in order to avoid interactions with charged 
species present into the cells and to facilitate the crossing through the 
cell membrane), 
 the oxidation state must be +2, 
 the geometric isomer must be the cis one, 
 the complex must have two leaving groups with modulable hydrolysis 
rate (e.g. halides or dicarboxylates) and two carrier groups with 
modulable steric hindrance (e.g. aliphatic or aromatic N-donors, often 
chelating agents such as diamines). 
For the cancer treatment, two dicarboxylate Pt(II) complexes are worldwide 
employed: carboplatin (or cis-diammine-(1,1’-
cyclobutanedicarboxylato)platinum(II), CBDCA) and oxaliplatin (or cis-(1R,2R-
cyclohexanediammine)oxalatoplatinum(II)). On the contrary, the approval of 
other Pt(II) complexes is restricted to some States: in particular, lobaplatin (or 
(1,2-di(aminomethyl)cyclobutane)lactatoplatinum(II)) in China, nedaplatin (or 
cis-diammineglycolatoplatinum(II)) in Japan, and heptaplatin (or cis-
malonato[(4R,5R)]-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] 
platinum(II)) in Korea (Figure 2.5). 
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Figure 2.5: Main platinum complexes of II generation 
 
The choice of carboplatin is related to several favorable characteristics that 
allow to reduce side effects. This compound reacts like cisplatin does: it forms 
intra-strand and inter-strand crosslinks with the nucleophilic sites of DNA. The 
replacement of the two chloride ligands has the main function of making 
carboplatin more resistant (even hundred times) to the hydrolysis reactions and 
this allows the drug to have a higher life time. In fact, the 
cyclobutanedicarboxylate ring makes the ligand more stable than the chloride 
groups in cisplatin: as a consequence, the nephrotoxic potential of the molecule 
is significantly reduced, due to the decrease of the complex reactivity. 
In vivo tests, carried out in order to determine the antitumoral characteristics of 
the several derivatives of cisplatin, led to the conclusion that carboplatin gives 
rise to a series of side effects, such as nephrotoxicity, myelosuppression, 
vomiting, neurotoxicity but, anyway, it shows a minimal non-haematologic 
toxicity if compared to cisplatin. 
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The more limited toxicological profile of carboplatin allows to perform studies 
in which a much higher chemotherapeutic drug dose, than the standard cisplatin 
dose, was employed. 
Pharmacokinetic studies indicate that cisplatin and carboplatin behaviors are 
different and this difference is clearly correlated to the different chemical 
stability of the two drugs. 
In vitro test with plasma showed that cisplatin rapidly decomposes with a half-
life time of about 2 hours at 37 °C. Carboplatin, instead, is much more stable 
and has a half-life time of about 30 hours. Therefore, cisplatin is inactivated 
mainly by the binding to plasma proteins which, after about 4 hours from the 
intravenous infusion, bind more than 90% of the administered cisplatin. On the 
contrary, carboplatin binds much less to blood proteins and, after 4 hours from 
the infusion, only 24% of the total platinum is bound to the proteins. 
The drug elimination occurs by glomerular filtration through the kidneys. For a 
period ranging from 4 to 6 hours after the administration, the carboplatin present 
in plasma remains intact and, only later, there is the formation of crosslinks 
between platinum and proteins. Moreover, about 65% of the administered 
carboplatin dose can be found in the urine within 24 hours, whereas for cisplatin 
only about 15%: this demonstrates that cisplatin-proteins crosslink can be 
formed more easily than the one between carboplatin and proteins. 
The introduction of carboplatin in clinical trials minimized the necessity of 
hyper-hydration or the use of antiemetics, and the consequence of this was a 
decrease of nephrotoxicity, neurotoxicity and ototoxicity. The suppression of the 
spinal cord activity, however, is its main side effect and this restricts the doses of 
this drug. 
After several studies, it is possible to state that carboplatin is 10-40 times less 
effective than cisplatin: in fact, in order to obtain tumoral cell growth inhibition 
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effects similar to those of cisplatin, carboplatin requires a 10 times higher 
concentration. 
However, carboplatin inhibits the hemopoietic cells growth as effectively as 
cisplatin does: therefore, carboplatin is a drug with a higher antiproliferative 
activity on hemopoietic cells, although the mechanism that explains this higher 
sensitivity is not completely clear. 
Clinically carboplatin can be replaced by cisplatin in the treatment of ovarian 
and lung cancers but is less effective than cisplatin in genitourinary system, 
head, neck and esophagus tumors. 
Oxaliplatin is a platinum complex different from both cisplatin and carboplatin 
and it shows no cross-resistance on the Pt-resistant tumoral cell lines. The 
oxaliplatin toxicity profile, more similar to cisplatin than to carboplatin, includes 
nausea, vomiting, diarrhea and hematological effects. Alopecia and 
nephrotoxicity, instead, are not associated with oxaliplatin. Neurological toxicity 
is the dose-limiting effect. As regards the clinical activity, oxaliplatin is the first 
platinum complex that shows cytotoxic activity towards colorectal cancer; 
moreover, it is also effective to the Pt-resistant ovarian tumors. 
 
2.5 Platinum(IV) Prodrugs: Characteristics and Mechanism of 
Action 
 
Even though the early SAR rules (see paragraph 2.4) pointed out that Pt(II) 
complexes are preferred, the antitumoral drugs based on Pt(IV) show several 
advantages, if compared to their Pt(II) analogues. In particular, they are less 
reactive and, therefore, they can undergo fewer side reactions, produce fewer 
side effects and they may be orally administered (because of their stability in 
biological fluids). Furthermore, they make possible many structural 
modifications, which are reflected on important physical and chemical 
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properties for the activity of these compounds, such as reduction potential, 
lipophilicity and, therefore, the cell uptake. 
Platinum(IV) compounds have an octahedral geometry and an electronic 
configuration [Xe] 4f
14
 5d
6
 and their higher inertness is due to the fact that they 
remain intact until their arrival into the cells and, only in the hypoxic and 
reducing tumor site, they can be activated by biological reducing agents. In 
particular, the generally accepted intracellular mechanism by which Pt 
complexes exert their antitumoral effects can be divided into four main phases 
[10]: 
 cell membrane crossing and entrance into the cells, 
 activation, i.e. reduction for Pt(IV) compounds and following aquation 
reactions of the Pt(II) metabolites, 
 interaction with the main biological target, i.e. DNA, 
 cell response to the DNA damage. 
The axial ligands (L) are released only at a cellular level, where substances such 
as ascorbate and reduced glutathione (GSH), present in higher concentration 
than in the extracellular fluid, reduce platinum from +4 to +2 oxidation states. 
For this reason, Pt(IV) mechanism of action is defined as “activation by 
reduction” and platinum(IV) compounds are defined as “prodrugs” because they 
are reduced to the more reactive Pt(II) species. Afterwards, the corresponding 
Pt(II) complexes, after their aquation reaction, can rapidly bind DNA [11] 
(Figure 2.6). 
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Figure 2.6: Mechanism of action of Pt(IV) complexes, the “activation by reduction” 
(A = carrier ligands, X = leaving ligands, L = axial ligands). The picture is a modification of that 
reported in literature [11] 
 
The ease with which a complex may be reduced will affect its biological activity 
and, in order to ensure the activity, the analogue Pt(II) compound must be active 
[12]. 
As regards the biological reducing agents, there is a higher concentration of 
these species into the cells: in particular, ascorbic acid concentration in blood 
plasma is 50-150 M, whereas in the intracellular site is about 1 mM. The same 
considerations can be made also for GSH: about 900 M in the extracellular 
fluid and about 2 mM into the cells [13]. 
The direct crosslink of the Pt(IV) complex to DNA was observed in vitro in a 
reductant free environment, but mechanistically these reactions are negligible 
because the half-life times are much higher than those of the reduction: in fact, it 
is unlikely that a platinum(IV) compound can resist the large amount of 
reducing agents present in vivo and arrive intact to the nucleus [14]. 
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If the reduction process occurs in the extracellular site, the Pt(II) complex, after 
the replacement of the leaving groups with two water molecules, binds to 
proteins and, therefore, it is deactivated. 
Although Pt(IV) compounds have been investigated less than those of Pt(II), 
some of them proved to be promising as antitumoral drugs for clinical trials. The 
most studied were iproplatin, tetraplatin and JM216 (satraplatin) (Figure 2.7). 
 
 
Figure 2.7: The most studied Pt(IV) complexes 
 
Iproplatin (JM9 or cis,trans,cis-[PtCl2(ipa)2OH2], where ipa is isopropylamine) 
was selected for its high solubility from a series of compounds synthesized by 
Tobe. It is well tolerated, entered the II and III phases [15] but then was 
abandoned because it is less active than cisplatin [16]. 
Tetraplatin (or [PtCl4(DACH)], where DACH is 1R,2R-diminocyclohexane) 
demonstrated to be very promising in preclinical studies but it was abandoned in 
the I phase, due to a severe induced neurotoxicity [17]. 
JM216 (satraplatin or cis,trans,cis-[Pt(c-C6H11NH2)Cl2(NH3)(OCOCH3)2]) has 
recently arrived in the III phase [18]. It was selected because it represents a 
compromise among the oral activity (similar to the intravenously administered 
carboplatin in most of the models), few emetic properties (studied on ferrets, 
since mice do not have any emetic responses) and favorable physicochemical 
properties, such as a good solubility in water. Furthermore, the complex shows a 
good stability in acidic solutions, with a half-life time of some hours in 1 M 
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HCl: this fact tends to decrease the risk of possible transformations in the 
stomach before the absorption. 
The fact that none of the clinically tested compounds revealed to be significantly 
more active than cisplatin was particularly disappointing for researchers, since 
the in vitro results obtained by Kelland et al. [19] demonstrated that JM216 
analogues are up to 840 times more active than cisplatin. This high activity was 
put in relation with the high cell uptake, but the in vivo reduction alters the 
pharmacological properties and, therefore, also the efficacy. Probably, the 
studied drugs are reduced too early in the bloodstream. 
 
2.6 Drug Targeting and Delivery 
 
The Drug Targeting and Delivery (DTD) methods [20] aim at synthesizing 
drugs selective towards tumoral tissues and administrable at lower doses with 
fewer side effects and with a high therapeutic index (TI, i.e. the ratio between 
the average lethal dose (LD50) and the effective dose, which causes a 90% 
reduction in tumor mass (ED90)). 
The DTD allows to achieve these aims by using vectors able to selectively lead 
cytotoxic agents to the tumoral cells, thus avoiding damages to the healthy ones, 
by exploiting the biochemical differences between neoplastic and normal 
cells/tissues, and limiting drug resistance. 
A century ago Paul Ehrlich introduced the concept of drug targeting and it 
considered a “magic bullet” as an entity composed of two components: the 
former recognizes and binds the target, whereas the latter provides a therapeutic 
action. At present, the concept of magic bullet includes a combined action of 
three components: the drug, the targeting moiety and the pharmaceutical carrier, 
employed in order to increase the number of drug molecules per single targeting 
moiety [21]. 
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Depending on the nature of the carrier substances, it is possible to distinguish 
active and passive targeting strategies [20]. 
 
2.6.1 Active Strategies 
 
The active drug targeting is the result of a specific biomolecular interaction 
between the drug and the cell/tissue. By definition, a molecular agent targeted 
(MTA) is a biomolecule characterized by specific properties in respect of a well-
defined molecular target, involved in disease processes. 
An active targeting strategy involves drugs transported by biologically active 
molecules, in which the specific functionality leads the drug towards the tumor 
site, due to its binding affinity (a nutrient in respect of its carrier, an antibody for 
its antigen or a ligand for its receptor). For example, the cell proliferation 
process requires high amounts of energy. A decrease of the contribution of 
nutrients leads to the cell death if the cell proliferation cannot be limited, such as 
in the case of tumors. In mammals, the cell proliferation is controlled by signals 
transduction pathways stimulated by specific growth factors, but in tumors an 
excessive activation of these pathways, through oncogenic mutations, leads to a 
significant increase of the nutrients uptake, in particular glucose, amino acids 
and their derivatives. 
In the 20s, Otto Warburg demonstrated that ascite tumor cells have high glucose 
consumption rate: the Warburg effect is considered a metabolic distinctive 
feature of aggressive tumors. For this reason, sugars and also amino acids (in 
particular glutamine) are useful as active vectors. Other types of employed 
biovectors are hormones, antimetabolites, bile acids and bisphosphonates. 
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2.6.2 Passive Strategies 
 
The passive drug targeting, instead, exploits the so-called Enhanced 
Permeability and Retention (EPR) effect (Figure 2.8): in the solid tumors, the 
tissue, being in rapid and uncontrolled growth, shows a high permeability of the 
blood vessels and an inefficient or absent lymphatic drainage [20]. 
 
 
Figure 2.8: Schematic representation of the EPR effect 
 
The vascular endothelium in tumors rapidly proliferates and is discontinuous 
with a high number of fenestrations in the blood vessels, where the endothelium 
is substantially quiescent. As a result, the particles with small enough 
dimensions (i.e. 50-200 nm) can passively cross the endothelial barrier of the 
tumor through the fenestrations. 
In addition, the absence of an efficient lymphatic drainage prevents the removal 
of the excess fluid from the solid tumor tissue. 
The combination of these two effects makes the tumor iperpermeable to 
circulating macromolecules (such as albumin, micelles, nanoparticles, 
liposomes, etc.), which come out and are accumulated, due to the inefficient 
lymphatic drainage. 
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In addition to the EPR effect, the tumor cells show a higher uptake of the 
macromolecules present in the peritumoral fluid by endocytosis than normal 
cells, as a result of their high metabolic activity. 
 
2.6.3 The Choice of Passive DTD Vectors 
 
In the last years, several potential passive DTD systems were employed, such as 
inorganic nanoparticles, polysaccharides, liposomes, polymeric micelles, etc. 
(Figure 2.9). 
 
 
Figure 2.9: Main passive DTD vehicles and their general stage of development [22] 
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Several types of inorganic nanoparticles were employed as carrier, such as silica 
nanoparticles (NPs) (both mesoporous and non porous), gold nanoparticles, 
magnetic iron oxide nanoparticles, quantum dots and carbon nanotubes. 
Silica nanoparticles obtained a significant interest because of their versatile 
silane chemistry (as regards the surface functionalization), their 
biocompatibility, ease of large-scale synthesis and low-cost of production. As 
previously mentioned, they can be distinguished into mesoporous and 
nonporous NPs: the former type is based on physical or chemical adsorption of 
the drug (and the release can be modulated by the use of the so-called 
“gatekeeper”), and the latter is based on drug conjugation and the release can be 
controlled by the use of appropriate linkers [23]. A detailed description is 
provided in Chapters IV and V. 
Gold nanoparticles are interesting vehicle because they are inert, nontoxic, 
biocompatible and easy to be prepared and functionalized. Some studies were 
carried out by employing this type of NPs functionalized with thiolated 28-mer 
oligonucleotides containing a terminal dodecyl amine for the Pt coupling, which 
is a cis,cis,trans-[Pt(NH3)2Cl2(OH)(O2CCH2CH2CO2H)] [24]. 
Magnetic iron oxide NPs are investigated since they have a double function: 
Magnetic Resonance Imaging (MRI) contrast agents and carrier platform for 
DTD strategies. Moreover, their biocompatibility and biodegradability are 
significant features that make these nanoparticles widely used in biomedical 
applications [25]. More details are reported in Chapter VII. 
As reported by Peer et al. [26], polysaccharides, which are polymers of 
monosaccharides linked by glycosidic bonds, are very versatile platforms: they 
have many reactive sites that can be exploited for further chemical 
modifications, such as esterification, amidation, grafting, etc. Moreover, another 
advantage is the bioadhesion, in particular for mucosal surfaces. Among the 
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polysaccharides employed, chitosan, dextran, alginate can be mentioned and, in 
particular, chitosan is discussed in Chapter VI. 
Liposomes, term derived from the Greek lipo, “fat”, and soma, “body”, to 
describe their phospholipids composition, were introduced in England in 1961 
by the haematologist Alec D. Bangham. In particular, they are concentric 
vesicles composed of a phospholipid bilayer and can be used to incorporate 
drugs within their structure. Some formulations of liposomes containing 
platinum complexes was successful in clinical trials: Lipoplatin
TM
 and 
Aroplatin
TM
, which contain cisplatin and cis-bis(neodecanoato)-(trans-R,R-1,2-
diaminocyclohexane)platinum(II), respectively [27]. More details as regards 
liposomes are shown in Chapter VIII. 
Polymeric micelles allow to incorporate drugs into their inner core by chemical 
conjugation or physical entrapment. Wang et al. reported a significant example, 
NC-6004 which is a block copolymer of PEG and poly(glutamic acid) (PGlu) 
coordinated with cis-diammineplatinum moieties: the hydrophilic PEG chain is 
the outer shell, whereas the PGlu-Pt complex chain is the inner core [27]. It is in 
phase III clinical trial in Asia for pancreatic cancer, in phase I in Japan and USA 
for head and neck tumors and in phase II in USA for non-small cell lung 
(NSCL), bladder and bile duct cancers [28]. 
 
2.6.4 Nanoparticles Properties 
 
As previously described, small particles can extravasate and accumulate into the 
interstitial spaces but, since the cut off size of the fenestrations can vary from 
case to case, the conjugates dimensions (and the NPs stability) must be 
controlled in order to achieve the highest efficiency. Bae et al. [29] summed up 
the relationship between NPs size and presumed bioactivities in the body (Table 
2.1). 
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Size Biological systems and remarks 
4.5 nm Abundant small pores present in normal tissue endothelium 
25 nm Relatively few large pores present in normal tissue endothelium 
20 - 50 
nm 
Average size of polymeric micelles without loaded drugs 
100 nm Frequently tested size of drug-loaded polymeric micelles 
150 nm 
Proposed cutoff size for particle extravasation in liver. This 
latter has blood vessels with fenestrations of 100–175 nm 
200 nm 
Nanoparticles less than 200 nm have significantly longer 
circulation time due to low uptake by the reticuloendothelial 
system (RES) 
380 nm 
A tumor-dependent functional pore cutoff size ranges from 200 
nm to 1.2 μm, but the pore cutoff size of porous blood vessels 
in majority tumors is known to be 380 - 780 nm. Thus, the 
range for the EPR effect should be similar. 
400 nm 
Sterically stabilized liposomes of 400 nm in diameter were able 
to penetrate into tumor interstitium. Accumulation of 
hyaluronic acid-coated nanoparticles (400 nm) in the tumor 
tissue 
500 nm 
The maximum size of nanoparticles allowing penetration 
through cell membranes is known to be 500 nm 
1 μm 
Particles below 1 μm were taken up by Peyer’s patches and 
then migrated to mesenteric lymph nodes 
5 μm 
The upper limit for rigid particles circulating within the 
smallest capillaries 
40 μm 
Particles larger than 40 μm have been used for embolization 
therapy 
Table 2.1: NPs size and their presumed bioactivity in the body [29] 
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2.6.5 The Drug Release 
 
An ideal DTD system is based on four main concepts: efficient drug loading on 
a vehicle (which should be non-toxic, non-immunogenic, biodegradable and 
physically and chemically stable in vitro and in vivo), prolonged circulation time 
in the blood vessels allowing the achievement of the prefixed target, retention 
into the targeting site and drug release within a time that allows an efficient drug 
function [29]. 
The targeting ensures the high efficiency of the drug and reduces side effects, 
but an efficient release at the target site is fundamental [20]. In this regard, the 
characteristics of the neoplastic tissue can be exploited. The microenvironment 
is highly hypoxic, since the hemoglobin in the erythrocytes is depleted of 
oxygen, and acidic. This latter is due to the fact that tumoral cells are in rapid 
growth, have not sufficient amount of oxygen for their methabolism and, 
therefore, use anaerobic glycolysis for their energy requirements. It is possible 
to assist to a high production of lactic acid, responsible for the acidification of 
the peritumoral environment: its pH is lower by about one unit than the one of 
normal cells. The pH gradient, therefore, can be exploited, from a therapeutic 
point of view, with antitumoral species which contain hydrolysable groups at 
acidic pH. 
When the drug arrives into the cells, it must be released from the carrier in order 
to exert its function. The release can occur by the cleavage of hydrolyzable bond 
at the tumoral cells pH or of an amide bond, after the attack of hydrolytic 
enzymes. In the framework of antitumor metal drugs, this is the case of Pt(II) 
complexes carried by nanovectors. On the contrary, in the case of Pt(IV) 
prodrugs, hydrolyzable groups are not required. In fact, the hypoxic and 
reducing features of the neoplastic site can be used for the “activation by 
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reduction” of the prodrugs producing the Pt(II) active species that are released 
from the NPs if they are linked in axial position (Figure 2.10). 
 
Figure 2.10: Schematic representation of the drug release from the vector 
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The aim of this Ph.D. work is focused on the exploration of several passive 
Drug Targeting and Delivery (DTD) methods in order to selectively carry Pt(IV) 
antitumor prodrugs to the tumor site, in which the corresponding Pt(II) active 
metabolite (obtained after the so-called activation by reduction, favoured in the 
hypoxic and reducing milieu of tumors) can exert its antitumor action. 
The first step of such work project consists in the synthesis of Pt(IV) complexes, 
containing suitable functionalities to be exploited in coupling reactions with 
nanosized vectors. Alternatively, platinum complexes can be encapsulated into 
lipophilic systems. Then, the work includes the loading of selected nanocarriers 
with the metal complexes and the biological evaluation of the resulting 
conjugates. 
In particular, the below reported projects have been developed: 
 
 synthesis and characterization of Pt(IV) complexes, their subsequent 
coupling reactions with different kinds of amino-functionalized core-
shell silica nanoparticles and, finally, in vitro studies of the 
corresponding conjugates; 
 coupling reactions of the previously prepared Pt(IV) complexes with 
chitosan and chitosan derivatives; 
 synthesis and characterization of Pt(IV) prodrugs able to link magnetic 
iron oxide nanoparticles and their coupling reactions with such vectors; 
 encapsulation of antitumor drugs into liposomes and their in vitro 
studies. 
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Capitolo 4  
Chapter IV 
 
 
 
 
 
 
 
 
 
 
Synthesis and Characterization of Pt(IV) Complexes and 
Coupling Reactions with Amino-Functionalized Fluorescent 
Core-Shell Silica Nanoparticles 
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4.1 Introduction 
 
Cisplatin represents the starting point for all the platinum(IV) complexes 
synthesized in this work. 
The oxidation of cisplatin (which involves the transition from the square-planar 
geometry to the octahedral one) was carried out by using hydrogen peroxide, as 
an oxidizing agent, and the reaction product depended on the mixture solvent. In 
fact, it is possible to assist to the coordination of two hydroxyl groups in axial 
position in the presence of water, or of a hydroxyl and an ethoxy functionalities 
in ethanol. In the first case, both of the axial groups can further react with other 
species (such as anhydrides, acyl chlorides, etc.), in order to form two esterified 
bonds. On the contrary, in the presence of an alkoxide, it remains inert during 
the subsequent synthetic procedures, whereas only the hydroxyl functionality 
can be further esterified. 
The synthesized Pt(IV) complexes show one or two free carboxylic groups and 
these functionalities can be exploited to form amidic bonds by reaction with 
amines. In particular, the mono- or di-functionalizable compounds can be 
coupled to the primary amines present on the surface of several vectors (such as 
silica nanoparticles, chitosan and iron oxide nanoparticles), suitable for passive 
Drug Targeting and Delivery (DTD) strategies. 
The synthesized platinum compounds and conjugates are here reported: 
▪ (SP-4-2)-diamminedichloridoplatinum(II), cisplatin, 
▪ (OC-6-33)-diamminedichloridodihydroxidoplatinum(IV) (1), 
▪ (OC-6-33)-diamminebis(4-carboxypropanoato)dichloridoplatinum(IV) 
(2), 
▪ Activated N-hydroxysuccinimidyl diester of 2 (3), 
▪ (OC-6-33)-diamminebis(4-oxo-4-(propylamino)butanoato)dichlorido 
      platinum(IV) (4), 
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▪ Difunctionalized Pt(IV) complex - silica NPs conjugates (5a-5d), 
▪ (OC-6-44)-diamminedichloridoethanolatohydroxidoplatinum(IV) (6), 
▪ (OC-6-44)-diammine(4-carboxypropanoato)dichloridoethanolato 
      platinum(IV) (7), 
▪ Activated N-hydroxysuccinimidyl ester of 7 (8), 
▪ (OC-6-44)-diamminedichloridoethanolato(4-oxo-4-(propylamino) 
      butanoato)platinum(IV) (9), 
▪ Monofunctionalized Pt(IV) complex - silica NPs conjugates (10a-10d). 
 
Each complex was characterized by High Performance Liquid Chromatography 
coupled with Mass Spectrometry (HPLC-MS), spectroscopic techniques such as 
Nuclear Magnetic Resonance Spectroscopy (multinuclear NMR) and Infrared 
Spectroscopy (IR), and Elemental Analysis (EA). 
In this chapter, compounds 3 and 8 were coupled with amino-functionalized 
nonporous core-shell silica nanoparticles, after checking their reaction with a 
primary amine (propylamine) as a model. Moreover, the behavior of a mono- 
and a di-functionalizable complexes was compared in order to evaluate the 
stability of the final NPs suspension and to verify the possibility of cross-links 
between nearby NPs (in the case of the presence of two available carboxylic 
functionalities), causing aggregation. 
As previously mentioned (Chapter II), in recent years, silica NPs have been 
highly employed for biochemical applications and two different types of 
particles are currently used: mesoporous and nonporous NPs. Such NPs are 
different as regards the anchoring of the drugs, another difference consists in the 
lower toxicity of the nonporous ones respect to the others [1], even though the 
cytotoxicity of the NPs is often cell type dependent and is related to geometry, 
surface functionalities and colloidal stability. For this reason, in this work, four 
types of nonporous silica NPs (which differ in size) were employed. These 
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particles show a core-shell structure based on a silica core, surrounded by a 
fluorescent dye and by another shell of silica. Finally, the surface was 
functionalized with alkyl chains ending with primary amino groups, which can 
be exploited in coupling reactions with Pt(IV) complexes and allow to pursue 
the DTD aims. The presence of a fluorophore (e.g. rhodamine B or fluorescein) 
is important to follow, by means of imaging techniques, the path of the drug - 
NP conjugates inside the cells and, then, in vivo. 
 
4.2 Instrumental Information 
 
The chromatographic analysis were performed by using a Waters HPLC-MS 
instrument equipped with an Alliance 2695 separations module, a 2487 dual 
lambda absorbance detector and a mass spectrometer 3100, as the second 
detector. The stationary phase consisted (except for the reduction kinetics 
studies, see paragraph 4.17.1.2) of a C18 Phenosphere-NEXT column 5 μm, 
250 × 4.60 mm ID. The mobile phase was a mixture of eluants, i.e. an aqueous 
solution of formic acid 15 mM and pure methanol, in different percentages 
(depending on the analyzed complex). The flow rate was 0.500 mL/min, 
isocratic elutions were performed and the analysis temperature was set at 37 °C. 
The UV-Visible detector was fixed at 210 nm wavelength. 
The Electrospray Ionization (ESI) mass spectra were collected by setting the 
source and the desolvation temperatures at 150 °C and 250 °C, respectively. In 
particular, the ESI source temperature was set to a higher value than the 
employed solvent boiling temperature, in order to avoid its condensation. 
Nitrogen was used with a double function: drying and nebulizer gas. 
Furthermore, the cone and the capillary voltages were fixed at 30 V or 20 V and 
at 2.70 kV, respectively. The internal pressure was 10
-5
 mbar and the employed 
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scan mode was “centroid”, i.e. the signal intensities are proportional to the ionic 
abundance. 
The NMR spectra were measured by using a NMR Bruker Avance III, operating 
at 500 MHz (
1
H), 125.7 MHz (
13
C) and 107.2 MHz (
195
Pt, with a spectral 
window of 2000 ppm), and a JEOL Eclipse Plus, operating at 400 MHz (
1
H), 
100.6 MHz (
13
C) and 86.0 MHz (
195
Pt, with a spectral window of 2000 ppm). 
1
H 
and 
13
C NMR chemical shifts were reported in ppm, referenced to solvent 
resonances, and, in the case of measurements in D2O, 1% methanol was added 
as internal reference. 
195
Pt NMR spectra were registered by using a solution of 
K2PtCl4 in saturated aqueous KCl, as external reference. The K2PtCl4 chemical 
shift was set at -1628 ppm from Na2PtCl6 (δ = 0 ppm). 
The elemental analyses were performed by means of a EA3000 CHN Elemental 
Analyzer (EuroVector, Milano). 
Particle size, size distribution and ζ potential were measured by scanning 
electron microscopy (SEM) and by dynamic light scattering (DLS), respectively. 
The Field Emission Gun-SEM micrographs were obtained by using an Inspect F 
SEM-FEG (FEI, Hillsboro, USA) with a beam diameter of 3 nm. From 200 to 
250 individual nanosphere diameters were measured for each sample and the 
images were elaborated by using the Scion Image processing program (Scion 
Corp., Frederick, USA). 
DLS and ζ potential analyses were performed at 25 °C, at a fixed ionic strength, 
with a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK) at 
a fixed scattering angle of 173°, using a He–Ne laser and DLS software for 
Windows (version 6.11, Malvern, UK). The instrument was checked with a 
standard polystyrene latex with a diameter of 100 nm. 
The mineralization of Pt-loaded silica nanoparticles was performed by means of 
a microwave assisted acid digestion apparatus Milestone Start D with an internal 
temperature sensor. 
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The quantification of the platinum content in conjugates and biological samples 
was performed by means of inductively coupled plasma-optical emission 
spectrometry (ICP-OES) with a Spectro Genesis ICP-OES spectrometer 
(Spectro Analytical Instruments, Kleve, Germany) equipped with a cross flow 
nebulizer, or by inductively coupled plasma-mass spectrometry (ICP-MS) with a 
Thermo Optek X Series 2. By ICP-OES the Pt concentration was determined by 
selecting the Pt 299.797 nm line, whereas by ICP-MS the most abundant 
isotopes of platinum and indium (used as internal standard) were measured at 
m/z 195 and 115, respectively. The calibration curve was prepared by dilution 
with 1.0% v/v nitric acid of a 1000 ppm platinum standard stock solution. 
 
4.3 Synthesis of the Nonporous Core-Shell Silica Nanoparticles 
 
In 1956 Gerhard Kolbe observed the formation of spherical silica particles when 
tetraethoxysilane (TEOS) was hydrolyzed in the presence of ammonia. In 1968, 
in particular, Stöber et al. took up and improved this process in order to observe 
exceptional monodispersed silica particles [2]. 
In this work, four types of NPs (defined as a, b, c and d) were synthesized by 
using a modified Stöber method [3, 4]. In particular, as reported by Ravera et al. 
[5], in a round-bottomed flask, equipped with a reflux condenser, a thermometer 
and a mechanical stirrer, a mixture of water (37.5 mL for a, 25 mL for b and c, 
30 mL for d) and ammonia (6.2 mL for a, 21 mL for b and c, 13 mL for d) were 
introduced and diluted with methanol to the final volume of 320 mL. The 
solution was heated to 30 °C in an oil bath at a stirring rate of 200 rpm, then 
tetraethoxysilane (TEOS, 20 mL, 90 mmol) was added and the reaction was 
carried out for 2.5 hours. Subsequently, the fluorescent layer was grown by 
adding a mixture of TEOS and the prepared fluorophore, i.e. rhodamine B 
isothiocyanate (RhBITC, for a and c) or fluorescein isothiocyanate (FITC, for b 
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and d). In particular, such fluorophore (3.6 mg of RhBITC and 2.7 mg of FITC, 
respectively, 6.7 μmol) were covalently bound to the silane coupling agent (3-
aminopropyl)trimethoxysilane (APTMS, 119 μL, 681 μmol) in 2 mL of ethanol. 
This mixture was stirred for 3 hours at room temperature and then added to the 
reaction flask with TEOS (340 μL, 1.5 mmol). The reaction was performed for 
16 hours and, after the established time, NPs were collected by centrifugation 
(900 rpm, 10 minutes) and washed by three cycles of suspension in ethanol and 
centrifugation. The external silica shell was obtained by reacting, for 8 hours at 
30 °C, 5.0 g of NPs with 2 mL of TEOS in a mixture of ammonia (4 mL), water 
(35 mL) and ethanol to a final volume of 320 mL. Then, APTMS (400 μL, 2.29 
mmol) were added to the suspension and the reaction was carried out for 16 
hours. The NPs were collected by centrifugation (900 rpm, 10 minutes) and 
purified by at least three cycles of dispersion in ethanol and centrifugation. 
In Figure 4.1 a scheme of the several procedures carried out to synthesize the 
silica nanoparticles is shown. 
 
Figure 4.1: Synthetic scheme to prepare silica NPs 
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The nanoparticles were then stored as an ethanol suspension: in fact, this is the 
only way to maintain their stability and to prevent their aggregation (which 
occurs in the case of lyophilized samples). 
In Figure 4.2, SEM images of one of the NPs samples (b) are shown in order to 
observe their size growth by adding shells. 
 
 
Figure 4.2: SEM micrographs at different growth phases of NPs b 
 
For each sample, in order to proceed with a quantitative determination of the 
fluorophore and of the exposed amino groups, the silica nanoparticles density 
(expressed as g NPs/mL of ethanol suspension) was measured. In particular, 1 
mL of each ethanol suspension was dried in an oven and, then, the dried product 
was weighed: the results obtained are shown in Table 4.1. 
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NPs NPs density (g NPs/mL) 
a 0.0350 
b 0.0206 
c 0.0128 
d 0.0137 
Table 4.1: a-d NPs suspensions density 
 
4.3.1 Quantification of the Fluorophore 
 
For the quantification of the fluorescent dye [5], 0.02 g of NPs were suspended 
(by means of 2 hours of sonication in an ultrasonic bath) in a mixture of 1 mL of 
ethanol and 1 mL of 1 M aqueous NaOH and it was stirred overnight. Then, it 
was centrifuged (10000 rpm, 5 minutes) to obtain a clear solution, whose 
absorbance value at 550 nm (for rhodamine B) or at 497 nm (for fluorescein) 
was measured and related to the fluorophore concentration using experimentally 
determined molar extinction coefficients ε (85434 M−1 cm−1 for fluorescein and 
109359 M
−1
 cm
−1
 for rhodamine B). Each value is the mean of at least three 
independent measurements. Data are expressed as fluorophore loading (μmol 
fluorophore/g NPs) and shown in Table 4.2. For all the samples, the fluorophore 
loading efficiency ranges from 16 to 38% and this value represents the molar 
ratio between the fluorophore molecules incorporated in the NPs and the ones 
employed in the synthesis. 
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NPs Fluorophore 
Fluorophore loading 
(μmol/g NPs) 
a Rhodamine B 0.250 ± 0.011 
b Fluorescein 0.403 ± 0.006 
c Rhodamine B 0.183 ± 0.003 
d Fluorescein 0.261 ± 0.004 
Table 4.2: a-d NPs fluorophore loading 
 
4.3.2 Quantification of the Amino Functionalities 
 
As regards the quantification of the amino groups [5], 0.5 g of NPs were washed 
with ethanol for at least five times in order to remove unreacted ammonia and 
APTMS. The pellet was then dispersed in 20 mL of an aqueous solution 
containing 0.2 M HCl and 0.5 M NaCl in order to allow complete protonation of 
amino groups, centrifuged and dispersed in 20 mL of water and then it was 
suspended in 20 mL of a 1 M aqueous KNO3. The suspension was left overnight 
under stirring to allow displacement of chloride by nitrate anions. The 
suspension was then centrifuged and the solution (containing chlorides) was 
directly titrated with a 0.01 M aqueous solution of AgNO3. In particular, the 
titration was based on the precipitation reaction of AgCl, which, being a very 
poorly soluble salt in the aqueous mixture (Kps at 25 °C = 1.1 × 10
-10
), 
precipitated. The titration was monitored by using an Ag
+
-selective electrode, by 
registering and studying the potential of the solution at 25 °C after each titrant 
addition, and it was considered complete when all the AgCl was precipitated. 
The titration curve of NPs a is shown in Figure 4.3, as an example. Then the 
data were processed, expressed as amino group density (mmol NH2/g NPs) and 
reported in Table 4.3. 
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Figure 4.3: Titration curve of silica NPs sample a 
 
NPs 
amino groups density 
(mmol NH2/g NPs) 
a 9.34 × 10
-2
 
b 2.32 × 10
-1
 
c 2.20 × 10
-1
 
d 2.80 × 10
-1
 
Table 4.3: a-d NPs amino functionalities density 
 
4.3.3 Size and Stability Investigations 
 
For each sample, SEM and DLS analyses were carried out in order to evaluate 
the NPs dimensions. In the first technique, a drop of the ethanol suspension was 
deposited on a sample holder, the alcohol was let evaporate and then the 
analysis was performed, after the introduction of the sample holder into the 
instrument and after the setting of the required parameters. 
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On the contrary, for DLS measurements, the NPs ethanol suspension was 
centrifuged and the pellet was dispersed in a 0.2 M aqueous solution of HCl (in 
order to reach a higher stability), centrifuged and suspended in 20 mL of a 10 
mM KNO3 solution (in order to perform the analyses at fixed ionic strength). 
About 1 mL of the prepared suspension was transferred into a plastic disposable 
cuvette which, in turn, was introduced into the instrument for the analysis. 
The same suspension prepared for the DLS was employed for the ζ potential 
analysis, which allows to evaluate the suspension stability. In this case, the 
sample was transferred into a cuvette suitable for ζ potential measurements and 
then introduced into the instrument for the analysis. All the results are 
summarized in Table 4.4. 
 
NPs SEM diameter (nm) DLS diameter (nm) ζ potential (mV) 
a 262 ± 16 380.6 ± 5.6 37.9 ± 2.5 
b 116 ± 17 161.0 ± 1.3 58.0 ± 2.8 
c 96 ± 13 178.9 ± 0.6 57.3 ± 2.4 
d 48 ± 5 122.8 ± 1.1 54.5 ± 1.1 
Table 4.4: a-d NPs dimensions and suspensions stability results 
 
The ζ potential is a measure of the stability of a suspension: a system is stable if 
an equilibrium between electrostatic interactions of opposite sign (i.e. attractive 
and repulsive forces) among the particles is established. As reported in literature 
[6], ζ potential ≥ |30| mV indicates a stable suspension, due to the electrostatic 
repulsion, among the nanoparticles, that avoid their aggregation. If the value is ≥ 
|60| mV the system shows a very high stability. Values < |20| mV, instead, are a 
measure of a limited stability because the attractive forces begin to prevail over 
the repulsive ones. When ζ potential < |5| mV aggregation occurs. 
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In this case (Table 4.4), all the four types of NPs exceed the threshold of 
stability, since their ζ potential values are higher than +30 mV. 
As regards the size, DLS diameter are bigger than those determined by SEM 
(Figure 4.4). 
 
  
  
Figure 4.4: SEM micrographs of the synthesized silica nanoparticles a-d 
 
This can be explained considering that, in solution, each nanoparticle is 
surrounded by water molecules, which form a solvation shell. Therefore, the 
DLS data take into account the hydrodynamic radius (considering the solvent 
effect), which is slightly bigger than the one of the particle itself: this justifies 
NPs a NPs b 
NPs c NPs d 
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the higher dimensions observed by DLS. In particular, the hydrodynamic radius 
is related to the ionic strength: the higher the ionic strength, the less expanded 
the hydrodynamic radius and, therefore, the smaller the NPs size. 
 
4.4 Synthesis of Cisplatin 
 
The cisplatin synthesis was carried out according to the Dhara’s method [7]. 
In the first synthetic phase, potassium tetrachloroplatinate(II) reacts with 
potassium iodide to allow the formation of potassium tetraiodoplatinate(II) and 
potassium chloride 
 
The product reacts with an ammonia solution 30% in order to synthesize the 
(SP-4-2)-diamminediiodidoplatinum(II). It is not possible to obtain the other 
geometric isomer, the trans one. In fact, when the first ammonia molecule 
replaces one of the ligands in the complex, giving rise to the 
monoamminetriiodidoplatinate(II) intermediate, the second ammonia molecule 
will place in trans mode with respect to one of the remaining iodides. This is 
due to the high trans-orienting effect of the iodide ligands. Therefore, we can 
assist to the formation of a cis complex. 
 
The (SP-4-2)-diamminediiodidoplatinum(II) reacts with silver nitrate: the role of 
silver(I) ions consists in precipitating iodide ions in the form of silver iodide 
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and, therefore, in replacing them with two molecules of water, as coordinated to 
the metal ligands. 
 
In the next phase the complex in aqueous solution reacts with potassium 
chloride: the water molecules are moved away from the coordination sphere of 
the metal and replaced by chloride ligands, thus obtaining cisplatin. 
 
 
4.4.1 Synthesis of (SP-4-2)-diamminediiodidoplatinum(II) 
 
1.00 × 10
3
 mg (2.41 mmol) of K2[PtCl4] was dissolved in 10 mL of ultrapure 
water, in the dark. Then, a 6-fold molar excess (respect to K2[PtCl4]) of 
potassium iodide (2.40 × 10
3
 mg, 14.45 mmol) was added and the reaction 
mixture was magnetically stirred at room temperature, in the dark, for 40 
minutes: during this period, we can assist to a change of color from red to 
brown. 
The next phase involves the dropwise addition of an ammonia solution 30%, 
3.3-fold molar excess respect to K2[PtCl4] (7.95 mmol), and after 30 minutes it 
was possible to observe the precipitation of a yellow compound: (SP-4-2)-
diamminediiodidoplatinum(II). The reaction product was separated from the 
solution by means of centrifugation and, then, it was washed with cold ultrapure 
water, ethanol and diethyl ether. Subsequently, it was properly dried and the 
reaction yield was calculated. 
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Yield: 1.12 × 10
3
 mg, 2.32 mmol, 96.3%. 
 
4.4.2 Synthesis of (SP-4-2)-diamminedichloridoplatinum(II) 
 
To the previously synthesized complex (1.12 × 10
3
 mg, 2.32 mmol), dissolved 
in 10 mL of ultrapure water, a 1.96-fold molar excess of silver nitrate (772 mg, 
4.55 mmol) respect to (SP-4-2)-diamminediiodidoplatinum(II) was added. The 
reaction was carried out at 50 °C for 24 hours in the dark. Then, the solution was 
centrifuged and filtered with a syringe microfilter (Regenerated Cellulose, 
porosity of 0.20 μm) to remove the precipitated silver iodide. The solution, 
when necessary, was also concentrated by means of a rotary evaporator in order 
to reduce its volume to some mL. 
Subsequently, a 21-fold molar excess of potassium chloride (3.63 × 10
3
 mg, 
48.7 mmol) with respect to (SP-4-2)-diamminediiodidoplatinum(II) was added 
to the previously concentrated solution and the reaction mixture was stirred for 
24 hours at room temperature in the dark. In this phase the precipitation of (SP-
4-2)-diamminedichloridoplatinum(II) occurred and this yellow compound was 
then separated from the solution by means of centrifugation, washed with cold 
ultrapure water, ethanol and diethyl ether and, finally, dried in vacuo. 
Yield: 546 mg, 1.82 mmol, 78.2%. 
 
4.4.2.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
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pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. The complex showed a 
retention time of 5.22 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.5). 
 
 
Figure 4.5: ESI-MS spectrum of cisplatin, prepared in ultrapure water 
 
Figure 4.5 shows the cisplatin ESI-MS spectrum corresponding to the HPLC 
peak and registered in negative ion mode with a cone voltage (CV) of 30V: it 
confirmed the success of the synthesis since it contained the pseudo-molecular 
ion [M-H]
-
 peak at 298.9 m/z and the peaks of adducts [M+Cl]
-
 and 
[M+formate]
-
 at 334.9 m/z and 344.8 m/z, respectively (the formate ion derived 
from the eluant). 
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Figure 4.6: 
195
Pt-NMR spectrum of cisplatin, registered in DMF-d7 
 
The cisplatin 
195
Pt-NMR spectrum (Figure 4.6) was registered in DMF-d7 (at a 
107.2 MHz NMR frequency) and shows a signal with a chemical shift value of 
-2093 ppm, which is consistent with a Pt(II) with two chlorides and two amines. 
 
4.5 Synthesis of (OC-6-33)-
diamminedichloridodihydroxidoplatinum(IV) (1) 
 
To a mixture of cisplatin (450 mg, 1.50 mmol) in 8 mL of ultrapure water, 35% 
w/w aqueous hydrogen peroxide (657 μL, 7.50 mmol) was added dropwise. The 
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reaction was carried out in continuous magnetic stirring at room temperature 
overnight. The precipitation of 1 was then favored by cooling the reaction 
mixture to -18 °C for 20 minutes. The resulting bright yellow solid was washed 
with cool ultrapure water, methanol and diethyl ether and, finally, dried in 
vacuo. 
Yield: 348 mg, 1.04 mmol, 69.5%. 
Elemental analysis calculated for Cl2H8N2O2Pt: H 2.41, N 8.39, Pt 58.40 %. 
Found: H 2.37, N 8.22, Pt 58.51 %. 
 
4.5.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 1 showed a 
retention time of 4.16 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.7). 
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Figure 4.7: ESI-MS spectrum of complex 1, prepared in ultrapure water 
 
The ESI-MS spectrum of complex 1, registered in negative ion mode with a 
cone voltage of 30V, shows the pseudo-molecular ion [M-H]
-
 at 333.0 m/z. 
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Figure 4.8: 
195
Pt-NMR spectrum of complex 1, registered in D2O 
 
The 
195
Pt-NMR spectrum of complex 1 (Figure 4.8) was registered in D2O (at a 
86.0 MHz NMR frequency) and shows a signal at 835 ppm (qt, 
1
J = 185.76 Hz), 
which is consistent with a Pt(IV) complex containing two chlorides, two amines 
and two hydroxido ligands. The signal multiplicity is typical for the coupling of 
195
Pt (spin quantum number I = ½) with two 
14
N atoms (I = 1). The signal is 
quite broad, due to the coupling with the quadrupolar nucleus 
14
N. 
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4.6 Synthesis of (OC-6-33)-diamminebis(4-
carboxypropanoato)dichloridoplatinum(IV) (2) 
 
 
Succinic anhydride (120 mg, 1.20 mmol) and complex 1 (100 mg, 0.299 mmol) 
were dissolved in 5 mL of anhydrous N,N-dimethylformamide (DMF). The 
reaction mixture was stirred at 70 °C overnight. The yellow solution obtained 
was filtered to eliminate possible unreacted starting reagents and then DMF was 
removed under reduced pressure. The addition of acetone (1 mL) and, 
subsequently, of cool diethyl ether led to the precipitation of a yellow solid, 
which was washed with diethyl ether and then dried in vacuo. 
Yield: 102 mg, 0.191 mmol, 63.8%. 
Elemental analysis calculated for C8H16Cl2N2O8Pt: C 17.99, H 3.02, N 5.24, Pt 
36.52 %. Found: C 17.67, H 3.25, N 5.32, Pt 36.25 %. 
 
4.6.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
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pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 2 showed a 
retention time of 6.33 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.9). 
 
 
Figure 4.9: ESI-MS spectrum of complex 2, prepared in ultrapure water 
 
In the ESI-MS spectrum reported in Figure 4.9, registered in positive ion mode 
with a CV of 30V, the presence of complex 2 is confirmed by the peaks of the 
pseudo-molecular ion [M+H]
+
 at 535.3 m/z and of its fragment [M-
O2C(CH2)2CO2H]
+
 at 417.3 m/z. 
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Figure 4.10: 
1
H-NMR spectrum of complex 2, registered in D2O 
 
The 
1
H-NMR (400 MHz, D2O) spectrum of complex 2 shows the following 
signals, δ: 2.59 (t, 4H, -CH2CO2H, 
3
J = 6.22 Hz), 2.69 (t, 4H, -CH2CO2, 
3
J = 
6.22 Hz) ppm. 
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Figure 4.11: 
13
C-NMR spectrum of complex 2, registered in D2O 
 
The 
13
C-NMR (100.6 MHz, D2O) spectrum of complex 2 shows the following 
signals, δ: 29.8 (-CH2CO2H), 30.3 (-CH2CO2), 177.7 (-COOH), 181.8 (-OCO) 
ppm. 
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Figure 4.12: 
195
Pt-NMR spectrum of complex 2, registered in D2O 
 
Figure 4.12 shows the 
195
Pt-NMR spectrum of complex 2. It was registered in 
D2O (at a 86.0 MHz NMR frequency) and it shows a signal at 1074 ppm (qt, 
1
J 
= 189.42 Hz), which is consistent with a Pt(IV) complex with two chlorides, two 
amines and two carboxylato ligands. Also in this case, the multiplicity and the 
broadness of the signal are due to the coupling of 
195
Pt with quadrupolar 
14
N. 
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4.7 Synthesis of the Activated N-hydroxysuccinimidyl Diester of 2 
(3) 
 
 
 
A mixture of 2 (100 mg, 0.187 mmol), N,N’-dicyclohexylcarbodiimide (DCC, 
85.0 mg, 0.412 mmol) and N-hydroxysuccinimide (NHS, 47.4 mg, 0.412 mmol) 
in anhydrous DMF was stirred at 0 °C for 1 hour and then overnight at room 
temperature. After that, the solution was cooled to -18 °C and the byproduct 
dicyclohexylurea was removed by filtration. DMF was eliminated under reduced 
pressure to form a brown oil. The compound was then precipitated with diethyl 
ether, yielding a pale yellow solid. 
Yield: 97.6 mg, 0.134 mmol, 71.6%. 
Elemental analysis calculated for C16H22Cl2N4O12Pt: C 26.38, H 3.04, N 7.69, Pt 
26.78 %. Found: C 26.17, H 3.37, N 7.39, Pt 26.51 %. 
 
4.7.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
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composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 3 showed a 
retention time of 5.71 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.13). 
 
 
 
Figure 4.13: ESI-MS spectrum of complex 3, prepared in a 50:50 mixture of ultrapure water and 
methanol 
 
Figure 4.13 shows the ESI-MS spectrum of complex 3, registered in positive ion 
mode with a cone voltage of 30V: the pseudo-molecular ion [M+H]
+
 at 729.2 
m/z and the adduct [M+Na]
+
 at 751.2 m/z can be observed. 
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1
H-NMR 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of complex 3 shows the 
following signal, δ: 2.64 (t, 4H, -CH2CO2N, 
3
J = 7.15 Hz), 2.81 (s, 8H, -
CH2CON), 2.82 (t, 4H, -CH2CO2, 
3
J = 7.15 Hz), 6.47 (m, 6H, -NH3) ppm. 
 
13
C-NMR 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 3 shows the 
following signals, δ: 25.7 (-CH2CO2N), 25.9 (-CH2CON), 27.2 (-CH2CO2), 
168.9 (-COON), 170.7 (-CON), 178.6 (-OCO) ppm. 
 
195
Pt-NMR 
 
Figure 4.14: 
195
Pt-NMR spectrum of complex 3, registered in DMSO-d6 
 
The complex 3 
195
Pt-NMR spectrum (Figure 4.14) was registered in DMSO-d6 
(at a 107.2 MHz NMR frequency) and shows a signal corresponding to a 
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chemical shift value of 1216 ppm, which is consistent with a Pt(IV) complex 
with two chlorides, two amines and two carboxylato ligands. 
 
4.8 Synthesis of (OC-6-33)-diamminebis(4-oxo-4-
(propylamino)butanoato)dichloridoplatinum(IV) (4) 
 
 
 
To a solution of 3 (50.0 mg, 0.0686 mmol) in 4 mL of anhydrous DMF, 
propylamine (56.7 μL, 0.686 mmol) was added and the mixture was stirred at 
room temperature for 24 hours.. The yellow solution was then cooled to -18 °C 
and then filtrated. The solvent was eliminated under reduced pressure and, 
during this phase, a pale yellow solid was formed and it was washed with 
diethyl ether. The product was washed with cool acetonitrile and diethyl ether 
and then dried in vacuo. 
Yield: 33.4 mg, 0.0542 mmol, 78.9%. 
Elemental analysis calculated for C14H30Cl2N4O6Pt: C 27.28, H 4.91, N 9.09, Pt 
31.65 %. Found: C 27.00, H 4.71, N 9.31, Pt 31.91 %. 
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4.8.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 4 showed a 
retention time of 9.06 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.15). 
 
 
Figure 4.15: ESI-MS spectrum of complex 4, prepared in a 50:50 mixture of ultrapure water and 
methanol 
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In the ESI-MS spectrum reported in Figure 4.15, registered in positive ion mode 
with a cone voltage of 30V, the presence of complex 4 is confirmed by the 
peaks of the pseudo-molecular ion [M+H]
+
 at 617.3 m/z, of the adduct [M+Na]
+
 
at 639.3 m/z and of the fragment [M-O2C(CH2)2CONH(CH2)2CH3]
+
 at 458.2 
m/z. 
 
1
H-NMR 
 
Figure 4.16: 
1
H-NMR spectrum of complex 4, registered in DMSO-d6 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of complex 4 (Figure 4.16) 
shows the following signals, δ: 0.83 (t, 6H, -CH2CH2CH3,
 3
J = 7.12 Hz), 1.39 
(sext, 4H, -CH2CH2CH3, 
3
J = 7.12 Hz), 2.26 (t, 4H, -CH2CON, 
3
J = 7.28 Hz), 
2.43 (t, 4H, -CH2CO2, 
3
J = 7.28 Hz), 2.98 (q, 4H, -CH2CH2CH3, 
3
J = 7.12 Hz), 
6.49 (m, 6H, -NH3), 7.78 (t, 2H, -NH, 
3
J = 5.20 Hz) ppm. 
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Figure 4.17: 
13
C -NMR spectrum of complex 4, registered in DMSO-d6 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 4 (Figure 4.17) 
shows the following signals, δ: 11.4 (-CH2CH2CH3), 22.3 (-CH2CH2CH3), 31.4 
(-CH2CON and -CH2CO2), 40.3 (-CH2CH2CH3), 171.1 (-CON), 180.0 (-OCO) 
ppm. 
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Heteronuclear Single Quantum Correlation (HSQC)-NMR 
 
Figure 4.18: hsqc -NMR spectrum of complex 4, registered in DMSO-d6 
 
The HSQC-NMR spectrum (Figure 4.18) allows to correctly assign the 
13
C 
signals, in particular the one at 31.4 ppm: in fact, it is possible to verify that the 
two methylenic groups of the succinate have the same chemical shift, at 31.4 
ppm. 
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Figure 4.19: 
195
Pt-NMR spectrum of complex 4, registered in DMSO-d6 
 
In Figure 4.19 the 
195
Pt-NMR spectrum of complex 4 is reported. It was 
registered in DMSO-d6 (at a 107.2 MHz NMR frequency) and shows a signal at 
1217 ppm, which is consistent with a Pt(IV) complex containing two chlorides, 
two amines and two carboxylato ligands. In this case, the signal has a very 
similar chemical shift to that observed for complex 3: in fact, the axial 
carboxylato of 3 and 4 show little differences in the chain but far from the 
platinum core, which results less affected. 
 
4.9 Synthesis of Conjugate 5a 
 
The synthesis of the conjugates was set up using NPs a because of its higher 
manageability and then the procedures were applied to the other NPs samples 
(b-d). 
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At first, the synthetic procedure was carried out using different reaction times 
(1, 2, 4 and 24 hours) in order to evaluate the best time necessary to reach the 
highest Pt loading on NPs. When the appropriate reaction time was found, it was 
fixed and applied to all the other conjugates syntheses (5b-5d). 
In particular, 1 mL of an ethanol suspension of NPs a (35.0 mg) was centrifuged 
(10 minutes, 10000 rpm) in order to separate and remove ethanol. Then the NPs 
were washed with anhydrous DMF and, finally, resuspended in this solvent. 
This suspension was added to a solution of the activated intermediate 3 (10-fold 
molar excess with respect to NPs amino groups) and the reaction was carried out 
for different periods of time (1, 2, 4 and 24 hours) at room temperature. 
After the established time, the suspension was centrifuged (10 minutes, 10000 
rpm) in order to separate the solution (containing the unreacted Pt(IV) complex) 
from the NPs. These latter were washed several times with ethanol, in order to 
remove DMF and the residual coupling reagents. The reaction product was then 
divided into two aliquots: the former was kept as an ethanol suspension and the 
latter was washed with ultrapure water, frozen by means of liquid nitrogen and 
then lyophilized. 
The suspension was used for SEM, DLS, and ζ potential analyses and for the 
biological tests. 
The lyophilized sample, instead, was employed for the microwave 
mineralization, in order to quantify the amount of Pt loaded on the conjugates. 
Initially the lyophilization was employed also for dimensional analyses but, 
once lyophilized, the sample was impossible to be resuspended in solution: this 
result was confirmed also by SEM micrographs. 
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4.9.1 Characterization of Conjugate 5a 
 
  
Figure 4.20: SEM micrographs of a) lyophilized and b) not lyophilized conjugate 5a 
 
SEM micrographs of conjugate 5a allow to observe two main events. At first, 
the lyophilization, since it completely dries the sample, leads to irreversible 
aggregation of the NPs (Figure 4.20a): also the sonication does not allow to 
resuspend the conjugate. For this reason, this technique cannot be employed for 
size measurements and biological tests because they require stable suspensions. 
Figure 4.20b shows the cross-links between nearby NPs, due to the fact that a 
difunctional complex can exploit the first functionality for the coupling with an 
amino group of a nanoparticle and the second functionality for the reaction with 
a -NH2 group of another nanoparticle. It results, therefore, in the formation of 
stable NPs aggregates. 
  
a) b) 
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4.9.2 Quantification of Pt Loading on Conjugate 5a 
 
The Pt loading of the conjugates was determined by means of ICP-MS, after 
microwave mineralization. This method consisted in an acid digestion of each 
conjugate (2-3 mg) in quartz cuvettes that were then put into a closed vessel in 
the microwave oven. For the digestion, 800 μL of 70% w/w nitric acid and 200 
μL of 35% w/w hydrogen peroxide in water were used. The microwaves (1200 
W) were applied for 45 minutes, with the temperature set at 200 °C, using a 
temperature-controlled microwave heating. 
When the mineralization was completed, the vessel was cooled down to room 
temperature and then opened to pull out the cuvettes, whose content was 
transferred into a marked flask using 1% v/v HNO3 and sonicated for 1 hour at 
60 °C. The samples were then centrifuged (10 minutes, 10000 rpm) in order to 
separate the silica residue from the solution, which was properly diluted with 
1% v/v HNO3 and analyzed by means of ICP-MS. 
Table 4.5 summarizes the Pt loadings of 5a (expressed as the percentage of Pt 
moles respect to the to the total available amino groups moles). The results point 
out that the highest loading was reached within 4 hours. This reaction time, 
therefore, was fixed and applied for the syntheses of conjugates 5b-5d. 
reaction time conjugate % Pt loading 
1 h 
5a 
26.09 (± 1.78) 
2 h 23.76 (± 0.72) 
4 h 26.70 (± 1.64) 
24 h 25.61 (± 2.98) 
Table 4.5: Pt loadings of conjugate 5a at different reaction time (at fixed Pt/amino groups ratio, 
10:1) 
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4.10 Synthesis of Conjugates 5b-5d 
 
Conjugates 5b-5d were synthesized by using the same synthetic procedure 
previously described. In particular, an ethanol suspension of nanoparticles (NPs 
b 20.6 mg, NPs c 12.8 mg, NPs d 13.67 mg in 1 mL of solvent) was centrifuged 
(10 minutes, 10000 rpm) to remove the solvent. Then the solid residue was 
washed with anhydrous DMF and, finally, resuspended in this solvent. This 
suspension was added to a solution of complex 3 (10:1 Pt/amino groups ratio) 
and the reaction was performed for 4 hours at room temperature. 
Each suspension was then centrifuged (10 minutes, 10000 rpm) to remove the 
solvent and the NPs were washed several times with ethanol. An aliquot of the 
synthesized conjugates was kept as an ethanol suspension and another one was 
washed with ultrapure water, frozen with liquid nitrogen and then lyophilized. 
After the mineralization (described in paragraph 4.9.2), each sample was 
analyzed by means of ICP-MS. The final results are the mean of at least three 
replicates. 
In Table 4.6 the Pt loadings of conjugates 5b-5d (together with the one of 5a, as 
a comparison) are reported: all the samples show values higher than 25%, with 
respect to the total amino groups, and, in particular, it seems that the smaller the 
employed NPs, the higher the Pt loading. 
reaction time conjugate % Pt loading 
4 h 
5a 26.70 (± 1.64) 
5b 29.22 (± 2.10) 
5c 35.87 (± 3.28) 
5d 35.53 (± 4.65) 
Table 4.6: Pt loadings of conjugates 5a-5d at fixed reaction time (4 hours) and Pt/amino groups 
ratio (10:1) 
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4.10.1 Characterization of Conjugates 5b-5d 
 
The SEM micrograph of the lyophilized conjugates showed large aggregates (a 
magnification of an area was reported in order to observe the NPs aggregation), 
whereas those of not lyophilized conjugates pointed out the cross-links 
formation between nearby NPs. Figure 4.21 shows the SEM micrographs 
obtained from lyophilized (a) and not lyophilized (b) conjugate 5b. 
 
  
Figure 4.21: SEM micrographs of a) lyophilized and b) not lyophilized conjugate 5b. In the first 
one, a magnification of an area is reported in order to point out the NPs aggregation 
 
The use of difunctionalized complexes, therefore, results to be not suitable for 
the following biological tests because an unstable suspension can precipitate in 
the culture medium, giving no reliable and consistent results. Moreover, too 
large conjugates are not useful for the exploitation of the EPR effect, typical of 
the tumor tissues. Therefore, the following platinum syntheses were focused on 
Pt(IV) complexes, whose axial ligands show one inert functionality (in this case, 
an ethanolato) and one functionalizable group, which should avoid the formation 
of aggregates between NPs. 
 
a) b) 
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4.11 Synthesis of (OC-6-44)-
diamminedichloridoethanolatohydroxidoplatinum(IV) (6) 
 
 
To a mixture of cisplatin (120 mg, 0.400 mmol) in 150 mL of absolute ethanol, 
an hydrogen peroxide solution (50% w/w in H2O, 3 mL) was added dropwise. 
The solution was stirred at 70 °C for 5 hours and then cooled to room 
temperature. The unreacted cisplatin was removed by centrifugation and the 
solvent was eliminated under reduced pressure. The compound was precipitated 
with diethyl ether, yielding a yellow solid, which was washed with cool ethanol 
and diethyl ether and then dried in vacuo. 
Yield: 116 mg, 0.320 mmol, 80.0%. 
Elemental analysis calculated for C2H12Cl2N2O2Pt: C 6.63, H 3.34, N 7.74, Pt 
53.87%. Found: C 6.41, H 3.67, N 7.91, and Pt 53.78%. 
 
4.11.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 6 showed a 
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retention time of 4.56 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.22). 
 
 
Figure 4.22: ESI-MS spectrum of complex 6, prepared in ultrapure water 
 
In Figure 4.22 the ESI-MS spectrum, registered in negative ion mode with a 
cone voltage of 20V, confirms the presence of complex 6 with the pseudo-
molecular ion [M-H]
-
 peak at 361.0 m/z. 
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1
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Figure 4.23: 
1
H-NMR spectrum of complex 6, registered in DMSO-d6 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of complex 6 shows the 
following signals, δ: 1.04 (t, 3H, –CH3, 
3
J = 6.89 Hz), 3.53 (q, 2H, –CH2, 
3
J = 
6.89 Hz), 5.43 (m, 6H, –NH3) ppm. 
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Figure 4.24: 
13
C-NMR spectrum of complex 6, registered in DMSO-d6 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 6 shows the 
following signals, δ: 18.6 (–CH3), 64.9 (–CH2) ppm. 
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Figure 4.25: 
195
Pt-NMR spectrum of complex 6, registered in DMSO-d6 
 
The 
195
Pt-NMR spectrum of complex 6 (Figure 4.25) was registered in DMSO-
d6 (at a 107.2 MHz NMR frequency) and shows a signal at 949 ppm, which is 
consistent with a Pt(IV) complex with an alcoxydo, two chlorides, two amines 
and a hydroxido ligand. 
 
4.12 Synthesis of (OC-6-44)-diammine(4-
carboxypropanoato)dichloridoethanolatoplatinum(IV) (7) 
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Complex 7 was synthesized according to slight modifications of a literature 
procedure [8]. In particular, succinic anhydride (66.3 mg, 0.663 mmol) was 
added dropwise to a solution of 6 (120 mg, 0.331 mmol) in anhydrous DMF. 
The reaction mixture was stirred at 40 °C overnight. The resulting yellow 
solution was filtered to remove possible unreacted starting material and then 
DMF was eliminated under reduced pressure. The subsequent addition of 1 mL 
of cool acetone led to the precipitation of a yellow solid, which was washed with 
diethyl ether and then dried in vacuo. 
Yield: 93.4 mg, 0.202 mmol, 61.0%. 
Elemental analysis calculated for C6H16Cl2N2O5Pt: C 15.59, H 3.49, N 6.06, Pt 
42.21%. Found: C 15.36, H 3.30, N 6.22, and Pt 42.10%. 
 
4.12.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 7 showed a 
retention time of 7.91 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.26). 
 
99 
 
 
Figure 4.26: ESI-MS spectrum of complex 7, prepared in ultrapure water 
 
Figure 4.26 shows the ESI-MS spectrum of complex 7, registered in negative 
ion mode with a CV of 30V, containing the pseudo-molecular ion [M-H]
-
 peak 
at 460.8 m/z. 
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Figure 4.27: 
1
H-NMR spectrum of complex 7, registered in DMSO-d6 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of complex 7 shows the 
following signals, δ: 1.04 (t, 3H, –CH3, 
3
J = 6.89 Hz), 2.37 (m, 2H, –CH2CO2H), 
2.40 (m, 2H, –CH2CO2), 3.40 (q, 2H, –OCH2, 
3
J = 6.89 Hz), 5.84 (m, 6H, –NH3) 
ppm. 
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Figure 4.28: 
13
C-NMR spectrum of complex 7, registered in DMSO-d6 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 7 shows the 
following signals, δ: 17.2 (–CH3), 30.7 (–CH2CO2H), 32.1 (–CH2CO2), 67.0 (–
OCH2), 174.5 (–COOH), 180.5 (–OCO) ppm. 
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195
Pt-NMR 
 
Figure 4.29: 
195
Pt-NMR spectrum of complex 7, registered in DMSO-d6 
 
Figure 4.29 shows the 
195
Pt-NMR spectrum of complex 7 in DMSO-d6 (at a 
107.2 MHz NMR frequency). It is possible to observe a signal with a chemical 
shift value of 1000 ppm, consistent with a Pt(IV) complex with an alkoxydo, 
two chlorides, two amines and a succinato ligand. 
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4.13 Synthesis of the Activated N-hydroxysuccinimidyl Ester of 7 
(8) 
 
 
 
A mixture of 7 (90.0 mg, 0.195 mmol), DCC (48.2 mg, 0.234 mmol) and NHS 
(26.9 mg, 0.234 mmol) in anhydrous DMF was stirred at 0 °C for 1 hour and 
then at room temperature overnight. To remove dicyclohexylurea, the solution 
was cooled to -18 °C and, subsequently, filtered. DMF was eliminated under 
reduced pressure to form a brown oil. The compound was then precipitated with 
diethyl ether, yielding a pale yellow solid. 
Yield: 73.9 mg, 0.132 mmol, 67.9%. 
Elemental analysis calculated for C10H19Cl2N3O7Pt: C 21.48, H 3.42, N 7.51, Pt 
34.88%. Found: C 21.26, H 3.31, N 7.72, and Pt 35.01%. 
 
4.13.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
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composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 8 showed a 
retention time of 6.26 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.30). 
 
 
 
Figure 4.30: ESI-MS spectrum of complex 8, prepared in a 50:50 mixture of ultrapure water and 
methanol 
 
In the ESI-MS spectrum reported in Figure 4.30, registered in positive ion mode 
with a cone voltage of 30V, the presence of complex 8 is confirmed by the 
pseudo-molecular ion [M+H]
+
 peak at 560.2 m/z and by the peaks of the adduct 
[M+Na]
+
 at 582.2 m/z and the fragment [M-OCH2CH3]
+
 at 514.2 m/z. 
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1
H-NMR 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of complex 8 shows the 
following signals, δ: 1.04 (t, 3H, –CH3, 
3
J = 6.59 Hz), 2.55 (t, 2H, –CH2CO2N, 
3
J = 6.96 Hz), 2.76 (t, 2H, –CH2CO2, 
3
J = 6.96 Hz), 2.80 (s, 4H, –CH2CON), 
3.40 (q, 2H, –OCH2, 
3
J = 6.59 Hz), 5.85 (m, 6H, –NH3) ppm. 
 
13
C-NMR 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 8 shows the 
following signals, δ: 17.2 (–CH3), 25.9 (–CH2CON), 27.6 (–CH2CO2N), 31.2 (–
CH2CO2), 67.1 (–OCH2), 170.7 (–CON), 174.4 (–COON), 179.0 (–OCO) ppm. 
 
195
Pt-NMR 
 
Figure 4.31: 
195
Pt-NMR spectrum of complex 8, registered in DMSO-d6 
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The 
195
Pt-NMR spectrum of complex 8 (Figure 4.31) was registered in DMSO-
d6 (at a 107.2 MHz NMR frequency) and shows a signal with a chemical shift 
value of 997 ppm, which is consistent with a Pt(IV) complex with an alkoxydo, 
two chlorides, two amines and a carboxylato ligand. 
 
4.14 Synthesis of (OC-6-44)-diamminedichloridoethanolato(4-oxo-
4-(propylamino)butanoato)platinum(IV) (9) 
 
 
 
To a solution of 8 (50.0 mg, 0.0894 mmol) in anhydrous DMF, propylamine 
(36.9 μL, 0.447 mmol) was added and the mixture was stirred at room 
temperature overnight. The solution was filtered and then the solvent was 
removed under reduced pressure to form a yellow-brown oil. The subsequent 
recrystallization of the product with ethanol/diethyl ether led to the precipitation 
of a pale-yellow solid. The product was dried in vacuo. 
Yield: 36.1 mg, 0.0717 mmol, 80.2%. 
Elemental analysis calculated for C9H23Cl2N3O4Pt: C 21.48, H 4.61, N 8.35, Pt 
38.76 %. Found: C 21.26, H 4.45, N 8.74, and Pt 38.88 %. 
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4.14.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 9 showed a 
retention time of 9.71 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 4.32). 
 
 
Figure 4.32: ESI-MS spectrum of complex 9, prepared in a 50:50 mixture of ultrapure water and 
methanol 
 
In the ESI-MS spectrum reported in Figure 4.32, registered in positive ion mode 
with a cone voltage of 30V, the presence of complex 9 is confirmed by the 
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pseudo-molecular ion [M+H]
+
 peak at 504.3 m/z and the peaks of the adduct 
[M+Na]
+
 at 526.3 m/z and the fragment [M-OCH2CH3]
+
 at 458.3 m/z. 
 
1
H-NMR 
 
Figure 4.33: 
1
H-NMR spectrum of complex 9, registered in DMSO-d6 
 
The 
1
H-NMR (400 MHz, DMSO-d6) spectrum of complex 9 shows the 
following signals, δ: 0.83 (t, 3H, -CH2CH2CH3, 
3
J = 7.08 Hz), 1.04 (t, 3H, -CH3, 
3
J = 6.96 Hz), 1.39 (sext, 2H, -CH2CH2CH3, 
3
J = 7.08 Hz), 2.26 (t, 2H, -
CH2CON, 
3
J = 6.96 Hz), 2.36 (t, 2H, -CH2CO2, 
3
J = 6.96 Hz), 2.98 (q, 2H, -
CH2CH2CH3, 
3
J = 7.08 Hz), 3.40 (q, 2H, -OCH2, 
3
J = 6.96 Hz), 5.88 (m, 6H, -
NH3), 7.77 (t, 1H, -NH, 
3
J = 5.49 Hz) ppm. 
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13
C-NMR 
 
Figure 4.34: 
13
C-NMR spectrum of complex 9, registered in DMSO-d6 
 
The 
13
C-NMR (100.6 MHz, DMSO-d6) spectrum of complex 9 shows the 
following signals, δ: 12.0 (-CH2CH2CH3), 17.3 (-CH3), 22.9 (-CH2CH2CH3), 
32.4 (-CH2CON and -CH2CO2), 40.9 (-CH2CH2CH3), 67.1 (-OCH2), 172.3 (-
CON), 181.2 (-OCO) ppm. 
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195
Pt-NMR 
 
Figure 4.35: 
195
Pt-NMR spectrum of complex 9, registered in DMSO-d6 
 
In Figure 4.35 the 
195
Pt-NMR spectrum of complex 9, registered in DMSO-d6 
(at a 86.0 MHz NMR frequency), is reported. It showed a signal at 1006 ppm, 
which is consistent with a Pt(IV) complex with an alkoxydo, two chlorides, two 
amines and a carboxylato ligand. 
 
4.15 Synthesis of Conjugates 10a-10d 
 
As previously described for the synthesis of conjugates 5a-5d, an ethanol 
suspension of each kind of nanoparticles (NPs a 35.0 mg, NPs b 20.6 mg, NPs c 
12.8 mg, NPs d 13.67 mg in 1 mL of solvent) was centrifuged (10 minutes, 
10000 rpm), then washed with anhydrous DMF and, finally, resuspended in this 
solvent. After changing the reaction time (1, 2, 4 and 24 hours) for the coupling 
of NPs a with the Pt(IV) complex to find the best condition, the suspension of 
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NPs b-d was added to a solution of the activated intermediate 8. At first, the 
Pt/NPs amino groups ratio and the reaction time was fixed at 10:1 and at 4 hours 
(at room temperature) respectively. Then, the Pt/NPs ratio was fixed at 5:1 in 
order to reduce the amount of Pt(IV) complex used in the coupling reaction, 
whereas the time was fixed at 4 hours. 
After the established time, the suspension was centrifuged (10 minutes, 10000 
rpm) in order to separate the supernatant (containing the unreacted Pt(IV) 
complex) from the NPs. These latter were washed several times with ethanol. 
The reaction product was then divided into two aliquots: the former was kept as 
an ethanol suspension and the latter was washed with ultrapure water, frozen 
with liquid nitrogen and then lyophilized. 
 
4.15.1 Characterization of Conjugates 10a-10d 
 
  
Figure 4.36: SEM micrographs of a) lyophilized and not lyophilized conjugate 10b 
 
The SEM micrographs of conjugates 10a-10d show large aggregates (Figure 
4.36a), due to the lyophilization process (the lyophilized conjugates cannot be 
resuspended). On the contrary, without lyophilization aggregates are not formed 
a) b) 
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(Figure 4.36b): in fact, the presence of only one available functionality avoids 
the formation of cross-links between NPs and made the suspension more stable. 
For this reason, the monofunctionalizable complexes were chosen for further 
studies, whereas the difunctionalizable ones were abandoned. 
 
4.15.2 Quantification of Pt Loading on 10a-10d 
 
After the mineralization of the lyophilized conjugates (described in paragraph 
4.9.2), each sample was analyzed by means of ICP-MS to determine the Pt 
loading. The data were the results of at least three replicates, were expressed as 
% respect to the total available amino groups) and are shown in Table 4.7. In 
particular, on the left side it is possible to observe the Pt loading of 10a at 
different reaction times: as in the case of conjugate 5a, the highest percentage of 
loading was reached within 4 hours. The right side of the table, instead, reports 
the Pt loadings get after fixed coupling time (4 hours) with two different Pt/NPs 
amino groups ratio: in the left column the usual 10:1 ratio is indicated, whereas 
the right column refers to the 5:1 ratio. From the analysis of these data, it is 
evident that there are no significant differences between the two sets of results 
and, therefore, the 10:1 ratio does not lead to a considerable loading increase. 
Moreover, as conjugates 5a-5d (paragraph 4.10), the smaller the NPs the higher 
the Pt loading. 
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conjugate 
10:1 
Pt/NH2 ratio conjugate 
 
10:1 
Pt/NH2 ratio 
5:1 
Pt/NH2 ratio 
reaction 
time 
% Pt loading 
reaction 
time 
% Pt loading % Pt loading 
10a 
1 h 16.51 (± 1.22) 10a 
4 h 
24.71 (± 3.61) 19.96 (± 0.11) 
2 h 15.91 (± 0.94) 10b 21.65 (± 2.06) 21.62 (± 2.17) 
4 h 24.71 (± 3.61) 10c 24.27 (± 1.88) 28.15 (± 1.06) 
24 h 23.77 (± 1.12) 10d 32.38 (± 1.45) 33.37 (± 2.17) 
Table 4.7: Pt loadings (respect to the total amino groups) of conjugate 10a at different reaction 
time (left) and Pt loadings of conjugates 10a-10d at fixed reaction time and with different 
Pt/NH2 ratio (right) 
 
4.16 Spontaneous Release of Platinum from Conjugates 
 
In order to verify the drug release from the NPs, in particular, 2-3 mg of each 
lyophilized conjugate were suspended in 3 mL of ultrapure water and the 
suspension was magnetically stirred for 4 hours (it corresponded to the time 
employed for cellular accumulation experiments). The suspension was then 
centrifuged (10 minutes, 10000 rpm) to separate the solution from the NPs and 
the platinum released in the solution was measured by means of ICP-MS. 
The test showed that, within 4 hours, the 15% of the Pt loaded on NPs 
(percentage calculated with respect to the total Pt loaded on the conjugate) was 
released. Moreover, the RP-HPLC-ESI-MS analysis allowed to identify the 
main species released from the NPs surface: it corresponds to complex 7 linked, 
via amidic bond, to the 3-aminopropylsilane (APS) arm (defined as 7-APS, 
Figure 4.37), detached from the NPs due to the hydrolysis of Si-O-Si bonds. 
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Figure 4.37: Structural formula of the main species released from the NPs surface 
 
 
Figure 4.38: ESI-MS spectrum which allowed to identify the main released species 7-APS 
 
The structure of 7-APS is confirmed by its ESI-MS spectrum (Figure 4.38), 
registered in negative ion mode with a cone voltage of 30V. It shows two peaks 
with the platinum pattern at 580.2 m/z and 643.3 m/z, which can be attributed to 
the pseudo-molecular ion [M-H]
-
 and the adduct [M+NO3]
-
, respectively, of 7-
APS (Figure 4.37). The correct attribution of the two peaks is confirmed by 
their simulations, reported in Figures 4.39 and 4.40. 
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Figure 4.39: MS simulation of the pseudo-molecular ion [M-H]
-
 
 
 
Figure 4.40: MS simulation of the adduct [M+NO3]
-
 
 
The observed behavior is justified by the detachment of the amino groups from 
the NPs surface, due to the hydrolysis of Si-O-Si bonds [9, 10, 11, 12]. This 
hydrolysis seems to depend on the chain length of the organic linker: APTMS, 
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in fact, have a primary amine at the end of a propyl chain, which can catalyze 
the hydrolysis of siloxane bonds both intra- and intermolecularly (Figure 4.41). 
In particular, intramolecular catalysis is achieved via the formation of stable 
five-membered cyclic intermediates [13], causing the loss of the APS. 
Moreover, the detachment can be induced by nearby amino groups 
(intermolecular catalysis) and, for this reason, the loss of not coupled APS arms 
or 7-APS may occur: in this latter case, this justifies the observed release in 
aqueous solution. 
 
 
Figure 4.41: Representation of the intra- and intermolecularly catalyzed hydrolysis of siloxane 
bonds. The picture was slightly modified by literature [13] 
 
The subsequent target was to evaluate the behavior of the conjugates in the 
presence of reducing agents (such as ascorbic acid, glutathione, etc.): in fact, to 
the spontaneous detachment, the Pt release due to the so-called “activation by 
reduction” must be added. In this latter case, however, the released complex 
should be cisplatin. 
 
4.17 The Mechanism of Action of the Pt(IV) Complexes: the 
Activation by Reduction 
 
The most accredited intracellular mechanism by which Pt(IV) complexes exert 
their antitumor effects, as described in paragraph 2.5, is the activation by 
reduction (Figure 4.42). 
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Figure 4.42: Schematic representation of the “activation by reduction”. The picture is adapted 
from literature [14] 
 
The selective reduction can be justified by the fact that the tumor is hypoxic (i.e. 
oxygen deficient) because of its continuous and uncontrolled growth and, 
therefore, there is not a sufficient supply of nutrients and the tumor site is more 
reducing than a healthy one. 
Into a neoplastic cell, several reducing agents (which show a higher 
concentration with respect to extracellular fluids) can activate a Pt(IV) complex 
and, among them, ascorbic acid and reduced glutathione (GSH) can be 
mentioned (Figure 4.43). 
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Figure 4.43: Structural formulas of the two main reducing agents present in a tumor cell (i.e. 
ascorbic acid and GSH). The groups involved in the activation reaction of a Pt(IV) complex are 
highlighted 
 
The reduction mechanism of Pt(IV) complexes has been the subject of many 
studies and it is still not completely clear. Both mechanisms of “outer sphere” 
and “inner sphere” were invoked. In particular, the latter is based on the 
formation of bonds between an equatorial chloride ligand of the Pt complex and 
a specific functionality of the reducing agent: -OH for the ascorbic acid and -SH 
for glutathione (Figure 4.43). 
Other researchers have proposed a reductive process, divided into two stages: 
during the first phase a reduction which involves an electron occurs leading to a 
Pt(III) species and an ascorbate radical, whereas in the second step a further 
reduction occurs, by using a single electron, to give rise to a Pt(II) compound. 
Other studies showed that the Pt(IV) complexes that present equatorial chloride 
ligands in trans each other, by reacting with ascorbic acid, favor the mechanism 
involving the inner sphere forming Pt(II) compounds in which the chloride 
ligands have been replaced by those which were previously the axial ligands. 
The presence of chlorides in cis position, however, provides the outer sphere 
mechanism, with the formation of a product with equatorial chloride ligands 
[15]. 
A similar behavior can be observed for GSH. 
It is not possible to define a precise mechanism for the reduction of each 
complex and, for this reason, it is possible only to make assumptions. What is 
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certain is that, if the reduction process involves the inner sphere, the ease of 
bonds rupture and formation is essential to allow a reaction to occur and the 
reagents steric hindrance plays an important role. The reduction potential gives 
only a thermodynamics information but the reaction kinetics is very important. 
It was experimentally verified that complexes containing hydroxido or chloride 
groups are faster reduced than those containing amines and carboxylates. This 
seems to be related to their ability to form bonds with the reductants. Moreover, 
when a good leaving ligand is in trans position to this “bridge” the reduction is 
faster. 
 
4.17.1  Study of the Reduction Process of the Synthesized Pt(IV) 
Complexes 
 
The reduction kinetics was studied for (OC-6-44)-diammine(4-
carboxypropanoato)dichloridoethanolatoplatinum(IV) (7) and (OC-6-44)-
diamminedichloridoethanolato(4-oxo-4-(propylamino)butanoato)platinum(IV) 
(9). 
The former is the complex coupled on the NPs, whereas the latter was chosen as 
a model of the conjugate itself. 
Among the possible bioreductants, L(+) ascorbic acid and L-reduced glutathione 
(GSH) were chosen to perform the reduction studies. 
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4.17.1.1 Reduction Kinetics of Complex 7 
4.17.1.2 Study of the Behavior with L(+) Ascorbic Acid 
 
A 1 mM solution of complex 7, in a 2 mM aqueous solution of HEPES buffer 
(pH 7.5), was prepared and then diluted with methanol to obtain a final 0.5 mM 
Pt concentration. 
L(+) ascorbic acid, in a molar ratio 10:1 with respect to 7, was then added. This 
addition must be rapid and immediately followed by the HPLC-MS analysis, 
which allowed to study the reduction process for about 16 hours, with a 
measurement every 30 minutes, at 37 °C and employing a mobile phase 
consisting of a 50/50 methanol/15 mM formic acid mixture. The stationary 
phase was, in this case, a C18 Phenomenex Gemini
®
 column 5 μm, 250 × 3.00 
mm ID. 
The chromatograms (Figure 4.44) show that the reducing agent peak has a 
retention time of 2.90 minutes and, therefore, does not interfere with the peak of 
the complex, which has a retention time of 3.78 minutes. 
After all the measurements, the chromatograms were analyzed to get the peak 
area of the complex signal: its decrease over time is indicative of the progressive 
reduction by ascorbic acid (Figure 4.44). 
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Figure 4.44: Chromatograms of complex 7 in presence of ascorbic acid, registered during the 
reduction process 
 
In addition, it is possible to observe the increase of an additional peak, near the 
one of the reducing agent (at 2.67 minutes). By examining the ESI-MS spectra 
registered during the reduction process, it is possible to observe the formation of 
a series of reduction products: cisplatin derivatives (all Pt(II) compounds), 
including some Pt(II) species in which the axial ligands have been coordinated 
instead of the equatorial ligands, as already reported by Gibson for other 
complexes [15]. 
Then the data analysis was carried out, by calculating the normalized areas and 
the corresponding natural logarithm values for a pseudo-first order kinetic 
analysis. 
The graph reported in Figure 4.45 shows the natural logarithm of the peak 
normalized area as a function of time. 
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Figure 4.45: Decrease of the chromatographic peak area of 7 during the reduction with ascorbic 
acid. In particular, the results of one of the three independent replicates are reported 
 
The data were processed with the initial rate method: the first 420 minutes were 
considered and the values in this range were fitted by a line of generic equation 
y = A + Bx (in Figure 4.45, A = 0.01544 and B = 0.00122), the slope of which 
represents the kinetic constant, k. 
Then it was possible to proceed with the determination of the half-life time t½ 
by using the following equation: 
  
  
  
   
 
 
 
Three independent samples of the same complex 7 were analyzed in triplicate. 
After the processing of the results, it was verified that the reduction of complex 
7 had an average half-life time of 9.36 (± 0.57) hours. 
 
 
 
 
y = 0.01544 + 0.00122x 
R
2
 = 0.997 
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4.17.1.3 Study of the Behavior with L-Reduced Glutathione (GSH) 
 
The sample of complex 7 was prepared according to the same procedure applied 
in the case of ascorbic acid (see paragraph 4.17.1.2). 
The reducing agent was eluted at 3.08 minutes giving no interferences to the 
complex, which had, instead, a retention time of 3.78 minutes. 
The recorded chromatograms (Figure 4.46) show that complex 7 was not 
reduced by GSH: the peak area of the complex signal, in fact, remained 
unchanged during the analysis time (16 hours). This behavior reflected the one 
reported by Gibson et al. for satraplatin [15]. 
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Figure 4.46: Chromatograms of complex 7 in presence of GSH, registered during the reduction 
process 
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4.17.2.1 Reduction Kinetics of Complex 9 
4.17.2.2 Study of the Behavior with L(+) Ascorbic Acid 
 
Complex 9 was dissolved in methanol in order to prepare a 1 mM solution. 
Subsequently, this latter was diluted with a 2 mM HEPES buffer aqueous 
solution (pH 7.5) to obtain a final complex concentration of 0.5 mM. Then L(+) 
ascorbic acid was added to the mixture, in a 10:1 molar ratio with respect to the 
Pt(IV) complex. 
The reduction process was followed by HPLC-MS, with a measurements every 
50 minutes, at 37 °C and by using a mobile phase consisting of a 60:40 
methanol/15 mM formic acid mixture. The chromatograms are reported in 
Figure 4.47. 
0 2 4 6
-0,1
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
A
U
Time (min)
 
Figure 4.47: Chromatograms of complex 9 in the presence of ascorbic acid 
 
Also in this case, ascorbic acid was found to be a suitable reducing agent: a 
decrease in the complex signal area (corresponding to a retention time of 3.53 
minutes) was observed, whereas no changes were found as regards the peak of 
ascorbic acid (eluted at 2.83 minutes). 
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Moreover, it was possible to observe the progressive formation of a new peak at 
3.23 minutes, attributed to the axial ligand detached from the complex. At the 
same time, an increase in intensity (and, therefore, in area) of the signals at 1.92 
and 2.45 minutes was verified: it was not possible to make correct attributions 
for the first species, whereas the second one was identified as the aquated form 
of cisplatin. 
After the complete reduction of the complex, the data (expressed as a mean of 
three independent analyses) were processed according to the procedure 
employed for complex 7 (see paragraph 4.17.1.2). 
Figure 4.48 shows the natural logarithms of the normalized areas in function of 
time for one of the three replicates, together with the interpolation of the data. 
 
 
Figure 4.48: Decrease of the peak area of 9 in the presence of ascorbic acid. 
In particular, the results of one of the three independent replicates are reported 
 
The data processing allowed to determine an average half-life time t½ of 10.38 
(± 0.20) hours. 
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y = 0.02757 + 0.00113x 
R
2
 = 0.996 
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4.17.2.3 Study of the Behavior with L-Reduced Glutathione (GSH) 
 
The activation by reduction of complex 9 with GSH did not occur: in fact, this 
reducing agent resulted to be ineffective in reducing the Pt(IV) complex, which 
remained unchanged during the whole analysis time (as well as complex 7). 
 
4.17.3 Conclusions of the Reduction Kinetics of Pt(IV) Complexes 
 
The studies carried out allow to verify that complexes 7 and 9 are reduced and 
activated to cisplatin and its derivatives by using ascorbic acid. Reduced 
glutathione, instead, results to be ineffective and this is consistent with the 
behavior of other studied Pt(IV) complexes [15]. Over the years, in fact, the 
reduction processes of numerous symmetrical compounds has been studied but 
almost all of them did not undergo reduction by GSH. Therefore, the results 
obtained can be considered useful in confirming this behavior even for this kind 
of asymmetrical complexes here presented, although it is not possible to say 
with certainty that this occurs for all the Pt(IV) compounds. 
The following target was the evaluation of the Pt release from conjugate 10b in 
the presence of reducing agents, in particular ascorbic acid. 
 
4.18 Platinum Release from Conjugates in Reducing Conditions 
 
Conjugate 10b (2-3 mg) was suspended in 3 mL of ultrapure water in the 
presence of ascorbic acid (10-fold molar excess respect to the platinum amount). 
The release test allows to observe that more than 90% of the Pt loaded is 
released in 24 hours (a time shorter than the one employed in the cellular 
viability experiments, i.e. 72 hours). Moreover, the ESI-MS analysis allowed to 
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identify the presence of the aquation products of cisplatin: therefore, in reducing 
conditions, cisplatin is released from conjugates, thus exploiting the activation 
by reduction mechanism. 
 
4.19 Biological In Vitro Studies 
 
After the phase of chemical characterization, it was necessary to evaluate the 
biological behavior in in vitro experiments. In particular, it was important to 
verify their ability in inhibiting cell growth and proliferation, their accumulation 
into the tumoral cells and their mechanisms of internalization. 
 
4.19.1 The Antiproliferative Activity (IC50) 
 
The IC50 (Half-Inhibiting Concentration) is a parameter employed for the 
evaluation of the efficacy of a drug: in particular, it represents the drug 
concentration able to inhibit the 50% of the tumoral cells growth. In this assay, 
the cells (seeded in 96-well plates the day before the treatment) are treated with 
increasing concentrations of the drug and the results are shown in a dose-
response graph (Figure 4.49), in which the cell viability is reported as a function 
of the logarithm of the drug concentration and the data are fitted by a sigmoidal 
curve. The IC50 is the concentration at which the 50% of the activity 
corresponds and the lower the value the more effective the drug (high efficacy is 
achieved with low drug concentrations). 
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Figure 4.49: Dose-response sigmoid from which the complex IC50 value is obtained 
 
In this work, compound 7, conjugates 10b-10d and cisplatin (as a comparison) 
were tested on A2780 human ovarian carcinoma cell line (European Collection 
of Cell Cultures, UK), which was grown in RPMI 1640 medium (GIBCO, 
Invitrogen Life Science, San Giuliano Milanese, Italy). This latter was 
supplemented with L-glutamine (2 mM), penicillin (100 IU/mL), streptomycin 
(100 mg/L) and 10% fetal bovine serum (FBS). 
The samples were prepared as described below: cisplatin was dissolved in 0.9% 
w/v NaCl aqueous solution brought to pH 3 (by using HCl), obtaining a 1 mM 
concentration, complex 7 was dissolved in ultrapure water and the concentration 
was 5 mM, and conjugates 10b-10d were provided as ethanol suspensions. 
In order to evaluate also the antiproliferative activity of the released species 7-
APS, conjugate 10b was suspended and magnetically stirred for 7 hours (in 
order to allow a higher complex amount to be released) in 7 mL of RPMI 1640 
medium (supplemented with penicillin and streptomycin) at room temperature. 
The suspension was centrifuged and, after the removal of the NPs pellet, an 
aliquot of the solution was employed for the viability test, after the 
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quantification of the Pt content of the released species present in the solution by 
means of ICP-OES. Before the use, 7-APS was sterilized by filtration (porosity 
0.45 μm). 
The treatments were performed at 37 °C in a 5% CO2 humidified chamber and 
cells were continuously treated for 72 hours. Then, in order to evaluate the 
remaining cellular viability, after the treatment with the previously mentioned 
compounds, the resazurin reduction assay was employed [16]. When a cell 
damage occurs, the intracellular enzyme Lactate Dehydrogenase (LDH) is 
rapidly released in the extracellular medium and the cell viability is inversely 
proportional to the LDH concentration. It can be quantified by means of a 
coupled enzymatic reaction, which is based on the reduction of the resazurin to 
the fluorescent resorufin, which emits at 590 nm (Figure 4.50), due to the 
Diaphorase enzyme. The process is accompanied by the oxidation of NADH to 
NAD
+
 and the reduction of pyruvate to lactate. 
 
Figure 4.50: Schematic reduction reaction of resazurin in the fluorescent resorufin, which is the 
assay employed for the measurement of the remaining cell viability. This reaction is 
accompanied by the reduction of lactate in pyruvate and the oxidation of NADH to NAD
+ 
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In particular, at the end of the treatment, the viability was assayed by 100 μg/mL 
resazurin in fresh medium for 1 hour at 37 °C: the live cells with an active 
metabolism are able to reduce resazurin in resorufin and, then, this latter was 
measured by means of its fluorescence with a Tecan Infinite F200Pro plate 
reader. Fluorescence (excitation λ at 535 nm, emission λ at 595 nm) is directly 
proportional to the cell viability. 
However, conjugate 10c contained rhodamine B as fluorophore and, therefore, it 
could interfere with the resazurin assay results. For this reason, all the IC50 
values were confirmed with the colorimetric assay based on methylene blue 
staining [17], which can be quantified by means of absorbance at 620 nm, thus 
being not affected by the presence of the fluorophore. 
Before carrying out the assay, pictures of cells were taken with an inverted 
microscope Leica DM IL LED, coupled with a camera to observe NPs 
aggregation. 
Each IC50 value, derived from the dose-response sigmoids shown in Figure 
4.51, was obtained as a mean of at least three independent replicates. The data 
were normalized to 100% of viability for not-treated cells and the 
fluorescence/absorbance of the medium without cells was used as a blank. 
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Figure 4.51: Dose-response curves of conjugates 10b-10d, compared to cisplatin, complex 7 and 
the released specie 7-APS. The compounds were tested for 72 hours on A2780 human ovarian 
carcinoma cell line 
 
The dose-response sigmoid of each sample allows to determine the 
corresponding IC50; the results are reported in Table 4.8 and Figure 4.52. 
 
Compound IC50 (nm) 
cisplatin 460 ± 110 
7 5070 ± 380 
b, c, d >> 20000 
10b 11 ± 3 
10c 70 ± 12 
10d 40 ± 14 
7-APS 960 ± 60 
Table 4.8: IC50 numerical values of conjugates 10b-10d, compared to cisplatin, 7, the released 
species and free NPs 
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Figure 4.52: Representation by bars graphs of the obtained IC50 values 
 
The data indicate that the conjugates, on A2780 cell line, are more effective than 
cisplatin. A higher efficacy is observed also respect to free complex 7 and, in 
particular, respect to the free NPs b-d, which do not show any activity. An 
important result is the IC50 of 7-APS: its lower activity with respect to 10b-10d 
(about two orders of magnitude) demonstrates that, even though a detachment of 
the complex from the NPs surface occurred, the activity of free conjugates is, in 
any case, elevated and thus not dependent on the species released by hydrolysis. 
After the determination of the antiproliferative activity, each sample was tested 
in order to evaluate its accumulation into the cells and, therefore, its ability to 
cross cell membrane. 
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4.19.2 The Cellular Accumulation 
 
The cytotoxic activity of a drug results from the combination of several factors, 
such as its diffusion through the cell membrane, its intracellular accumulation, 
its activation to obtain the active metabolite and its reactivity towards the DNA. 
The accumulation into the cells, in particular, can occur by mechanisms of 
passive diffusion, transport mediated by membrane proteins, endocytosis, etc. 
and depends on the drug concentration, the treatment time and the cell line. 
The so-called accumulation, defined also as uptake or influx and abbreviated as 
A, represents the amount of drug that, after crossing the cell membrane, 
accumulates into the cell. This value is normalized upon the cells number 
(expressed as 10
6
 of cells) and depends on the extracellular drug concentration 
(in fact, it considers the actually intracellular concentration without taking into 
account the extracellular one): this makes the accumulation a little comparable 
parameter from a system to another one. 
   
    
            
 
A more correct way to indicate an effective accumulation result is to consider 
the Accumulation Ratio (AR) [18]: this value represents the ratio between the 
intracellular compound concentration ([Pt]IC) and the extracellular one ([Pt]EC), 
i.e. that of the culture medium, and is comparable between different systems, 
since it does not depend on the initial concentration of the administered drug. 
    
      
      
 
In particular, in this work, cisplatin, complex 7, conjugates 10b-10d and the 
released species 7-APS were tested on A2780 human ovarian carcinoma cell 
line with a 4 hours treatment. The concentrations were 10 μM cisplatin and 7, 
0.1 μM conjugates 10b-10d and the release sample was tenfold diluted in 
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complete medium. Immediately after the treatment, 100 μL of culture medium 
were harvested to measure the neat extracellular platinum concentration 
following adsorption to sterile plasticware. After the treatment, cells were 
washed three times in phosphate buffer saline (PBS), detached from the 25 cm
2
 
flasks using 1 mL of 0.05% Trypsin EDTA (HyClone, Thermo Fisher Scientific) 
and harvested in fresh complete medium. An automatic cell counting device 
(Countess®, Life Technologies) was used to measure the cells number and the 
mean diameter from every cell count. About 5 × 10
6
 cells were transferred into a 
glass tube and spun at 1100 rpm for 5 minutes at room temperature. The 
supernatant was carefully removed by aspiration and, in order to limit the 
cellular loss, about 200 μL of the supernatant were left. Cell pellet was stored at 
-20 °C. After defrosting, 350 μL of 70% w/w HNO3 were added and left 1 hour 
at 60 °C in an ultrasonic bath. Then the sample was diluted with a 1% aqueous 
solution of HNO3 (by adding 5650 μL) to a final 3% of acid concentration and 
the platinum content was quantified by means of ICP-MS. 
The ICP-MS results were expressed as μg/L (ppb) of Pt and, then, they were 
divided by Pt atomic weight (195 u) to determine the Pt concentration (μM) of 
that sample. The intracellular platinum quantity, even though Pt(IV) complexes 
undergo reduction and aquation processes, corresponds to the initially entered 
drug amount. 
The data processing, after the normalization of the Pt amount found into the 
cells upon the cells number and volume (calculated from the actual mean cell 
diameter measured for every sample) allowed to obtain the intracellular 
platinum concentration. The ratio between the intra- and extracellular 
concentration of Pt allowed to obtain the AR value of each studied sample. The 
obtained AR data are shown in Table 4.9 and as Figure 4.53. 
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Compound AR 
cisplatin 1.39 ± 0.52 
7 0.38 ± 0.09 
10b 64.56 ± 19.02 
10c 76.07 ± 12.94 
10d 41.28 ± 10.08 
7-APS 0.60 ± 0.20 
Table 4.9: AR data for conjugates 10b-10d, compared with cisplatin, 7 and the released species 
 
 
Figure 4.53: Bars graphs of the AR data 
 
The results indicate that the conjugates present high accumulation ratio values 
(higher than cisplatin, complex 7 and the released species 7-APS of more than 
one order of magnitude). These results demonstrate that there is a correlation 
between IC50 and AR: conjugates 10b-10d show a high antiproliferative activity 
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due to the fact that they enter cells in large quantity and accumulate inside them, 
allowing the drug to exert its cytotoxic activity. 
 
4.19.3 Confocal Microscopy 
 
The effective cellular accumulation can be verified by the use of the Confocal 
Microscopy (Figure 4.54). This technique is based on the fact that the resulting 
picture and the observed object have the same focal plane: in fact, it is able to 
filter out the out-of-focus light by the employment of two pinholes, spatially 
located immediately after the source of light and immediately before the 
detector. This results in an improvement in the image resolution because the 
confocal microscope removes the light above and below the focal plane (unlike 
Fluorescence Microscopy), allowing to obtain an in focus image. 
 
 
Figure 4.54: Scheme of a confocal microscope [19] 
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In the specific case of NPs, this technique allowed to focus on the nanoparticles 
accumulated into the cells, by employing appropriate filters: in particular, 
excitation λ at 488 nm and emission λ at 505-550 nm for fluorescein (Figures 
4.55, 4.56, 4.59, 4.60), and excitation λ at 550 nm and emission λ at 570 nm for 
rhodamine B (Figures 4.57 and 4.58). 
The instrument employed was a Zeiss LSM 510 confocal system, Carl Zeiss 
Microscopy GmbH, Germany. 
In particular, the day before the tests, the A2780 cells were seeded in 4 wells-
chambered slides (Nunc
TM
 Lab-Tek
TM
 II Chamber Slide
TM
 System, Thermo 
Fisher Scientific). They were treated with free NPs b-d and the corresponding 
conjugates (10b-10d) for 4 hours (by employing the same treatment protocol 
described for AR experiments). The cells were then washed with phosphate-
buffered saline (PBS), rinsed in Ringer’s solution (140 mM NaCl, 5 mM KCl, 2 
mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 5.2 mM sucrose, pH = 7.4), and 
fixed 30 minutes at 4 °C in fixing solution (3% w/v paraformaldehyde in PBS, 
pH = 7.5) for the confocal analyses. 
For each sample, the pictures of the fluorescent channel (top, left), the contrast 
phase image (top, right) and the merged one (bottom) of the same microscope 
field at 20× magnification are reported (Figures 4.55-4.60). The results showed 
the efficacy of the NPs as vectors that were internalized by the cells. 
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Figure 4.55: Confocal microscopy images for free NPs b 
 
 
Figure 4.56: Confocal microscopy images for conjugate 10b 
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Figure 4.57: Confocal microscopy images for free NPs c 
 
 
Figure 4.58: Confocal microscopy images for conjugate 10c 
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Figure 4.59: Confocal microscopy images for free NPs d 
 
 
Figure 4.60: Confocal microscopy images for conjugate 10d 
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4.19.4 Studies on the NPs Internalization Mechanisms 
 
The endocytosis is a mechanism of active transport that allows macromolecules 
to enter cells. In particular, a substance is wound through a portion of the cell 
plasmatic membrane, which invaginates inside the cell and then is detached 
giving rise to an endocytic vesicle containing the species. 
Since this is an active mechanism, the cell requires energy to maintain it. For 
this reason, the endocytosis is inhibited by low temperatures (4 °C) and by 
agents that block the cell metabolism (such as sodium azide). This latter 
decouples the cell respiration and, therefore, depletes the cellular ATP. Usually 
the electron flow in the transport chain to reach the final acceptor (that is the 
oxygen) is closely related to the phosphorylation of ADP in ATP. NaN3 is able 
to inhibit the electron transport chain, since it reacts with the ferric form of heme 
group and, thus, leads to the inhibition of the ATP synthesis, because the proton-
motive force can no longer be generated [20]. 
 
In order to verify if an inhibition of the NPs internalization occurred at 4 °C, 
some experiments were performed at this temperature. The results were the 
same obtained for the control cells, suggesting that an active transport 
mechanism is involved; this was confirmed by the use of sodium azide (Figure 
4.61). 
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Figure 4.61: Study of the inhibition of the NPs active transport mechanism, in the presence of 
NaN3. 
norm RFU = fluorescence normalized to the viability, control NP = cells not treated with NaN3, 
NT = cells not treated with both NPs and NaN3 
 
The endocytosis mechanisms (Figure 4.62) can be classified in: proper 
endocytosis, performed by all the cells, which consists of the ingestion of fluid 
or solid materials of small size, and phatocytosis, i.e. the ingestion of big 
particles, carried out by professional phagocytes (such as neutrophils, 
eosinophils, etc.) or rarely by optional phagocytic cells (fibroblasts, endothelial 
cells, etc.). 
 
 
Figure 4.62: Possible mechanisms of endocytosis [21] 
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The proper endocytosis, depending on the mechanism with which the endocytic 
vesicle are formed, can be distinguished in macropinocytosis, clathrin- or 
caveolae-mediated endocytosis. 
The macropinocytosis begins with the formation of extended protrusions of the 
plasma membrane, sustained by actin cytoskeletal elements. These protrusions 
are then merged with the membrane itself to form large endocytic vesicles 
containing extracellular material. 
The clathrin-mediated endocytosis is a highly selective process that begins with 
the recognition between ligands and specific plasma membrane receptors, 
followed by the accumulation of ligand-receptor adduct in specific points of the 
membrane, known as clathrin coated pits. The formation of clathrin coated 
endocytic vesicle is mediated by actin cytoskeletal elements. The just formed 
vesicle loses the clathrin coating and the not-coated vesicle will subsequently 
merge with an endosome to form a premature endosome. 
Another mechanism based on  the formation of endocytotic vesicles is the 
caveolae-mediated one. The caveolae are formed in those areas of the membrane 
constituted by the so-called "lipid rafts", which are areas rich in cholesterol, 
glycosphingolipids and membrane proteins. 
In order to verify the mechanism responsible for the internalization of the 
studied vectors, species able to inhibit these specific mechanisms are employed: 
a decrease of the biological response (and, therefore, of the internalized vector 
amount) indicates that the inhibitor fulfills its role and that this particular 
endocytic process is involved. 
One of the macropinocytosis inhibitors is amiloride: it inhibits the reabsorption 
of sodium through the sodium channels (sodium-hydrogen antiporter or 
exchanger). The mechanism by which it inhibits macropinocytosis is unknown 
[22]. 
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The mechanism mediated by clathrin is inhibited by various species, among 
which chlorpromazine [23], the mechanism of action of which is not yet clear.  
As regards the endocytosis mediated by caveolae, genistein can be mentioned. It 
is an inhibitor of the receptor associated tyrosine kinases, proteins involved in 
the "lipid raft" structure. Moreover, in previous studies on A549 human lung 
carcinoma cell line, genistein was effective in inhibiting the endocytosis of 200 
nm size NPs, with a 50% decrease of uptake with respect to control cells [23]. 
 
In order to verify the mechanisms of endocytosis (phagocytosis, 
macropinocytosis, clathrin-dependent endocytosis, caveolae-mediated 
endocytosis, etc.) involved in the internalization of the studied NPs, specific 
inhibitors of the various endocytosis mechanisms were employed. Only the free 
NPs were tested but the same behavior was expected for the conjugates. 
For this purpose, another cell line (A549, human lung carcinoma) was employed 
because A2780 cells showed problems during their use. In particular, after being 
washed with PBS, the number of A2780 cells was markedly lower than the 
number of initially treated cells: in fact, PBS (without Ca
2+
 and Mg
2+
 ions) 
caused a massive cellular detachment from the plastics support. For this reason, 
it was initially substituted by the buffer EBSS (Earle's Balanced Salt Solution, a 
saline solution of glucose and sodium bicarbonate containing calcium and 
magnesium cations, which are crucial for cellular adhesion) resulting in a 
decreased but still significant detachment of the cells. On the contrary, A549 
cells were less affected by the washing step and, therefore, were chosen for the 
following experiments. In particular, the cells were treated with 100 μL of a 50 
μg/mL suspension of NPs and the experiments were carried out for 4 hours at 37 
°C in the presence of chlorpromazine (CPZ), genistein (G) or amiloride (AM), 
as endocytosis inhibitors. After the established 4 hours, each well was washed 
with 100 μL of EBSS in order to remove the NPs excess. Furthermore, Trypan 
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Blue was added to switch off the fluorescent signal of the NPs remained on the 
cells surface. Then, a microplate reader allowed to observe the results (Figure 
4.63). 
 
 
Figure 4.63: a) Uptake of NPs b (116 nm), b) NPs c (96 nm) and c) NPs d (48 nm), in the 
presence of inhibitors. 
norm RFU = fluorescence normalized to the viability, control NP = cells not treated with 
inhibitors, NT = cells not treated with both NPs and inhibitors 
 
The bars graphs in Figures 4.63a and 4.63c show that NPs b and d are 
internalized into the cells mostly by caveolae-mediated endocytosis: in fact, the 
genistein is the most effective inhibitor. The NPs c (Figure 4.63b), instead, give 
no clear results: amiloride seems to be the most effective but genistein result is 
a) b) 
c) 
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not much different from amiloride. Therefore, NPs c are probably internalized 
by both macropinocytosis and caveolae-mediated endocytosis. 
 
4.20 Conclusions 
 
In this chapter, two different Pt(IV) complexes, containing one (7) or two (2) 
free carboxylic groups, were synthesized, activated and coupled to amino-
functionalized fluorescent silica NPs of different sizes (a-d). Conjugates 5a-5d 
showed irreversible aggregation, due to the formation of cross-links between 
nearby NPs. On the contrary, stable suspensions of conjugates 10a-10d were 
obtained: this aspect confirmed that the use of monofunctionalizable Pt(IV) 
compounds avoids the formation of large aggregates. 
The release studies in aqueous solutions allowed to observe the spontaneous 
detachment of the complex bound to the aminopropylsilane (7-APS), due to the 
hydrolysis of the Si-O bond on the NPs surface: this can represent a decrease of 
the therapeutic potential of the conjugate because of an aspecific loss before the 
drug arrival to the cells. However, the released amount resulted to be about the 
15% within 4 hours: therefore, in the case of in vivo tests, the detachment in the 
extracellular fluids should be limited. Then, once inside the cells, the activation 
by reduction can occur, due to the presence of reducing agents, and the active 
species, i.e. cisplatin, can be released (as suggested by the release tests of 
conjugate 10b in reducing conditions). 
Furthermore, conjugates 10b-10d were tested on A2780 human ovarian 
carcinoma cell line in order to evaluate their antiproliferative activity, which 
resulted to be higher than that of cisplatin, 7, free NPs and 7-APS. This 
increased efficacy was ascribed to the high cellular accumulation of the 
conjugates, verified by means of ICP-MS measurements of the Pt uptake and 
observed by confocal microscopy. Moreover, the mechanism of internalization 
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was evaluated by means of the use of specific inhibitors, which allowed to 
verify that caveolae-mediated endocytosis was the main mechanism involved. 
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Capitolo 5  
Chapter V 
 
 
 
 
 
 
 
 
 
 
Synthesis, Characterization of Platinum Complexes and 
Coupling Reactions with New Amino-Functionalized Silica 
Nanoparticles 
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5.1 Introduction 
 
The NPs described in Chapter IV were decorated with a prone-to-hydrolysis 
amino arm and this caused a partial loss of the loaded complex. Therefore, in 
order to avoid this detachment, new types of silica nanoparticles were prepared. 
At first, NPs similar to the previous ones (i.e. the same amino arm was exposed) 
were synthesized but their structure did not include any fluorophore, in order to 
verify if, even in the absence of the fluorescent dye, the Si-O-Si bonds 
hydrolysis may occur. Then, another type of NPs was prepared: also in this case, 
the structure did not include any fluorophore and, moreover, a new amino arm 
decorated the surface of the nanoparticles. In fact, in this case, the N-(6-
aminohexyl)aminomethyltriethoxysilane (AHAMTES) was employed since it 
was reported that its use allowed to obtain hydrolytically stable amino-
functionalized silica substrates [1]. 
The (3-aminopropyl)trimethoxysilane (APTMS) and (3-
aminopropyl)triethoxysilane (APTES) have a primary amino group in the propyl 
position and it can catalyze the formation and hydrolysis of siloxane bonds both 
intra- and intermolecularly (as described in paragraph 3.16). In particular, 
intramolecular catalysis is achieved via the formation of stable five-membered 
cyclic intermediates (or a six-membered cyclic intermediate in the case of amine 
in butyl position). The same behavior can be observed with species containing a 
secondary amino group in propyl/butyl position but not with AHAMTES [1]. 
The hydrolytic stability derived from the use of AHAMTES indicates that the 
intramolecularly catalyzed detachment can be minimized by controlling the 
length of the alkyl linker in aminosilanes [2]. 
Based on the results reported in Chapter IV, the two mentioned types of NPs 
were coupled only to mono-functionalizable complexes to avoid the formation 
of irreversible aggregates [3]. For this reason, the NPs were coupled to the 
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activated N-hydroxysuccinimidyl ester of (OC-6-44)-diammine(4-
carboxypropanoato)dichloridoethanolatoplatinum(IV) (8), in order to study the 
behavior with these NPs types and to make a comparison with the conjugates 
described in Chapter IV, and to the activated N-hydroxysuccinimidyl ester of 
(OC-6-44)-(acetylamido-N)diammine(4-carboxypropanoato)dichloridoplatinum 
(IV). Its precursor, the (OC-6-44)-(acetylamido-
N)diamminedichloridohydroxidoplatinum(IV), represents the only case in which 
a N-donor ligand is directly coordinated to the platinum core during the 
oxidation process. Other Pt(IV) compounds contain coordinated nitriles 
(therefore, a N-donor ligand), such as the iminol- or imino ester-Pt(IV) series, 
but in equatorial position [4, 5]. 
For the synthesis of (OC-6-44)-(acetylamido-
N)diamminedichloridohydroxidoplatinum(IV), the Radziszewski reaction 
between acetonitrile and hydrogen peroxide was exploited: in fact, it proceeds 
through the formation of the highly reactive intermediate peroxyacetimidic acid 
(PAIA) [6, 7, 8]. Its subsequent reaction with cisplatin allows to obtain a Pt(IV) 
compound, whose axial ligands are provided by PAIA itself. In particular, the 
acetylamido represents the inert functionality, whereas the hydroxido can react 
with succinic anhydride in order to introduce a further functionalizable group. 
The synthesized Pt(IV) complexes are listed in order of discussion: 
 (OC-6-44)-(acetylamido-N)diamminedichloridohydroxidoplatinum(IV) 
(11), 
 (OC-6-44)-(acetylamido-N)diammine(4-carboxypropanoato)dichlorido 
      platinum(IV) (12), 
 Activated N-hydroxysuccinimidyl ester of 12 (13). 
 
 
154 
 
5.2 Synthesis of (OC-6-44)-(acetylamido-
N)diamminedichloridohydroxidoplatinum(IV) (11) 
 
 
The employed synthetic procedure was reported in the literature [9]. In 
particular, a mixture of acetonitrile (ACN, 10 mL) and a 50% w/w aqueous 
solution of hydrogen peroxide (1 mL) was stirred at room temperature for 30 
minutes. Then cisplatin (100 mg, 0.333 mmol) was added and the resulting 
suspension was stirred for 5 minutes. Methanol (5 mL) was added and the 
reaction was carried out at room temperature for 24 hours. The resulting pale 
yellow solid was separated by centrifugation, washed with acetonitrile and dried 
in vacuo. 
Yield: 95.0 mg, 0.253 mmol, 76.0%. 
Elemental analysis calculated for C2H11Cl2N3O2Pt: C 6.40, H 2.96, N 11.20. 
Found: C 6.20, H 2.71, N 10.98. 
 
5.2.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 90:10 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
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of 37 °C and the UV-Visible detector set at 210 nm. Compound 11 showed a 
retention time of 4.77 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 5.1). 
 
 
Figure 5.1: ESI-MS spectrum of complex 11, prepared in ultrapure water 
 
The ESI-MS spectrum of complex 11 (Figure 5.1), registered in positive ion 
mode with a 30V cone voltage, shows the pseudo-molecular ion [M+H]
+
 peak at 
376.1 m/z and the peak of the fragment [M-OH]
+
 at 358.1 m/z. 
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1
H-NMR 
 
Figure 5.2: 
1
H-NMR spectrum of complex 11, registered in DMSO-d6 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of complex 11 shows the 
following signals, : 1.90 (s, 3H,-CH3), 4.33 (t, 1H, -NH-, 
3
J = 4.9 Hz), 5.97 (m, 
6H, -NH3) ppm. 
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13
C-NMR 
 
Figure 5.3: 
13
C-NMR spectrum of complex 11, registered in DMSO-d6 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 11 shows the 
following signals, : 25.9 (-CH3), 176.5 (-CO) ppm. 
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195
Pt-NMR 
 Figure 5.4: 195Pt-NMR spectrum of complex 11, registered in DMSO-d6 
 
The 
195
Pt-NMR spectrum of complex 11 (Figure 5.4) was registered in DMSO-
d6 (at a 107.2 MHz NMR frequency) and shows a signal at 422 ppm (qt, 
1
J = 
128.04 Hz). The chemical shift is consistent with a Pt(IV) complex with two 
chlorides, three N-coordinated ligands and a hydroxido. The signal multiplicity 
is typical of the coupling of 
195
Pt (spin quantum number I = ½) with two 
14
N 
atoms (I = 1) and the signal is quite broad, due to the coupling with the 
quadrupolar nucleus 
14
N. 
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5.3 Synthesis of (OC-6-44)-(acetylamido-N)diammine(4-
carboxypropanoato)dichloridoplatinum(IV) (12) 
 
 
The synthetic procedure was reported in the literature [9]. In particular, succinic 
anhydride (266 mg, 2.66 mmol) was added dropwise to a mixture of 11 (100 
mg, 0.266 mmol) in 5 mL of DMF and the reaction was carried out at 50 °C 
until the yellow solution became completely clear (about 3 hours). Then it was 
filtered and the DMF was removed under reduced pressure. A pale yellow 
powder was precipitated with acetone/diethyl ether, then washed with diethyl 
ether and dried in vacuo. 
Yield: 91.0 mg, 0.192 mmol, 71.8%. 
 
5.3.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 12 showed a 
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retention time of 6.24 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 5.5). 
 
 
Figure 5.5: ESI-MS spectrum of complex 12, prepared in ultrapure water 
 
The ESI-MS spectrum of complex 12, registered in negative ion mode with a 
cone voltage of 30V (Figure 5.5), confirms the success of the synthesis showing 
the pseudo-molecular ion [M-H]
-
 peak at 474.0 m/z. 
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1
H-NMR 
 
Figure 5.6: 
1
H-NMR spectrum of complex 12, registered in DMSO-d6 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of complex 12 shows the 
following signals, : 1.93 (s, 3H, -CH3), 2.38 (m, 2H, -CH2-CO2H), 2.42 (m, 2H, 
-CH2-CO2), 5.16 (s, 1H, -NH-), 6.46 (m, 6H, -NH3) ppm. 
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13
C-NMR 
 
Figure 5.7: 
13
C-NMR spectrum of complex 12, registered in DMSO-d6 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 12 shows the 
following signals, : 25.1 (-CH3), 30.1 (-CH2-CO2H), 31.4 (-CH2-CO2), 174.0 (-
CH2-CO2H), 175.5 (-CO-CH3), 179.5 (-CH2-CO2) ppm. 
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195
Pt-NMR 
 
Figure 5.8: 
195
Pt-NMR spectrum of complex 12, registered in DMSO-d6 
 
The 
195
Pt-NMR spectrum of complex 12 (Figure 5.8) was registered in DMSO-
d6 (at a 107.2 MHz NMR frequency) and shows a signal at 494 ppm, which is 
consistent with a Pt(IV) complex containing two chlorides, three N-coordinated 
ligands and a carboxylato. 
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5.4 Synthesis of the Activated N-hydroxysuccinimidyl Ester of 12 
(13) 
 
 
 
A mixture of 12 (50.0 mg, 0.105 mmol), DCC (26.1 mg, 0.126 mmol) and NHS 
(14.5 mg, 0.126 mmol) in 2 mL of anhydrous DMF was stirred at 0 °C for 1 
hour and at room temperature overnight. Then the solution was cooled to -18 °C 
and filtered in order to remove dicyclohexylurea. The DMF was removed under 
reduced pressure and a pale yellow powder was precipitated by the addition of a 
mixture of acetone/diethyl ether. It was washed with diethyl ether and then dried 
in vacuo. 
Yield: 41.8 mg, 0.0730 mmol, 69.4%. 
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5.4.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 13 showed a 
retention time of 6.54 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 5.9). 
 
 
Figure 5.9: ESI-MS spectrum of complex 13, prepared in a 50:50 mixture of ultrapure water and 
methanol 
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The ESI-MS spectrum of complex 13 (Figure 5.9), registered in positive ion 
mode with a 30V cone voltage, shows the pseudo-molecular ion [M+H]
+
 peak at 
573.2 m/z: it confirms the success of the synthesis. 
 
1
H-NMR 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of complex 13 shows the 
following signals, δ: 1.93 (s, 3H, -CH3), 2.38 (m, 2H, -CH2-CO2N), 2.42 (m, 2H, 
-CH2-CO2), 2.81 (s, 4H, –CH2CON), 5.16 (s, 1H, -NH-), 6.45 (m, 6H, -NH3) 
ppm. 
 
13
C-NMR 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 13 shows the 
following signals, δ: 25.1 (-CH3), 25.4 (–CH2CON), 30.0 (-CH2-CO2N), 31.4 (-
CH2-CO2), 170.2 (–CON), 174.0 (-CH2-CO2N), 175.5 (-CO-CH3), 179.5 (-CH2-
CO2) ppm. 
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195
Pt-NMR 
 
Figure 5.10: 
195
Pt-NMR spectrum of complex 13, registered in DMSO-d6 
 
Figure 5.10 shows the 
195
Pt-NMR spectrum of complex 13, registered in 
DMSO-d6 (at a 107.2 MHz NMR frequency), containing a signal at 493 ppm, 
consistent with a Pt(IV) complex with two chlorides, three N-coordinated 
ligands and a carboxylato. 
 
5.5 Synthesis of NPs Decorated with APTES (e) 
 
Figure 5.11: Synthetic scheme for the preparation of NPs e 
 
The silica nanoparticles were synthesized by using a similar procedure (Figure 
5.11) to the one described in Chapter IV [3]. In particular, in a three-necked 
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flask equipped with a reflux condenser, 20 mL of a 28% w/w ammonia solution 
were added to 25 mL of ultrapure water, they were diluted with methanol to the 
final volume of 320 mL and magnetically stirred at 830 rpm, with a temperature 
set to 30 °C. Subsequently, TEOS (20 mL, 90 mmol) was added to the mixture 
and the reaction was carried out for 2.5 hours. Then the silica nanoparticles were 
collected by centrifugation (8500 rpm, 35 minutes), resuspended in ethanol by 
means of ultrasonic tip (power 117 W, 5 minutes) and these two steps were 
repeated three times. 
The ethanol suspension was added to a mixture of 35 mL of ultrapure water, 6 
mL of a 28% w/w ammonia solution and methanol to the final volume of 320 
mL, and then (3-aminopropyl)triethoxysilane (APTES, 536 μL, 2.29 mmol) was 
added. The suspension was magnetically stirred at 830 rpm, at 30 °C and the 
reaction was carried out for 16 hours. The NPs were collected by centrifugation 
(8500 rpm, 35 minutes) and washed with ethanol by means of five cycles of 
resuspension (by ultrasonic tip) and centrifugation. The synthesized NPs were 
stored in ethanol at 4 °C. 
 
5.5.1 Quantification of the Amino Functionalities 
 
In order to proceed with the quantification of the exposed amino groups, 1 mL 
of the ethanol suspension was dried in an oven (20 minutes at 100 °C) and, then, 
the dried product was weighed to calculate the content of the suspension (0.0630 
g NPs / mL ethanol suspension). 
The amino groups present on the NPs surface were quantified by employing the 
same procedure described in paragraph 4.3.2. In particular, 7.94 mL of ethanol 
suspension were centrifuged to get 0.500 g of NPs that were suspended in 20 
mL of a 0.2 M HCl and 0.5 M NaCl aqueous solution, in order to protonate all 
the available amino groups. After the centrifugation, they were suspended in 20 
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mL of ultrapure water, in order to remove the HCl and NaCl excess, and then 
centrifuged. They were suspended in 20 mL of a 1 M aqueous solution of KNO3 
and the suspension was mechanically shaken overnight, in order to exchange 
chloride with nitrate anions. Then the suspension was centrifuged and the 
chlorides, present in the solution, were titrated with a 0.01 M AgNO3 aqueous 
solution by means of an Ag
+
 selective electrode (the titration is based on the 
AgCl precipitation). The potential of the solution was registered, at 25 °C, after 
each addition of AgNO3 and is reported in a graph as a function of the titrant 
volume (Figure 5.12). Then the data were processed and expressed as amino 
group density: 0.283 mmol NH2 / g NPs. 
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Figure 5.12: Titration curve of silica NPs e 
 
5.5.2 Size and Stability Investigations 
 
Dynamic Light Scattering (DLS) and  potential analyses were carried out in 
order to study the NPs size and the suspension stability, respectively. These 
measurements were performed in a 10 mM KNO3 aqueous solution (after being 
treated with a 0.2 M HCl aqueous solution and then centrifuged) at 25 °C with a 
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Malvern Zetasizer Nano ZS (see paragraph 4.2 for the instrumental 
information). The nanoparticles diameter was also verified by Transmission 
Electron Microscope (TEM) analysis. In particular, for the TEM investigation of 
particle shape, small amounts of the synthesized products (free NPs and 
conjugates), dispersed in ethanol, were transferred onto 200-mesh Cu TEM 
grids with formvar support film. Grids were observed through a Philips CM 10 
(Eindhoven, Netherland) Transmission Electron Microscope operating at 100 
kV (Figure 5.13). 
 
 
Figure 5.13: TEM micrograph of NPs e (the bar represents 100 nm) 
 
The ζ potential is a measure of the stability of a suspension (as described in 
paragraph 4.3.3) and a value ≥ |30| mV indicates a stable suspension. NPs e 
result to be very stable, since they exceed the threshold of stability (in fact, their 
ζ potential was 53 ± 2 mV) and the possibility of aggregation is avoided. 
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As regards the size, as observed in paragraph 4.3.3, the same NPs analyzed by 
means of DLS (125 ± 2 nm) result to be bigger than the one analyzed by TEM 
(51 ± 1 nm) since the hydrodynamic radius have to be considered and, therefore, 
the NPs appear larger. 
 
5.5.3 Solid-State NMR Characterization 
 
29
Si solid-state NMR applied to silica NPs allows to verify the types of covalent 
bonds present on their surface. 
Usually, the Si sites are indicated by the formula (SiO)nSiRmX4-n-m, in which X 
represents -OCH3, -OCH2CH3, -OH or -Cl groups, R can be a methyl or a group 
different from X (in this work, R = 3-aminopropylic arm) [10]. Furthermore, the 
Si sites are defined with a specific nomenclature, which indicates mono- (M), 
di- (D), tri- (T) and quaternary (Q) coordination of oxygen (or, in some cases, 
Cl) atoms to Si (Figure 5.14). 
 
 
Figure 5.14: Coordinated groups to a Si atom on a silica material surface. 
The picture was adapted from literature [11] 
 
Such abbreviations are indicated as M
n
, D
n
, T
n
 and Q
n
 (where n is the number of 
linked “SiO”). In particular, the silica core of the employed NPs is composed of 
tetrafunctional units (i.e. silicon bound to four “SiO” units, i.e. [(SiO)4Si]), 
corresponding to Q
4
. 
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Free silanols are indicated as Q
3
 ([(SiO)3Si(OH)]): in fact, Si is bound to four 
oxygen atoms (three from “SiO” units and one from -OH group (i.e. X = 1, R = 
0, m = 0). 
A Si atom bound to three oxygens (SiO) and one R group (such as a 3-
aminopropyl), [(SiO)3SiR], showed m = 1 and X = 0: therefore, it was defined 
as T
3
. On the contrary, when silicon is bound to three oxygen atoms, one from -
OH (X = 1), and to a 3-aminopropyl group (m = 1), the attribution is T
2
 
([(SiO)2SiR(OH)]). 
A silicon bound to two R (m = 2) and two oxygen groups from “SiO” (n = 2) is 
considered difunctional and is indicated as [(SiO)2SiR2] (D
2
). 
If the Si atom is bound to three R groups (m = 3) and only one oxygen (from 
“SiO”), it is defined monofunctional and is described as [(SiO)SiR3] (M
1
). 
All the possible combinations, corresponding to precise ranges of 
29
Si chemical 
shift, are reported in Tables 5.1 and 5.2. 
 
 (SiO)nSiRmX4-n-m 
Si site n m R X 
Q
n
 0, 1, 2, 3, 4 0 
groups 
different from 
X 
-OCH3, 
-OCH2CH3, 
-OH, -Cl 
T
n
 0, 1, 2, 3 1 
D
n
 0, 1, 2 2 
M
n
 0, 1 3 
Table 5.1: Symbols of the functional groups present on silica materials 
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             n 
  m             
0 1 2 3 4 
0 
Si(X)4 
(Q
0
) 
(SiO)Si(X)3 
(Q
1
) 
(SiO)2Si(X)2 
(Q
2
) 
(SiO)3Si(X) 
(Q
3
) 
(SiO)4Si 
(Q
4
) 
1 
SiR(X)3 
(T
0
) 
(SiO)SiR(X)2 
(T
1
) 
(SiO)2SiR(X) 
(T
2
) 
(SiO)3SiR 
(T
3
) 
- 
2 
SiR2(X)2 
(D
0
) 
(SiO)SiR2(X) 
(D
1
) 
(SiO)2SiR2 
(D
2
) 
- - 
3 
SiR3(X) 
(M
0
) 
(SiO)SiR3 
(M
1
) 
- - - 
Table 5.2: All the possible combinations of n and m in the general formula [(SiO)nSiRmX4-n-m] 
and their symbols are indicated below, in brackets 
 
In particular, the solid state 
29
Si-NMR spectra were acquired on a Bruker 
Avance III 500 spectrometer and a wide bore 11.7 T magnet with operational 
frequencies for 
1
H and 
29
Si of 500.13 and 99.35 MHz, respectively. A 4 mm 
triple resonance probe with Magic Angle Spinning (MAS) was employed in all 
the experiments. NPs e (previously lyophilized) were packed on a Zirconia rotor 
and spun at a MAS rate of 10 kHz. The relaxation delays (d1) between 
accumulations were 2.5 seconds. For the 
29
Si{
1
H} CPMAS experiments, the 
radio frequency (RF) fields (υrfH) of 55 and 28 kHz were used for the initial 
excitation and the decoupling, respectively. During the Cross-Polarization (CP) 
period, the 
1
H RF field υrfH was ramped using 100 increments, whereas the 
29
Si 
RF field (υrfSi) was maintained at a constant level. During the acquisition, the 
protons were decoupled from the silicons by using a TPPM (Two Pulse Phase 
Modulation) decoupling scheme. A moderate ramped RF field υrfH of 62 kHz 
was used for spin locking, while the carbon RF field υrfSi was matched to obtain 
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optimal signal and the CP contact time of 2000 μseconds was used. The 
chemical shifts were externally referenced to TMS at 0 ppm. 
The results of the analysis were shown in Figure 5.15. 
 
 
Figure 5.15: 
29
Si{
1
H} CPMAS NMR spectrum of NPs e 
 
The spectrum reported in Figure 5.15 confirmed the functionalization of NPs e 
and gave information on the NPs surface. In particular, the peak at about -100 
ppm was ascribed to isolated silanol groups [(SiO)3Si(OH)] (Q
3
) and the one at -
110 ppm indicated surface siloxane bridges [(SiO)4Si] (Q
4
). The two peaks at -
60 and -68 ppm, instead, allowed to verify the decoration with the amino silane 
(in this case, APTES): they were attributed to [(SiO)2SiR(OH)] (T
2
) and 
[(SiO)3SiR] (T
3
), respectively, in which R was -CH2CH2CH2NH2. 
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5.6 Synthesis of Conjugates 14e and 15e 
 
The ethanol suspension e (1 mL, 63.0 mg NPs, 0.0178 mmol amino groups) was 
centrifuged, washed once with anhydrous DMF and then suspended in 
anhydrous DMF. This suspension was added to a solution of 8 (10.0 mg, 0.0178 
mmol), prepared in 1 mL of DMF, and the mixture was magnetically stirred for 
4 hours at room temperature. The suspension was centrifuged (9000 rpm, 15 
minutes) and the conjugate (14e) was washed with ultrapure water and ethanol, 
in order to completely remove not coupled 8, NHS and DMF. 
The same procedure was employed for the synthesis of conjugate 15e: in 
particular, 1 mL of the anhydrous DMF suspension e was added to a solution of 
13 (10.2 mg, 0.0178 mmol), prepared in 1 mL of anhydrous DMF. 
 
5.6.1 Quantification of the Pt Content in 14e and 15e 
 
An aliquot of the ethanol suspensions 14e and 15e was centrifuged and the pellet 
was dried in order to be mineralized by means of microwaves. Each 
mineralization was carried out at least in triplicate by following the same 
procedure employed for conjugates 5a-5d and 10a-10d (see paragraph 4.9.2). 
Each mineralized sample was transferred into a marked flask by means of 1% 
v/v nitric acid and sonicated for 1 hour at 60 °C. After that, the samples were 
centrifuged (9000 rpm, 15 minutes) in order to separate the silica residue from 
the solution. The Pt content of the supernatants was quantified by means of ICP-
OES analysis and the results are reported in Table 5.3. 
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Conjugate 
% Pt loading 
(respect to the total available amino 
groups) 
mol Pt/g NPs 
14e 30.8 ± 1.1 7.89 (± 0.28)  10-5 
15e 22.5  1.5 5.77 (± 0.38)  10-5 
Table 5.3: Pt loading of conjugates 14e and 15e. Each result was obtained from at least three 
independent coupling reactions 
 
The data showed that conjugate 14e had a higher Pt content with respect to 15e: 
probably, complex 8 resulted to be more reactive than 13. 
  
5.6.2 Characterization of Conjugates 14e and 15e 
 
Conjugates 14e and 15e were characterized by DLS and TEM, in order to verify 
their size, and by ζ potential to evaluate the stability of their suspensions. Table 
5.4 and Figure 5.16 show the results. 
 
Conjugate TEM diameter DLS diameter  potential 
e 51 ± 1 nm 125 ± 2 nm 53 ± 2 mV 
14e 59 ± 5 nm 124  2 nm 40  3 mV 
15e 57 ± 4 nm 120  2 nm 38  2 mV 
Table 5.4: Diameter and ζ potential of conjugates 14e and 15e, compared with e 
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Figure 5.16: TEM micrographs of conjugates a) 14e and b) 15e (the bars represent 100 nm and 
200 nm, respectively) 
 
As regards the size, the new conjugates showed the same behavior in solution 
(i.e. the increased dimensions, due to the hydrodynamic radius) observed for the 
previous NPs. Furthermore, a preservation of the size, after the coupling 
reaction, was observed: in fact, 14e and 15e nano-systems resulted only slightly 
grown with respect to e. 
Moreover, the suspensions were stable, since the ζ potential values were higher 
than +30 mV (Table 5.4), even though there was a decrease in the ζ potential 
data from e to 14e and 15e (from about +53 mV to about +40 mV). It is known 
that the value observed for free NPs is due to the protonated amino groups 
exposed from the nanoparticles surface and, therefore, the coupling of the Pt(IV) 
complex to the amino functionalities leads to a loss of positive charge, since an 
amount of these amines is occupied in an amidic bond: this justified the lower ζ 
potential values with respect to the one of free e. 
 
b) a) 
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5.6.3 Platinum Release from Conjugates 14e and 15e in Reducing 
Conditions 
 
Conjugates 14e and 15e were centrifuged, the ethanol solutions were removed 
and the pellets were suspended in 1 mM HEPES buffer solution (pH 7.4) and 
ascorbic acid (10-fold molar excess respect to the Pt content) was added. The 
mixtures were mechanically shaken both for 8 and 24 hours and then the 
suspensions were centrifuged (9000 rpm, 15 minutes). The solutions were 
analyzed by means of ICP-MS, in order to quantify the Pt released: the 62% (± 
8) of the total platinum loaded on 14e was released within 8 hours and after 24 
hours almost all the platinum was released. 
For conjugate 15e, instead, the ascorbic acid reduced only a little amount of 
complex and this behavior was in agreement with the one observed in the 
reduction kinetics studies of other acetylamido derivatives [12] that were, 
however, reduced by cell extracts. 
 
5.6.4 Spontaneous Platinum Release from Conjugates 14e and 15e 
 
The spontaneous release of Pt complex from 14e and 15e, in the absence of any 
reducing agents, was studied in order to evaluate the behavior of NPs e and to 
compare it with the previously synthesized NPs a-d (see Chapter IV and, in 
particular, paragraph 4.16). 
As reported in paragraph 5.6.3, the conjugates were centrifuged, the ethanol 
solution was removed and the pellet was suspended in 1 mM HEPES buffer 
solution (pH 7.4) and mechanically shaken for 4 hours. Then the suspension was 
centrifuged (9000 rpm, 15 minutes) and the solution was analyzed by means of 
ICP-MS, in order to quantify the Pt released. Furthermore, the pellet was 
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suspended again in HEPES solution and the suspension was mechanically 
shaken for further 4 hours, in order to verify if, after the replacement of the 
solution, a further detachment still occurred. Also in this case, the suspension 
was centrifuged and the Pt content in the solution was determined by ICP-MS. 
The results indicated that, for both 14e and 15e, the 15% of the total loaded 
complex was detached within 4 hours: the released amount was similar to the 
one obtained for conjugate 10b in water in Chapter IV (paragraph 4.16). 
Moreover, the complex continued to be released after the renewal of the buffer 
solution: in fact, after further 4 hours, the Pt detached represented the 20% and it 
was cumulative with the first 15%. These data suggested that, without the 
replacement of the solution, an equilibrium between conjugate and released 
species was established but the renewal destabilized the equilibrium and favored 
a further detachment. The species detached was the same identified in 
paragraph 4.16 and defined as 7-APS. Therefore, even though the type of NPs 
was slightly different from the previous ones (a-d), in fact there were no 
fluorophores and core-shell structure and the amino silane arm was different 
(APTES, instead of APTMS), a loss of Pt was observed. It was attributed to the 
previously mentioned formation of stable five-membered cyclic intermediates 
and to the detachment induced by nearby amino groups [1]. The detachment 
results to be, therefore, independent from the nature of the alkoxy group of the 
silane arm (methoxy for APTMS and ethoxy for APTES) but is closely related 
to the presence of amino groups (primary in both cases, but also in the case of 
secondary amines) in propyl position, which are very suitable for the formation 
of cyclic intermediates. 
For this reason, it was necessary to synthesize NPs with a longer chain amino 
silane, i.e. N-(6-aminohexyl)aminomethyltriethoxysilane (AHAMTES), the 
hydrolytic stability of which was demonstrated to be higher, due to the absence 
of intramolecularly catalyzed detachments [2] (Figure 5.17). 
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Figure 5.17: The correlation between the position of the amino group in the alkylic chain of 
different amino silanes and the intra-molecularly catalyzed detachment from the NPs surface. 
The picture is a modification of that in literature [1] 
 
5.7 Synthesis of NPs Decorated with AHAMTES (f - i) 
 
Figure 5.18: Schematic synthesis of NPs f-i 
 
The synthetic procedure to prepare these types of NPs (Figure 5.18) was the 
same employed for the synthesis of NPs e (paragraph 5.5) but differed in the 
reaction time used to decorate the silica core. In particular, in a three-necked 
flask equipped with a reflux condenser, 20 mL of a 28% w/w ammonia solution 
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were added to 25 mL of ultrapure water, they were diluted with methanol to the 
final volume of 320 mL, magnetically stirred at 830 rpm and the temperature 
was set to 30 °C. Subsequently, TEOS (20 mL, 90 mmol) was added to the 
mixture and the reaction was carried out for 2.5 hours. Then the silica 
nanoparticles were collected by centrifugation (8500 rpm, 35 minutes), 
resuspended in ethanol by means of ultrasonic tip (power 117 W, 5 minutes) and 
these two steps were repeated three times. 
The ethanol suspension was added to a mixture of 35 mL of ultrapure water, 6 
mL of a 28% w/w ammonia solution and methanol to the final volume of 320 
mL, and then AHAMTES (2.89 mL, 9.17 mmol) was added. The suspension 
was magnetically stirred at 830 rpm, the temperature was set to 30 °C and the 
reaction was carried out for different times (in particular for 16 (f), 27 (g), 38 
(h), 62 hours (i)), in order to study the kinetics of AHAMTES loading on the 
silica surface. Subsequently, the NPs were collected by centrifugation (8500 
rpm, 35 minutes) and washed with ethanol by means of five cycles of 
resuspension (by ultrasonic tip) and centrifugation. The synthesized NPs were 
stored in ethanol at 4 °C. 
 
5.7.1 Quantification of the Amino Functionalities 
 
For the quantification of the amino groups, 0.5 g of NPs f-i were washed several 
times with ethanol, in order to completely remove not reacted ammonia and 
AHAMTES. Then, they were suspended twice in 20 mL of a 0.2 M HCl and 0.5 
M NaCl aqueous solution. After the centrifugation, they were suspended in 20 
mL of ultrapure water and then centrifuged. They were suspended in 20 mL of 1 
M KNO3 and the suspension was mechanically shaken overnight, in order to 
allow the exchange of chloride anions with nitrates. Then the suspension was 
centrifuged and the solution containing chloride anions was titrated with a 0.01 
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M AgNO3 aqueous solution by means of a Ag
+
-selective electrode. The results 
were expressed as total amino groups density, mmol/g NPs (Table 5.5) and the 
titration curve of NPs h is reported as an example in Figure 5.19. 
 
 
Figure 5.19: Titration curve of NPs h (in this case the nanoparticles amount employed for the 
quantification of the amino functionalities was 0.4 g, instead of 0.5 g) 
 
NPs total amino groups density (mmol/gNPs) 
f 0.057 ± 0.006 
g 0.079 ± 0.008 
h 0.131 ± 0.013 
i 0.129 ± 0.013 
Table 5.5: NPs f-i total amino groups density 
 
The results, compared to the -NH2 density of NPs e (i.e. 0.283 mmol/g), indicate 
a lower amino silane loading in the case of AHAMTES (i.e. NPs f-i). In fact, the 
hydrolysis (and, therefore, the reactivity) of the amino silane arm, process 
necessary for the functionalization of the NPs surface, depends on the length of 
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the arm chain: a longer amino silane (such as AHAMTES) hydrolyzes more 
slowly than a shorter chain silane (such as APTES or APTMS) [13]. For this 
reason, being AHAMTES less reactive than APTES and being its hydrolysis 
fundamental for the NPs functionalization, a lower number of amino groups is 
present on the NPs surface. 
The total amino groups densities are reported in Figure 5.20 as a function of the 
reaction time with AHAMTES, to set the experimental conditions in order to get 
the highest silane loading. 
 
 
Figure 5.20: AHAMTES loading on NPs surface as a function of the reaction time. Each data 
point is the mean of three independent samples 
 
The results indicate that the maximum amount of AHAMTES loaded on the NPs 
surface was reached within 38 hours of reaction. For this reason, the reaction 
time was set at 38 hours and NPs h were employed for the coupling procedures. 
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5.7.2 Size and Stability Investigations of NPs f - i 
 
DLS and ζ potential analyses of NPs f-i were performed in order to the verify 
their size and suspension stability (see paragraph 5.5.2). The results are 
reported in Table 5.6. 
 
NPs DLS diameter ζ potential 
f 135  6 nm 23  2 mV 
g 151  6 nm 26  1 mV 
h 131  5 nm 26  2 mV 
i 188  1 nm 25  2 mV 
Table 5.6: DLS and ζ potential data of NPs f-i 
 
The DLS data show that all the NPs samples have similar dimensions, except for 
NPs i which result to be larger than the others: this is probably due to the fact 
that the decoration reaction lasts more than two days and a half (i.e. 62 hours). 
This could be explained by considering the fact that the size of the NPs as such 
increased or numerous multilayers of the amino silane were formed [2] and, 
therefore, the NPs result to be larger. 
The ζ potential results point out that, even though all the four NPs types do not 
exceed the threshold of stability (i.e. values ≥ |30| mV), they show values very 
close to the required one. Therefore, they are considered reasonably stable. 
As regards TEM analysis, only NPs h (i.e. the most relevant sample) were 
analyzed. Figure 5.21 shows the micrographs of the silica core (without amino 
groups) and the protonated NPs h (silica core with amino groups, after their 
protonation). The protonated sample was obtained by centrifugation of the 
ethanol suspension, subsequent resuspension in 0.2 M HCl (in order to create a 
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repulsion among the amino arms), centrifugation and resuspension in ethanol. 
The TEM and DLS diameters and ζ potential of these two samples are reported 
in the Table 5.7. 
 
  
Figure 5.21: TEM micrographs of NPs h a) without amino functionalities and b) with protonated 
amino groups. The bars represents 100 nm 
 
NPs h DLS diameter  potential TEM diameter 
without amino 
groups 
112  4 nm -13  1 mV 45 ± 4 nm 
with protonated 
amino groups 
131  5 nm 26  2 mV 50 ± 5 nm 
Table 5.7: Size and suspension stability of NPs h without amino groups and with protonated 
amino groups 
 
b) a) 
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The comparison between DLS and TEM analyses of the silica core and the 
protonated NPs h indicate that a size increase occurred after the 
functionalization of the nanoparticles surface. 
As far as ζ potential is concerned, the final NPs show a positive value, typical of 
the amino functionalities (exposed from the NPs surface) in their protonated 
form. The silica core, instead, has a negative ζ potential: it is due to the free 
hydroxyl groups of silica, present before the surface functionalization (Figure 
5.18, before the II synthetic step of the NPs). 
 
5.7.3 Solid-State NMR Characterization 
 
In order to evaluate the functionalization of NPs h, an aliquot of the NPs was 
lyophilized and then analyzed by means of Solid-State NMR technique: in 
Figure 5.22, the CPMAS NMR spectrum is shown. 
 
 
Figure 5.22: CPMAS NMR spectrum of NPs h 
 
The spectrum reported in Figure 5.22 confirms the functionalization of NPs h 
and gives information as regards the NPs surface. Similarly to the previous NPs, 
the peak at about -100 ppm is ascribed to isolated silanol groups [(SiO)3Si(OH)] 
(Q
3
) and the one at -110 ppm indicates surface siloxane bridges [(SiO)4Si] (Q
4
). 
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In this case, T
2
 and T
3
 (indicated by a red oval) result to be very weaker than Q
3
 
and Q
4
: this suggests the presence of a lower number of amino silane arms on 
the NPs surface, with respect to the previous NPs, in agreement with the 
measured amino groups density of NPs h (Table 5.5) and NPs e (i.e. 0.283 
mmol NH2 / g NPs). 
Although the available amino functionalities number was lower, this type of 
NPs was coupled to the complexes 8 and 13 and compared with the previous 
NPs (i.e. a-d and e). 
 
5.8 Synthesis of Conjugate 14h at Different Reaction Times 
 
The coupling procedure was slightly different from the one employed for the 
synthesis of conjugates 14e and 15e (paragraph 5.6): in fact, it was necessary to 
create a repulsion among the amino arms in order to avoid the aggregation of 
nearby NPs, favored by the longer chains of AHAMTES. In this case, the 
aggregation was reversible: in fact, the use of an acidic solution allowed the 
protonation of the amino groups, the repulsion among the arms and, therefore, 
the disaggregation of eventual agglomerates. 
In particular, the ethanol suspension h (1 mL, 78.9 mg NPs, 0.0104 mmol amino 
groups) was centrifuged, washed once with 0.2 M HCl, once with ultrapure 
water (to remove HCl excess), once with ethanol and once with anhydrous 
DMF, then the NPs were suspended in anhydrous DMF. This suspension was 
added to a solution of 8 (5.8 mg, 0.0104 mmol) in 1 mL of DMF and, then, an 
appropriate amount of N,N-diisopropylethylamine (DIPEA) was added till the 
formation of a NPs agglomeration (visible to naked eye). The synthesis was 
carried out at room temperature for different reaction times (such as 1, 2, 4 and 8 
hours). 
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The suspensions were centrifuged (9000 rpm, 15 minutes) and the conjugates 
were washed with ultrapure water and ethanol, in order to completely remove 
not coupled 8, NHS and DMF. 
 
5.8.1 Quantification of the Pt Content in Conjugates 14h (at 1, 2, 4 
and 8 hours) 
 
An aliquot of the ethanol suspensions 14h (at 1, 2, 4 and 8 hours) was 
centrifuged and the pellet was dried in order to be mineralized by means of 
microwaves. For each sample, the results were expressed as the average of the 
Pt loading obtained after three independent couplings, according to the 
previously described procedure (paragraph 4.9.2). The couplings data at 
different reaction time are shown in Table 5.8. 
 
conjugate reaction time 
% Pt loading 
(respect to the total amino groups) 
14h 
1 h 10.6  0.1 
2 h 13.4  0.7 
4 h 16.2  0.8 
8 h 10.4  0.4 
Table 5.8: Pt loadings on conjugates 14h obtained at different reaction times 
 
The data show that the highest platinum loading is obtained within 4 hours, even 
though, by a comparison with the previously synthesized conjugates, the loaded 
amount is lower than the one observed for 10a-10d, 14e and 15e. 
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5.9 Synthesis of Conjugate 14h and 15h at Fixed Reaction Time 
but with Different Pt/Total Amino Groups Ratios 
 
After fixing the reaction time at 4 hours, the conjugates were synthesized by 
using different Pt/amino groups ratios (such as 0.5:1, 1:1, 2:1 and 5:1) in order 
to evaluate the loading capability of the NPs. Some aliquots of the ethanol 
suspension h (1 mL, 78.9 mg NPs, 0.0104 mmol amino groups) were 
centrifuged, washed with 0.2 M HCl, ultrapure water, ethanol, anhydrous DMF 
and then suspended in anhydrous DMF. These suspensions were added to 1 mL 
of anhydrous DMF containing 8: 2.9 mg, 0.00518 mmol (Pt/N = 0.5:1); 5.8 mg, 
0.0104 mmol (1:1); 11.6 mg, 0.0207 mmol (2:1); 28.9 mg, 0.0518 mmol (5:1). 
After the addition of an appropriate quantity of DIPEA (till a NPs agglomeration 
was observed), the reaction was carried out at room temperature for 4 hours. 
The same procedure was employed for the synthesis of conjugates 15h, in which 
some NPs suspension aliquots (1 mL, 78.9 mg NPs, 0.0104 mmol amino 
groups) were added to 1 mL of anhydrous DMF containing 13: 3.0 mg, 0.00518 
mmol (0.5:1); 5.9 mg, 0.0104 mmol (1:1); 11.8 mg, 0.0207 mmol (2:1); 29.6 
mg, 0.0518 mmol (5:1). Then DIPEA was added and the reaction was 
performed at room temperature for 4 hours. 
The suspensions were centrifuged (9000 rpm, 15 minutes) and the conjugates 
were washed with ultrapure water and ethanol. 
 
5.9.1 Quantification of the Pt Content in 14h and 15h (Different 
Pt/Amino Groups Ratios) 
 
An aliquot of the ethanol suspensions of both 14h and 15h (with different 
Pt/amines ratio) was treated as previously described (paragraph 4.9.2) to 
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quantify the Pt loading. The results are shown in Table 5.9 for conjugates 14h 
and in Table 5.10 for conjugates 15h. Each coupling result was the average of at 
least three synthetic reactions. 
 
Conjugate 
Pt/total amino groups 
ratio 
% Pt loading mol Pt/g NPs 
14h 
0.5:1 13.3  1.0 1.74 (± 0.13) × 10
-5
 
1:1 16.2  0.8 1.94 (± 0.10) × 10
-5
 
2:1 15.8  1.7 1.90 (± 0.21) × 10
-5
 
5:1 18.2  0.6 2.38 (± 0.08) × 10
-5
 
Table 5.9: Pt loadings on conjugates 14h at different Pt/amines ratios but at fixed reaction time 
 
The coupling results for 14h show that there are no significant differences 
between the different ratios. Therefore, since the 2:1 and 5:1 ratios do not lead 
to a considerable loading increase, the 1:1 ratio was employed for the 
preparation of further conjugates. 
 
Conjugate 
Pt/total amino groups 
ratio 
% Pt loading mol Pt/g NPs 
15h 
0.5:1 9.4  0.3 1.23 (± 0.04) × 10
-5
 
1:1 12.1  2.0 1.45 (± 0.24) × 10
-5
 
2:1 14.9  0.5 1.79 (± 0.06) × 10
-5
 
5:1 17.3  0.9 2.26 (± 0.11) × 10
-5
 
Table 5.10: Pt loadings on conjugates 15h at different Pt/amines ratios but at fixed reaction time 
 
In the case of 15h, the results show that there is an increase of the Pt loading by 
increasing the amount of complex employed in the synthesis. However, since 
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the increase is not significant, the ratio was fixed at 1:1 in order to avoid the 
employment of large amount of Pt(IV) complex and to use the same procedure 
described for the conjugate 14h. 
 
5.9.2 Characterization of Conjugates 14h and 15h with 1:1 
Pt/Total Amino Groups Ratio 
 
The two conjugates were analyzed by means of DLS and TEM in order to verify 
their size and then the ζ potential values were determined to evaluate their 
suspensions stability. The results are shown in Table 5.11 and Figure 5.23. 
 
Conjugate DLS diameter  potential TEM diameter 
14h (1:1 ratio) 126  3 nm 19  1 mV 49 ± 3 nm 
15h (1:1 ratio) 127  4 nm 17  1 mV 52 ± 5 nm 
Table 5.11: Size and suspension stability results of conjugates 14h (1:1 ratio) and 15h (1:1 ratio) 
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Figure 5.23: TEM micrographs of conjugates a) 14h (1:1 ratio) and b) 15h (1:1 ratio). 
The bars represents 100 nm 
 
An increase in the NPs size by passing from TEM to DLS (Table 5.11 and 
Figure 5.23) is observed also in this case, due to the hydrodynamic radius 
present in aqueous solutions. Moreover, the comparison between NPs h and 
conjugates 14h (1:1 ratio) and 15h (1:1 ratio) points out that, after the coupling 
with the Pt(IV) complexes, there is not a significant size increase: the 
dimensions are preserved. 
As regards the ζ potential values (Table 5.11), they are lower than +30 mV, 
indicating a limited stability because the attractive forces begin to prevail over 
the repulsive ones. However, in the case of 14h (1:1 ratio) and 15h (1:1 ratio), 
no aggregation processes were observed. Moreover, ζ potential values result to 
be decreased with respect to the free NPs h: in fact, they turn from about +26 
mV to about +20 mV. This fact can be attributed to the coupling of some amino 
groups, causing a decrease of the positive charge and, therefore, of the ζ 
potential values. 
b) a) 
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5.9.3 Releases from Conjugates 14h and 15h: Spontaneous and in 
Reducing Conditions 
 
The spontaneous Pt release from 14h and 15h, in the absence of any reducing 
agents, was verified by mechanically stirring the conjugates (after being dried) 
in 1 mM HEPES buffer solution (pH 7.4). After 1, 4 or 8 hours, the suspensions 
were centrifuged (9000 rpm, 15 minutes) and the platinum content in the 
solutions was measured by ICP-MS. 
The results indicate that only the 5 % ( 1) of the total loaded complex is 
detached, independently on the time and on the renewal of the buffer solution. 
These data show that the synthesized conjugates are hydrolytically stable (after 
the renewal of the solution no further release was observed, unlike conjugate 
10b) and the first amount detached could be attributed to possible multilayers, 
obtained due to the long silanization time [2]. 
In the presence of ascorbic acid (10-fold molar excess respect to Pt), the release 
test for 14h gave the results reported in Table 5.12: 
 
Conjugate Test time 
% released Pt (respect to the total Pt 
loaded on 14h) 
14h 
1 h 35  1 
4 h 51  3 
8 h 71  2 
Table 5.12: Pt release from conjugate 14h in reducing conditions (i.e. in the presence of ascorbic 
acid) 
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The data show that the platinum complex is progressively released due to the 
action of the ascorbic acid, which allows the so-called activation by reduction, 
which can go to completion within 24 hours, ensuring a complete reduction into 
the cells during the viability assays (i.e. 72 hours). 
For conjugate 15h, instead, as observed in paragraph 5.6.3, this reducing agent 
does not show a significant effect: only the 10% ( 2) of the total Pt loaded was 
released within 24 hours. 
 
5.10 Biological In Vitro Studies 
 
After the phase of characterization of the synthesized nano-systems 14e, 15e, 
14h (1:1 ratio) and 15h (1:1 ratio), their in vitro ability in the inhibition of the 
cell growth and proliferation (IC50) and their cellular accumulation were 
verified. 
 
5.10.1 The Antiproliferative Activity (IC50) 
 
The conjugates 14e, 15e, 14h, 15h, and complexes 7 and 12 were tested on 
human ovarian carcinoma A2780 cell line, grown in RPMI 1640 medium. This 
latter was supplemented with L-glutamine (2 mM), penicillin (100 IU/mL), 
streptomycin (100 mg/L) and 10% fetal bovine serum (FBS). 
The treatments were performed at 37 °C in a 5% CO2 humidified chamber and 
cells were continuously treated for 72 hours. Then, in order to evaluate the 
remaining cellular viability, after the treatment with the previously mentioned 
compounds, the resazurin reduction assay was employed [14]. In particular, at 
the end of the treatment, the viability was assayed by 100 μg/mL resazurin in 
fresh medium for 1 hour at 37 °C: the live cells with an active metabolism are 
195 
 
able to reduce resazurin in resorufin and, then, this latter was measured by 
means of its fluorescence with a Tecan Infinite F200Pro plate reader. 
Fluorescence (excitation λ at 535 nm, emission λ at 595 nm) is directly 
proportional to the cell viability. 
Each IC50 value (Table 5.13 and Figure 5.24), derived from the dose-response 
sigmoids, was obtained as a mean of at least three independent replicates and the 
data were normalized to 100% of viability for not-treated cells and the 
fluorescence/absorbance of the medium without cells was used as blank. 
 
Compound IC50 (μM) 
cisplatin 0.5 ± 0.1 
7 5.02 ± 0.66 
14e 0.015 ± 0.004 
15e 0.020 ± 0.005 
12 20.5 ± 1.7 
14h 0.240 ± 0.071 
15h 0.280 ± 0.037 
Table 5.13: IC50 values of the conjugates, compared to the two free Pt(IV) complexes 7 and 12 
and to cisplatin, on A2780 cells 
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Figure 5.24: Bars graph of the IC50 values on A2780 cell line 
 
The results allow to evaluate that all the conjugates are more effective than 
cisplatin and free Pt(IV) complexes. Moreover, these latter are less cytotoxic 
with respect to cisplatin itself (in particular, 12 is less active than 7). 
These data, compared to the results shown in paragraph 4.19.1, indicate that 
14e and 15e have a very similar antiproliferative activity to the one observed for 
10b-10d (Figure 5.25). However, conjugates 14h and 15h are less effective (of 
about one order of magnitude) than 10b-10d. 
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Figure 5.25: Bars graph of the IC50 values for all the conjugates (i.e. 10b-10d, 14e and 15e, 14h 
and 15h) 
 
5.10.2 The Cellular Accumulation 
 
In order to find a possible reason of the lower cytotoxicity of 14h and 15h, their 
cellular accumulation was measured to evaluate the possible correlation between 
the IC50 value and the accumulation of the drug into the cells. 
In particular, 10 μM suspensions of the conjugates 14e, 15e, 14h, 15h and 10 
μM solutions of the platinum complexes (i.e. cisplatin, 7 and 12) were tested on 
A2780 human ovarian carcinoma cell line. After 4 h treatment, 100 μL of 
culture medium were harvested to measure the neat extracellular platinum 
concentration (to take into account the adsorption on plasticware) and the cells 
were washed three times in PBS, detached from the 25 cm
2
 flasks using 1 mL of 
0.05% Trypsin EDTA and harvested in fresh complete medium. An automatic 
cell counting device was used to measure the cells number and the mean 
diameter from every cell count. About 5 × 10
6
 cells were transferred into a glass 
tube and spun at 1100 rpm for 5 minutes at room temperature. The supernatant 
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was almost completely removed by aspiration (200 μL were left) and the cell 
pellet was stored at -20 °C. Before ICP-MS measurement, the pellet was 
defrosted and 350 μL of 70% w/w HNO3 were added to each glass tube. The 
samples were mineralized for 1 hour at 60 °C in an ultrasonic bath and then 
diluted with a 1% v/v HNO3 aqueous solution (by adding 5650 μL) to a final 3% 
v/v of acid concentration. The platinum content present in each solution was 
quantified by means of ICP-MS. 
The results were expressed as μM Pt concentration. 
The data processing, after the normalization of the Pt amount found into the 
cells upon the cells number and volume (calculated from the actual mean cell 
diameter of every sample) allowed to obtain the intracellular platinum 
concentration. The ratio between the intra- and extracellular concentration of Pt 
allowed to obtain the AR value of each sample. The obtained AR data are shown 
in Table 5.14 and Figure 5.26. 
 
Compound AR 
cisplatin 1.4  0.6 
7 0.38 ± 0.09 
14e 68.44 ± 11.89 
15e 55.00 ± 10.50 
12 0.22 ± 0.01 
14h 31.71 ± 2.27 
15h 33.98 ± 5.94 
Table 5.14: Accumulation Ratio values on A2780 cell line 
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Figure 5.26: Bars graph of the AR values on A2780 cells 
 
The results show that all the conjugates are accumulated into the cells more than 
cisplatin and the free platinum complexes: in particular, the order of magnitude 
of the AR value is the same observed for 10b-10d (Figure 5.27). 
 
 
Figure 5.27: Comparison of the AR values of the three types of conjugates 
(i.e. 10b-10d, 14e and 15e, 14h and 15h) 
cisplatin 7 14e 15e 12 14h 15h
0
2
30
40
50
60
70
80
90
A
R
Compounds
10b 10c 10d 14e 15e 14h 15h
0
20
40
60
80
100
A
R
Conjugates
APTES NPs
AHAMTES NPs
APTMS NPs
200 
 
 
As regards the higher efficacy of 14e and 15e than the hydrolytically stable 14h 
and 15h, it can be justified by their higher cellular accumulation: the lower 
amino groups density on NPs h (functionalized with AHAMTES) than the NPs 
e (with APTES) leads to a lower amount of drug accumulated into the cells. The 
lower AR and, in turn, the antiproliferative activity can be explained also by 
considering the ζ potential: in fact, positively charged nanoparticles are 
accumulated by endocytosis mechanisms much more than the ones with 
negative charges [16, 17, 18] and a positive ζ potential value of the NPs favored 
the electrostatic interaction with the cell membrane. According to these 
considerations, conjugates 14e and 15e were more accumulated than conjugates 
14h and 15h by virtue of their higher ζ potential. 
 
5.11 Conclusions 
 
In this chapter, two monofunctionalized Pt(IV) complexes were synthesized and 
coupled to two different types of amino-functionalized nonporous silica 
nanoparticles: the first was decorated with the aminopropyl arm APTES (e), 
whereas the second with the aminohexylaminomethyl arm AHAMTES (h). 
Spontaneous release tests of all the conjugates (14e, 15e, 14h and 15h) were 
performed in buffer solution (pH 7.4) and showed that the NPs h were 
hydrolytically stable (unlike NPs e, which behaved like the nanoparticles 
described in Chapter IV). In the presence of ascorbic acid, the conjugates 14e 
and 14h showed an almost complete release due to the typical activation by 
reduction of Pt(IV) compounds, whereas 15e and 15h did not release a large 
amount of complex (this behavior was observed also for other acetylamido 
species). However, since many reducing agents are present into the tumor cells, 
the active metabolite is ensured to be formed. 
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Then, the four conjugates were tested on A2780 cell line: their antiproliferative 
activities and cellular accumulations resulted to be much higher than cisplatin 
and the free Pt(IV) complexes (7 and 12), due to the internalization mechanisms 
by endocytosis. However, the higher stability of conjugates 14h and 15h was 
not accompanied by an increase of the in vitro cytotoxic activity. 
In any case, the results confirm that NPs are vectors able to ensure more 
enhanced in vitro cellular accumulation and antiproliferative activity than a free 
platinum complex. Moreover, thinking about in vivo application, it is important 
to have a delivery system with a more controlled release such as in the case of 
hydrolytically stable NPs. 
 
5.12 Perspectives 
  
Aiming at exploiting the previously prepared silica NPs with different kinds  of 
Pt(IV) complexes functionalized with a 4-carboxypropanoato, another Pt(II) 
complex was synthesized: a tridentate aromatic ligand (i.e. a terpyridine) was 
used to prepare cationic monodentate Pt(II) complexes able to interact with 
DNA in a different manner with respect to cisplatin. Such complexes could 
intercalate DNA (apart from coordination) and could also interact with a 
particular structure of DNA: the quadruple helix DNA [19]. 
Only some regions of DNA show this unusual structure: in particular, the 
guanine rich sequences. If four of these DNA sequences occupy adjacent 
positions, a quadruple helix structure can be formed (through hydrogen bonds 
among four guanines) and it is called G-quadruplex (Figure 5.28). These 
conformations are stabilized by ions or charged molecules which are placed in 
the middle of the structure itself. 
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Figure 5.28: Schematic representation of G-quadruplex DNA structure. The picture is adapted 
from literature [20] 
 
The G-quadruplex affects the activity of a particular enzyme, the telomerase 
(regulating the elongation process of telomeres, i.e. the end of chromosomes), 
which is involved in almost all the tumor processes. For this reason, the G-
quadruplex structures are emerging as new distinctive targets for the 
development of new anticancer drugs. In this regard, in recent years, many 
studies are being carried out for the design and synthesis of new and efficient G-
quadruplex ligands, which must show a higher affinity for the quadruple helix 
than for the double one. 
The main requirements of these ligands for the stabilization of the quadruple 
helix are a large aromatic planar surface, the presence of positive charges and 
the stacking ability. These characteristics can be found in metal complexes with 
a positive charge that allows them to effectively bind to the negatively charged 
G-quadruplex DNA. In particular, square planar copper(II) and nickel(II) 
complexes are effective stabilizers of telomeres. Furthermore, porphyrins- and 
terpiridine-based ligands were tested and the Cu(II) and Pt(II) complexes 
resulted to be more selective for the G-quadruplex than for the double helix 
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[21]. This latter feature makes these compounds suitable for the use as 
anticancer drugs: in fact, their lower affinity for the double helix results in a 
reduction of side effects. To increase this affinity it is possible to employ ligands 
containing more than one planar polyaromatic interconnected structure (for 
example, anthracene). In this regard, a recent study was focused on the synthesis 
of platinum(II) and copper(II) complexes, coordinated to an anthracene-
terpyridine ligand [22]. 
In the following paragraphs, the syntheses and characterizations of some 
platinum complexes containing terpyridine are described and they are 
exploitable for future coupling reactions with amino-functionalized vectors, 
suitable for passive Drug Targeting and Delivery (DTD) strategies. 
The synthesized platinum complexes are here reported: 
 (SP-4-3)-dichlorido((1Z,5Z)-cycloocta-1,5-diene)platinum(II) (16), 
 (SP-4-3)-chlorido(2,2':6',2''-terpyridine)platinum(II) chloride (17), 
 (OC-6-33)-chloridodihydroxido(2,2':6',2''-terpyridine)platinum(IV) 
chloride (18), 
 (OC-6-33)-(4-carboxypropanoato)chloridohydroxidoplatinum(IV) (19). 
 
5.12.1 Synthesis of the (SP-4-3)-dichlorido((1Z,5Z)-cycloocta-1,5-
diene)platinum(II) (16) 
 
 
 
Potassium tetrachloroplatinate(II) (1.00 g, 2.41 mmol) was dissolved in 16 mL 
of ultrapure water and the red solution was filtered to remove possible solid 
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residues. Then, 24 mL of glacial acetic acid and (1Z,5Z)-cycloocta-1,5-diene 
(COD, 1.00 mL, 8.15 mmol) were added and the mixture was magnetically 
stirred for 2 hours in a steam bath at 90 °C, in the dark. During this time, the 
solution changed color (from red to pale yellow) and a white solid precipitated 
in the mixture. When significant changes were no more observed, ¾ of the 
volume were removed under reduced pressure. Subsequently, the solid was 
collected by centrifugation and was washed three times with ultrapure water, 
three times with ethanol and once with diethyl ether. The white reaction product 
was dried in vacuo. 
Yield: 703 mg, 1.88 mmol, 78.0%. 
 
5.12.2 Characterization of the Complex 
 
1
H-NMR 
 
Figure 5.29: 
1
H-NMR spectrum of complex 16, registered in CDCl3 
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The 
1
H-NMR (500 MHz, CDCl3) spectrum of complex 16 (Figure 5.29) shows 
the following signals, δ: 2.27 and 2.71 (m, H3, H4, H7, H8, 8H), 5.61 (m, H1, 
H2, H5, H6, 4H) ppm. 
 
13
C-NMR 
 
Figure 5.30: 
13
C-NMR spectrum of complex 16, registered in CDCl3 
 
The 
13
C-NMR (125.7 MHz, CDCl3) spectrum of complex 16 (Figure 5.30) 
shows the following signals, δ: 31.0 (C3, C4, C7, C8), 100.2 (C1, C2, C5, C6) 
ppm. 
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Figure 5.31: 
195
Pt-NMR spectrum of complex 16, registered in CDCl3 
 
The 
195
Pt-NMR spectrum (Figure 5.31) of complex 16 (with a 107.2 MHz NMR 
frequency) shows a signal at -3342 ppm: it is consistent with a Pt(II) complex 
containing two chlorides and the (1Z,5Z)-cycloocta-1,5-diene ligand. 
 
The preparation of the Pt(II)-terpyridine precursor successfully occurred and this 
complex was employed for the synthesis of the desired Pt(II) 17. 
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5.13 Synthesis of the (SP-4-3)-chlorido(2,2':6',2''-
terpyridine)platinum(II) Chloride (17) 
 
 
 
Complex 16 (154 mg, 0.412 mmol) was suspended in 10 mL of ultrapure water. 
Then, terpyridine (101 mg, 0.433 mmol) was added to the mixture, which was 
magnetically stirred for 30 minutes at 70 °C. After the established time, the 
water of the red solution was removed under reduced pressure and a red product 
was precipitated, washed with diethyl ether and then dried in vacuo. 
Yield: 170 mg, 0.341 mmol, 82.7%. 
 
5.13.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. In this case, the sample was 
prepared by dissolving it in a 20 mM NaCl aqueous solution in order to avoid 
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the complex hydrolysis, i.e. the loss of the chloride ligand and its replacement 
by a water molecule, typical of the Pt(II) species in water. Compound 17 
showed a retention time of 10.91 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 5.32). 
 
 
Figure 5.32: ESI-MS spectrum of complex 17, prepared in a 20 mM NaCl solution 
 
The ESI-MS spectrum (Figure 5.32), registered in positive ion mode with a 
cone voltage of 30V, shows a value at 464.3 m/z, corresponding to the species 
[M-Cl]
+
 of complex 17 and this confirms the success of the reaction. 
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Figure 5.33: 
1
H-NMR spectrum of complex 17, registered in MeOD-d4 
 
The 
1
H-NMR (400 MHz, MeOD-d4) spectrum of complex 17 (Figure 5.33) 
shows the following signals, δ: 7.79 (m, H2, H14, 2H), 8.40 (m, H1, H15, H3, 
H13, H7, H9, 6H), 8.47 (m, H8, 1H), 8.82 (m, H4, H12, 2H) ppm. 
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Figure 5.34: 
13
C-NMR spectrum of complex 17, registered in MeOD-d4 
 
The 
13
C-NMR (100.6 MHz, MeOD-d4) spectrum of complex 17 (Figure 5.34) 
shows the following signals, δ: 124.1 (C2, C14), 125.3 (C7, C9), 128.7 (C4, 
C12), 141.7 (C8), 142.4 (C3, C13), 151.4 (C1, C15), 154.9 (C6, C10), 158.8 
(C5, C11) ppm. 
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Figure 5.35: 
195
Pt-NMR spectrum of complex 17, registered in MeOD-d4 
 
The 
195
Pt-NMR spectrum (Figure 5.35) of complex 17 (with a 86.0 MHz NMR 
frequency) shows a signal at -2734 ppm,  consistent with a Pt(II) complex with 
one chloride and three amines. 
 
This complex was successfully prepared and the subsequent phase consisted of 
its oxidation by the use of hydrogen peroxide, in order to synthesize a more 
stable and inert Pt(IV) compound. 
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5.14 Synthesis of the (OC-6-33)-chloridodihydroxido(2,2':6',2''-
terpyridine)platinum(IV) Chloride (18) 
 
 
 
Complex 17 (40.0 mg, 0.0801 mmol) was dissolved in a 50% w/w aqueous 
solution of hydrogen peroxide (2.00 mL, 35.2 mmol) and the reaction was 
assisted by microwaves by using a CEM Discover
®
 SP System, equipped with a 
focused single mode and self-tuning cavity, an air cooling system, an automated 
power control based on temperature feedback, and was performed for 2 hours at 
70 °C. After the established time, the water of the yellow solution was removed 
under reduced pressure. The yellow compound was collected by adding 
acetone/diethyl ether, washed with diethyl ether and then dried in vacuo. 
Yield: 35.0 mg, 0.0656 mmol, 81.9%. 
 
5.14.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
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pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 18 showed a 
retention time of 3.95 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 5.36). 
 
 
Figure 5.36: ESI-MS spectrum of complex 18, prepared in ultrapure water 
 
The ESI-MS spectrum (Figure 5.36), registered in positive ion mode with a 
cone voltage of 30V, confirms the presence of the desired product: in fact, a 
value at 498.3 m/z, corresponding to the species [M-Cl]
+
 of complex 18, is 
observed. 
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Figure 5.37: 
1
H-NMR spectrum of complex 18, registered in D2O 
 
The 
1
H-NMR (500 MHz, D2O) spectrum of complex 18 (Figure 5.37) shows the 
following signals, δ: 8.16 (t, H2, H14, 2H, 3J = 6.7 Hz), 8.64 (t, H7, H9, 2H, 3J = 
7.8 Hz), 8.73 (d, H1, H15, 2H, 
3
J = 7.8 Hz), 8.81 (s, H3, H8, H13, 3H), 9.35 (d, 
H4, H12, 2H, 
3
J = 5.6 Hz) ppm. 
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Figure 5.38: 
13
C-NMR spectrum of complex 18, registered in D2O 
 
The 
13
C-NMR (125.7 MHz, D2O) spectrum of complex 18 (Figure 5.38) shows 
the following signals, δ: 126.9 (C2, C14), 128.0 (C7, C9), 130.6 (C4, C12), 
144.9 (C3, C13), 146.0 (C8), 151.6 (C1, C15), 152.2 (C6, C10), 156.7 (C5, C11) 
ppm. 
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Figure 5.39: 
195
Pt-NMR spectrum of complex 18, registered in D2O 
 
The 
195
Pt-NMR spectrum (Figure 5.39) of complex 18 (with a 107.2 MHz NMR 
frequency) shows a signal at 387 ppm, consistent with a Pt(IV) complex 
containing a chloride, three amines and two hydroxido ligands. 
 
The Pt(II) oxidation occurred giving rise to a completely pure complex. 
However, the conditions reaction were very strict: in fact, no additional water 
was employed and microwaves resulted to be necessary. The prepared 
compound was further functionalized in order to expose a 4-carboxypropanoato 
group. 
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5.15 Synthesis of the (OC-6-33)-(4-
carboxypropanoato)chloridohydroxidoplatinum(IV) (19) 
 
 
A solution of succinic anhydride (46.9 mg, 0.469 mmol) in 1 mL of DMF was 
added to a suspension of complex 18 (50.0 mg, 0.0938 mmol) in 2 mL of DMF 
and the reaction was carried out at 40 °C overnight. The solvent was then 
removed from the suspension under reduced pressure and an orange solid was 
collected by the addition of acetone/diethyl ether. It was purified with an anionic 
exchange resin (Amberlite
®
 IRA-400(OH) Supelco), in which the hydroxido 
groups were replaced by chloride anions, and then dried in vacuo. 
Yield: 44.8 mg, 0.0707 mmol, 75.4%. 
 
5.15.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 90:10 mixture of a 15 mM aqueous solution of formic acid and 
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pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 19 showed a 
retention time of 9.06 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 5.40). 
 
 
Figure 5.40: ESI-MS spectrum of complex 19, prepared in ultrapure water 
 
The ESI-MS spectrum (Figure 5.40), registered in positive ion mode with a 
cone voltage of 30V, shows a value at 598.2 m/z, corresponding to the species 
[M-Cl]
+
 of complex 19 and this confirms that the complex was successfully 
synthesized. 
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Figure 5.41: 
1
H-NMR spectrum of complex 19, registered in D2O 
 
The 
1
H-NMR (500 MHz, D2O) spectrum of complex 19 (Figure 5.41) shows the 
following signals, δ: 2.62 (s, H17, H18, 4H), 8.13 (m, H2, H14, 2H), 8.60 (t, H7, 
H9, 2H, 
3
J = 7.9 Hz), 8.69 (d, H1, H15, 2H, 
3
J = 7.9 Hz), 8.75 (s, H3, H8, H13, 
3H), 9.34 (d, H4, H12, 2H, 
3
J = 5.7 Hz) ppm. 
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Figure 5.42: 
13
C-NMR spectrum of complex 19, registered in D2O 
 
The 
13
C-NMR (125.7 MHz, D2O) spectrum of complex 19 (Figure 5.42) shows 
the following signals, δ: 29.9 (C17, C18), 126.5 (C2, C14), 127.6 (C7, C9), 
130.3 (C4, C12), 144.9 (C3, C13), 146.0 (C8), 151.7 (C1, C15), 152.8 (C6, 
C10), 157.3 (C5, C11), 177.2 (C19), 180.3 (C16) ppm. 
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Figure 5.43: 
195
Pt-NMR spectrum of complex 19, registered in D2O 
 
The 
195
Pt-NMR spectrum (Figure 5.43) of complex 19 (with a 107.2 MHz NMR 
frequency) shows a signal at 524 ppm: it is consistent with a Pt(IV) complex 
containing a chloride, three amines, a hydroxido and a succinato ligand. 
 
The successfully synthesized complex can be exploited for further coupling 
reactions with amino-functionalized vectors, suitable for passive DTD 
strategies: this is the purpose of future projects. 
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Capitolo 6  
Chapter VI 
 
 
 
 
 
 
 
 
 
 
Coupling Reactions with Chitosan and Chitosan 
Derivatives 
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6.1 Introduction 
 
Chitosan is a linear polysaccharide composed of randomly distributed β-(1-4)-
linked D-glucosamine and N-acetyl-D-glucosamine (Figure 6.1). 
 
 
Figure 6.1: Chitosan structure with deacetylated and acetylated units 
(AD = acetylation degree) 
 
This biopolymer shows several advantages that allow it to be widely employed 
in many fields (such as pharmaceutical, cosmetic and food industries, 
agriculture, etc.): in fact, it is nontoxic, biodegradable, biocompatible and it has 
many other biological properties [1]. 
Chitosan is not widely present in nature (only in some fungi, such as 
Mucoraceae) but it is a chitin derivative, which is the second most abundant 
polysaccharide in nature after cellulose and one of the main components of the 
exoskeleton of crustaceans and insects. In particular, it is produced by 
crustaceans shells [2]. 
Chitin is a chitosan in which there are no amines but only N-acetyl groups. 
Therefore, chitosan is obtained by means of the deacetylation of chitin, 
occurring by the hydrolysis under alkali conditions at high temperature (110-140 
°C) for 4-6 hours: these strict conditions are necessary because the N-acetyl 
group is stable against hydrolysis due to the presence of hydrogen bonds 
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between C=O and N-H groups of nearby units. However, the deacetylation 
process is not complete and the number of N-acetyl groups, expressed as molar 
percentage, is defined acetylation degree (AD). If AD is lower than 60%, chitin 
is considered chitosan. Another characteristic that allows to evaluate the nature 
of the polysaccharide is the solubility in aqueous solution of organic acids (such 
as acetic acid), which is verified for AD lower than 50-60%: in fact, chitin is 
insoluble in such aqueous solutions (as well as in the most of the solvents), 
whereas chitosan in soluble [2]. 
Chitosan is a polycation and its charge density depends on the acetylation 
degree and pH [3], therefore, on the content of protonated amino groups. These 
latter (pKa from 6.2 to 7.0) are totally protonated in acids whose pKa is lower 
than 6.2: only in this conditions chitosan in soluble, whereas it cannot be 
dissolved in water, aqueous solutions at alkaline or physiological pH and 
organic solvents [4]. 
In order to improve the solubility in water of chitosan, it is possible to employ 
the much expensive chitosan oligomers or to make chemical modifications (e.g. 
the grafting of small cationic molecules or polymers (such as PEG [5]) on the 
chitosan structure or to carry out the quaternarization of the amines) [3]. In 
particular, in the past, many chitosan derivatives were synthesized, such as N-
carboxymethylated chitosan (CMC) and N-trimethyl chitosan chloride (TMC), 
and this latter was highly studied because of its well-defined structure, improved 
solubility and easy preparation [6]. However, its synthesis requires the use of 
methyl iodide which is classified as a potential carcinogen. It can damage lung, 
liver, kidneys and, in particular, the central nervous system. Its toxicity is due to 
its methylating action: the enzymes that contain thiols are particularly affected 
and, therefore, inhibited. The lack of these enzymes in the central nervous 
system causes serious damages. 
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In order to avoid the employment of methyl iodide, another possibility was 
considered: the reaction of chitosan with a quaternized species [7]. This latter 
can overcome the solubility limits of chitosan by the exposure of a positively 
charged group. 
Furthermore, the quaternarization allows chitosan to be soluble in water, 
regardless of pH, only if the quaternarization degree represents at least the 25% 
of the total available groups [8] and the maximum limit is about 64%. 
In this chapter, chitosan from shrimp shell (low viscosity and estimated 
molecular weight of 60-120 kDa) was employed. Several studies were carried 
out to perform modifications in order to make it more soluble in aqueous 
solutions, independently of the pH: in particular, the (3-
carboxypropyl)trimethylammonium chloride was used. Then the modified 
chitosan was coupled to the complex 8, the activated form of (OC-6-44)-
diammine(4-carboxypropanoato)dichloridoethanolatoplatinum(IV) (7) (Figure 
6.2). 
 
 
Figure 6.2: Structure of the complex 7 and its activated form (8), which was coupled to chitosan 
 
Subsequently, the conjugate was coupled to other species (characterized by the 
presence of a carboxylic group) in order to evaluate the possibility to further 
functionalize chitosan: in particular, the main purpose was to load a tridentate 
ligand (i.e. 4-(bis(quinolin-2-ylmethyl)amino)butanoic acid), able to chelate Re 
and 
99m
Tc compounds. This latter, being a γ-rays emitter, is commonly exploited 
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for imaging techniques for the diagnosis of some tumors. Therefore, technetium, 
in combination with the Pt complex, could make chitosan a useful vehicle for 
“theranostics”, which is based on the use of vectors that can be employed both 
from a therapeutic and a diagnostic point of view (Figure 6.3). 
 
 
Figure 6.3: Theranostics purposes in the diseases treatment. 
The picture is a modification of that reported in literature [9] 
 
In particular, the therapy is ensured by DTD strategies which, by the use of 
vectors, reduce dosages because one particle binds a high number of complexes 
(if the complex is effective, the conjugate is more effective and, therefore, a 
lower dosage is required) and minimize side-effects because the drug is 
selectively led to the tumor site (in which it is activated) and accumulated by 
EPR effect. The diagnosis (which provides for the localization and 
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characterization of the disease), instead, is made possible by non-invasive 
techniques, which exploit the presence of magnetic fields, fluorophores or 
radiopharmaceutical compounds (such as 
99m
Tc derivatives). 
Furthermore, it is important to note that the use of passive DTD vectors, such as 
nanoparticles or macromolecules, containing several functional groups allows to 
load the vectors with different amount of therapeutic and diagnostic agents. This 
is very important since a Pt complex acts at μM level and a 99mTc derivative 
works in the nM range. 
The studies of the chitosan couplings with complex 8 were preceded by the 
evaluation of the reaction of the platinum compound with glucosamine, which 
represents a chitosan unit. 
The synthesized conjugates are reported in order of discussion: 
▪ (OC-6-44)-diamminedichloridoethanolato(4-oxo-4-(((3S,4S,5S)-2,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino) 
      butanoato)platinum(IV) (20), 
▪ Protonated chitosan - Pt(IV) complex conjugates (21a-21f), 
▪ Chitosan modified with (3-carboxypropyl)trimethylammonium chloride 
(22), 
▪ Modified chitosan - Pt(IV) complex conjugates at different reaction time 
and with different amounts of platinum compound (22a-22h), 
▪ Activated N-hydroxysuccinimidyl ester of 4-(methylsulphonyl)benzoic 
acid (23), 
▪ Modified chitosan 22b - complex 23 conjugate (24), 
▪ Modified chitosan 22b - 4-(bis(quinolin-2-ylmethyl)amino)butanoic acid 
conjugate (25), 
▪ Rhenium(I) complex - diethylenetriamine chelate (26), 
▪ Rhenium(I) complex - 4-(bis(quinolin-2-ylmethyl)amino)butanoic acid 
chelate (27), 
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▪ Conjugate 25 - rhenium(I) complex chelate (28). 
 
6.2 Synthesis of the (OC-6-44)-diamminedichloridoethanolato(4-
oxo-4-(((3S,4S,5S)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-3-yl)amino)butanoato)platinum(IV) (20) 
 
 
 
Glucosamine hydrochloride (8.40 mg, 0.0390 mmol) was added to a solution of 
8 (21.8 mg, 0.0390 mmol) in 2.5 mL of anhydrous DMF. Then N,N-
diisopropylethylamine (DIPEA, 13.6 μL, 0.0780 mmol) was added in order to 
deprotonate the amino group of glucosamine and the reaction was carried out at 
room temperature overnight. The solution was filtered (porosity 0.45 μm) and 
the DMF was removed under reduced pressure to obtain a yellow oil. A yellow 
powder was precipitated by the addition of some drops of acetone and then 
diethyl ether and was dried in vacuo. 
Yield: 29.9 mg. 
 
6.2.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
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methanol (isocratic elution), a flow rate of 0.500 mL/min, a temperature of 37 
°C and the UV-Visible detector set at 210 nm. 
In particular, in Figure 6.4 is reported the chromatogram of the synthesized 
species. 
 
 
Figure 6.4: Chromatogram of the product obtained after the coupling of glucosamine with 
complex 8 
 
The Figure 6.4 shows the presence of two main species (eluted at 3.82 and 6.33 
minutes, respectively), identified by their ESI-MS spectra (Figures 6.5a and 
6.5b). 
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Figures 6.5: ESI-MS spectra of the two main species observed in Figure 6.4, eluted at a) 3.82 
and b) 6.33 minutes 
 
The ESI-MS spectrum in Figure 6.5a, registered in positive ion mode with a 
cone voltage of 30V, allows to verify the presence of DIPEA (probably in the 
form of a chloride salt), corresponding to the peak eluted at 3.82 minutes: in 
a) 
b) 
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fact, it is possible to observe the value at 130.3 m/z which can be attributed to 
the pseudo-molecular ion [M+H]
+
 (M = DIPEA). The peak eluted at 6.33 
minutes is identified by the ESI-MS spectrum reported in Figure 6.5b, registered 
in positive ion mode with a cone voltage of 30V: it represents the pseudo-
molecular ion of the desired product (20), corresponding to 624.4 m/z ([M+H]
+
, 
where M = complex 20). 
Other peaks are observed in the chromatogram (Figure 6.4), between 5 and 6 
minutes: they are attributed to platinum complexes, basing on their isotopic 
pattern, but there is not a precise identification. 
In order to remove all the organic residues, the compound was purified by 
means of Cl-loaded anionic (Amberlite
®
 IRA-400(OH)) and K-loaded cationic 
(Amberlite
®
 IR-120(H)) exchange resins. 
After the purification process, complex 20 resulted to be purer (Figure 6.6) 
because the diisopropylethylamine/diisopropylethylammonium were almost 
completely removed by the use of the cationic resin. 
 
 
Figure 6.6: Chromatogram of complex 20, after purification with ionic exchangers 
 
However, the resins were not useful in the removal of the Pt complexes, eluted 
between 5 and 6 minutes: in fact, they have a similar behavior to complex 20 
and, therefore, it is not possible to effectively separate them. 
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Although the desired product seemed to be not completely purifiable, a similar 
synthetic procedure was applied to chitosan because it has an advantage with 
respect to glucosamine: in fact, its estimated molecular mass is 60-120 kDa and 
this feature allows to perform the purification by dialysis in ultrapure water. 
 
6.3 Conductometric Titration of Chitosan 
 
Several methods can be employed for the determination of the deacetylation 
degree (DD) and, therefore, the quantification of the chitosan amino groups 
(such as some types of titration, elemental analysis, IR, NMR, solid-state NMR, 
etc.). In this work, the chosen procedure was the conductometric titration and it 
was reported in literature [4]. In particular, 93.3 mg of chitosan were dissolved 
in 20 mL of 0.0540 M HCl and then the solution was titrated with 0.158 M 
NaOH, by using a conductivitymeter: the conductivity of the solution (expressed 
in mS/cm), due to H
+
 and OH
-
 ions, was registered after each titrant addition and 
the titration curve is reported in Figure 6.7. 
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Figure 6.7: Conductometric titration of chitosan, dissolved in 0.0540 M HCl, using 0.158 M 
NaOH as a titrant 
 
The titration curve shows three trends: the first (blue diamonds) represents the 
HCl excess neutralization by NaOH, the second (red square) indicates the 
progressive titration (i.e. neutralization) of the amino groups exposed from the 
chitosan surface, whereas the third (green triangle) corresponds to the excess of 
titrant. The elaboration of the titration results allowed to determine 5.16 mmol -
NH2 groups/g chitosan, with a deacetylation degree (DD) of 83.1 mol% and, 
therefore, a degree of acetylation (AD) of 16.9 mol%. 
 
6.4 Acid-Base Titration of Chitosan 
 
The same titration described in paragraph 6.3 was repeated using a pHmeter in 
order to verify the pH range at which the chitosan was in its protonated form 
and, therefore, soluble in aqueous solutions. In particular, 93.3 mg of chitosan 
were dissolved in 20 mL of 0.0540 M HCl, then the solution was titrated with 
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0.158 M NaOH and the pH was measured after each titrant addition. In Figure 
6.8 the titration results are reported: the pH values as a function of the titrant 
volume. 
 
 
Figure 6.8: Acid-base titration of chitosan, dissolved in 0.0540 M HCl, using 0.158 M NaOH as 
a titrant 
 
The titration curve shows three main trends: the first (blue diamonds) represents 
the pH values corresponding to the HCl excess, the second (red square) indicates 
the progressive titration of the amino groups exposed from the chitosan surface, 
whereas the third (green triangle) reports the pH values of the titrant excess. 
When the NH2 groups are titrated, are deprotonated and begin to cause a loss in 
solubility of chitosan. The pH range of deprotonation is from 4 to about 7: at 
about 4 almost all the amino functionalities are still protonated and no particular 
behaviors are observed in solution. However, when the deprotonation proceeds 
(pH around 4.5-5), chitosan precipitation occurs and at almost neutral pH it is 
completely precipitated. Therefore, in order to obtain a stable chitosan solution, 
acidic pH values (about 4) must be ensured. 
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6.5 Synthesis of the Chitosan Conjugates (21a-21f) 
 
The chitosan employed showed no solubility in all the solvents, except for acidic 
aqueous solutions. Therefore, in order to overcome this problem and to make 
chitosan more soluble, its amino groups were appropriately protonated: in 
particular, 100 mg were dissolved in 0.0540 M HCl (21.5 mL), then the aqueous 
solution was removed under reduced pressure and the product was dried in 
vacuo in order to obtain a beige powder. 
Moreover, in order to verify the loading capacity on chitosan, six different 
conjugates (21a-21f) were synthesized using different amounts of Pt(IV) 
complex (percentage of theoretically coupled amino groups ranging from 1 to 
15%). In particular, after the protonation treatment, a suitable quantity of 
complex 8 (Table 6.1) was dissolved in 3 mL of anhydrous DMF. Then, the 
protonated chitosan (100 mg, 0.516 mmol of -NH2 groups) and a 2:1 molar 
excess (respect to 8) of N,N-diisopropylethylamine (DIPEA) were added to each 
previously prepared solution. 
 
Conjugate 
Theoretical coupling % 
(respect to the total amino 
groups mmol) 
Employed amount of 
complex 8 
21a 1 2.9 mg, 0.00516 mmol 
21b 2 5.8 mg, 0.0103 mmol 
21c 3 8.7 mg, 0.0155 mmol 
21d 5 14.4 mg, 0.0258 mmol 
21e 10 28.9 mg, 0.0516 mmol 
21f 15 43.3 mg, 0.0774 mmol 
Table 6.1: Amounts of complex 8 employed for each conjugate (21a-21f) 
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Each suspension was stirred at room temperature for 24 hours. Then, the solvent 
was removed under reduced pressure and the products were dialyzed in 
ultrapure water for 2 days, by using a dialysis tubing cellulose membrane 
(molecular mass cut-off of 14 kDa). After the dialysis, each conjugate was not 
completely dissolved. The compounds were then frozen by means of liquid 
nitrogen and lyophilized to obtain a beige powder. The lyophilization process, as 
observed for the silica NPs in Chapter IV, did not allow the conjugates to be 
resuspended, due to the formation of large irreversible aggregates, but it was 
employed for the preparation of the samples to be mineralized. 
Each product (4-5 mg) was mineralized by means of an acid digestion, 
according to which 800 μL of 70% w/w HNO3 were added to each sample that 
was left 1 hour at 60 °C in an ultrasonic bath. Then they were diluted with 1% 
v/v HNO3 and analyzed by means of ICP-OES. The results (expressed as means 
± standard deviation of at least three independent replicates) are reported in 
Table 6.2. 
 
Conjugate 
Theoretical 
% Pt loading 
Effective 
% Pt loading 
mmol Pt complex/g 
chitosan 
% coupling 
efficiency 
21a 1 0.76 ± 0.12 0.00391 ± 0.00061 75.8 ± 11.8 
21b 2 1.42 ± 0.22 0.00733 ± 0.00112 71.1 ± 10.8 
21c 3 2.03 ± 0.25 0.0105 ± 0.0013 67.7 ± 8.5 
21d 5 2.83 ± 0.90 0.0146 ± 0.0046 56.6 ± 18.0 
21e 10 5.85 ± 0.14 0.0302 ± 0.0007 58.5 ± 1.4 
21f 15 8.34 ± 0.29 0.0430 ± 0.0015 55.6 ± 2.0 
Table 6.2: Pt loadings of conjugates 21a-21f and corresponding coupling efficiency. The results 
are expressed as percentage respect to the amino groups density (5.16 mmol/g chitosan) 
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The data shown in Table 6.2 allows to evaluate that the coupling efficiency is 
higher (about 70%) in the case of low values of theoretical loading (i.e. 1-3% 
respect to the total amino groups in 21a-21c), whereas if the theoretical loading 
is higher (i.e. 5-15% for 21d-21f) the effectively coupled amount of complex is 
about 60% of the desired one. Furthermore, the effective and the theoretical 
loadings are reported in a graph (Figure 6.9), showing an almost linear 
correlation (Radj
2
 = 0.999), which indicates that the yield of coupling is about 
55%. 
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Figure 6.9: Effective vs. theoretical loadings of conjugates 21a-21f 
 
Moreover, in spite of the protonation, the chitosan conjugates were not 
completely soluble in aqueous solutions: part of the amines lost its positive 
charge, causing a solubility decrease, and, probably, other amino groups were 
deprotonated by DIPEA (not only the ones involved in the amidic bonds). The 
conjugates, therefore, resulted to be only partially soluble in aqueous solutions 
and this was observed after the dialysis process. For this reason, it was necessary 
y = 0.55x + 0.26 
Radj
2
 = 0.999 
241 
 
to couple a charged species to the chitosan in order to ensure a permanent 
positive charge on its surface and, therefore, to make it more soluble. In 
particular, a derivative of the ammonium chloride, the (3-
carboxypropyl)trimethylammonium chloride, was employed. 
 
6.6 Synthesis of the Chitosan Modified with (3-
carboxypropyl)trimethylammonium Chloride (22) 
 
The (3-carboxypropyl)trimethylammonium chloride needs to be opportunely 
activated, since the carboxylic group cannot be directly bound to the amino 
groups exposed on the chitosan surface. The ammonium derivative, therefore, 
was activated by the use of the coupling agent HBTU (N,N,N′,N′-tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate, belonging to the uronium 
salt family), in the presence of a tertiary amine (i.e. DIPEA, N,N-
diisopropylethylamine). The synthesized activated intermediate was not isolated 
but was reacted with the nucleophilic species (i.e. the -NH2 group of chitosan) in 
order to carry out a coupling by exploiting the formation of an amidic bond. The 
mechanism of this reaction is shown in Figure 6.10. 
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Figure 6.10: Activation mechanism of the (3-carboxypropyl)trimethylammonium chloride by 
means of the coupling agent HBTU and subsequent nucleophilic attack by the chitosan amino 
group 
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A mixture of ammonium derivative (256 mg, 1.41 mmol), HBTU (803 mg, 2.12 
mmol) and DIPEA (738 μL, 4.24 mmol) in 4 mL of anhydrous DMF was 
magnetically stirred for 30 minutes. Then the protonated chitosan (228 mg, 1.18 
mmol) and DIPEA (615 μL, 3.53 mmol) were added and the resulting mixture 
was stirred at room temperature for 24 hours. Subsequently, the suspension 
followed two different paths: an aliquot was processed for the quantification of 
the loaded species, whereas the remaining amount was employed for the further 
functionalizations. In particular, in the first case, the DMF was removed under 
reduced pressure and the product was dialyzed (also in this case, the dialysis 
tubing cellulose membrane molecular weight cut-off was 14 kDa) in ultrapure 
water for 2 days. After the dialysis, the chitosan was completely dissolved: the 
ammonium derivative was successful in increasing the chitosan solubility. Then 
the sample was frozen by means of liquid nitrogen and lyophilized to obtain a 
beige powder, which was used for the quantification of the charged species. 
In order to determine the amount of the ammonium derivative loaded on 
chitosan, the same procedure employed to quantify the amino functionalities of 
chitosan was performed (paragraph 6.2). In particular, 21.0 mg of the sample 
were dissolved in 10 mL of 0.054 M HCl and titrated with 0.2 M NaOH by 
using a conductivitymeter. The titration results allowed to evaluate the number 
of remaining free amino groups, which were then subtracted from the initially 
available ones to obtain the amount of amino groups involved in the amidic 
bonds with the ammonium derivative. After the data processing, it was verified 
that the amount loaded was 29.5% respect to the total amino groups present in 
21.0 mg (i.e. 0.108 mmol -NH2) and corresponded to 1.52 mmol/g chitosan: the 
quantity loaded was about a quarter of the theoretical loading of ammonium 
derivative (6.18 mmol/g chitosan). 
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6.6.1 Size and Stability Investigations 
 
The DLS technique was employed in order to evaluate the size of chitosan 22. In 
particular, being 22 completely dissolved in water, the analysis was performed 
in this solvent, not adding any salts to modify the ionic strength. About 1 mL of 
the solution was transferred into a plastic disposable cuvette which was 
introduced into the instrument, a Malvern Zetasizer Nano ZS (Malvern 
Instruments Ltd., Malvern, UK) at a fixed scattering angle of 173°, using a He-
Ne laser and DLS software for Windows (version 6.11, Malvern, UK) and 
setting the temperature at 25 °C. 
The same solution, transferred into a suitable cuvette, was employed for the ζ 
potential measurements, which were carried out in order to evaluate the stability 
of the suspension. 
The ζ potential data (41.5 ± 3.1 mV) allows to verify that the system exceeds the 
threshold of stability because its ζ potential value is higher than +30 mV: in 
particular, the positive charge is ensured by the presence of the ammonium 
derivative. 
As regards the size (DLS diameter = 180 ± 10 nm), it is important to point out 
that, in water, each particle is surrounded by water molecules and, therefore, the 
result takes into account the hydrodynamic radius. Moreover, in this case, the 
analysis was carried out in the absence of any modifications of the ionic 
strength: the hydrodynamic radius, therefore, results the largest possible. 
 
After the decoration of the chitosan surface with the (3-
carboxypropyl)trimethylammonium chloride, the subsequent phase consisted of 
the coupling of this chitosan derivative with the platinum complex 8. At first, it 
was necessary to evaluate the effect of the reaction time on the loading on 
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chitosan and then, after fixing this parameter, the loading efficiency by using 
different amounts of the platinum prodrug was studied. 
 
6.7 Synthesis of the Modified Chitosan Conjugates at Different 
Reaction Times (22a-22e) 
 
To the previously prepared chitosan suspension (22, i.e. the not dialyzed 
aliquot), complex 8 (13.2 mg, 0.0236 mmol, corresponding to 2% respect to the 
initial amino groups, i.e. 1.18 mmol) was added and the mixture was stirred for 
different reaction times: 2 hours (22a), 4 hours (22b), 6 hours (22c), 8 hours 
(22d), and 24 hours (22e). After the established times, a small aliquot of the 
suspensions was processed: DMF was removed under reduced pressure and each 
conjugate was dialyzed in ultrapure water for 2 days, obtaining completely 
water soluble conjugates. Then they were frozen by means of liquid nitrogen 
and lyophilized. 
All the conjugates (4-5 mg) were mineralized by using the previously described 
procedure (paragraph 6.5), diluted with 1% v/v HNO3 and analyzed by means 
of ICP-OES. The coupling results, expressed as means ± standard deviation of at 
least three independent replicates, are reported in Table 6.3. 
 
Conjugate 
Reaction 
time 
Theoretical % 
Pt loading 
Effective %  
Pt loading 
mmol Pt complex/g 
chitosan 
18a 2 h 
2 
0.78 ± 0.02 0.0400 ± 0.0009 
18b 4 h 0.68 ± 0.19 0.0348 ± 0.0098 
18c 6 h 0.86 ± 0.03 0.0441 ± 0.0015 
18d 8 h 0.61 ± 0.08 0.0314 ± 0.0039 
18e 24 h 0.99 ± 0.22 0.0513 ± 0.0112 
Table 6.3: Pt loadings on chitosan at different reaction times but by the use of a fixed complex 8 
amount. The results are expressed as percentage respect to the amino groups density (5.16 
mmol/g chitosan) 
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Since no significant differences among the obtained Pt loadings were observed, 
the reaction time was fixed at 4 hours as a suitable compromise between 
reaction time and Pt loading. 
The subsequent phase consisted in the evaluation of the Pt loading on chitosan at 
fixed coupling time but employing different quantities of complex, in order to 
verify the coupling efficiency in the presence of the (3-
carboxypropyl)trimethylammonium chloride. 
 
6.7.1 Synthesis of the Modified Chitosan Conjugates at Fixed 
Reaction Time but by using Different Prodrug Amounts (22b, 22f-
22h) 
 
To the previously prepared chitosan suspension (22, i.e. the not dialyzed 
aliquot), complex 8 was added and the mixture was stirred for 24 hours. Four 
different conjugates (22b, 22f-22h) were synthesized using different amounts of 
Pt(IV) complex: these latter were expressed as percentage (from 1 to 10%) with 
respect to the total mmol of chitosan amino groups (Table 6.4). 
 
Conjugate 
Theoretical coupling % (respect 
to the total amino groups mmol) 
Employed amount of 
complex 8 
22f 1 6.6 mg, 0.0118 mmol 
22b 2 13.2 mg, 0.0235 mmol 
22g 5 32.9 mg, 0.0588 mmol 
22h 10 65.8 mg, 0.118 mmol 
Table 6.4: Amounts of complex 8, expressed as percentage with respect to the total available 
amino groups mmol, employed to synthesize conjugates 22b, 22f-22h 
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After the established coupling time, a small aliquot of each suspension was 
processed: DMF was removed under reduced pressure and the dialysis was 
carried out in ultrapure water for 2 days, obtaining completely water soluble 
conjugates. Then they were frozen by means of liquid nitrogen and lyophilized. 
Each conjugate (4-5 mg) was mineralized by using the previously described 
procedure (paragraph 6.5), diluted with 1% v/v HNO3 and analyzed by means 
of ICP-OES. The coupling results, expressed as a mean of at least three 
independent replicates, are reported in Table 6.5. 
 
Conjugate 
Reaction 
time 
Theoretical % 
Pt loading 
Effective %  
Pt loading 
mmol Pt complex/g 
chitosan 
22f 
24 h 
1 0.45 ± 0.03 0.0232 ± 0.0015 
22b 2 0.68 ± 0.19 0.0348 ± 0.0098 
22g 5 1.38 ± 0.12 0.0710 ± 0.0062 
22h 10 2.63 ± 0.05 0.135 ± 0.003 
Table 6.5: Pt loadings on chitosan at fixed reaction time but by using different amounts of 
complex 8. The results are expressed as percentage respect to the amino groups density 
 
The results allows to evaluate that the loadings on chitosan are much lower than 
those reported in Table 6.2 for conjugates 21a-21f without the ammonium 
groups. Probably, the presence of a large quantity of another species (i.e. the (3-
carboxypropyl)trimethylammonium functionality) influenced the subsequent 
loading, decreasing the number of available and accessible amino groups. For 
this reason, the Pt loading on conjugates 22b, 22f-22h resulted to be lower with 
respect to 21a-21f. 
The effective vs. theoretical loadings reported in a graph (Figure 6.11) shows a 
linear correlation (Radj
2
 = 0.999). 
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Figure 6.11: Effective vs. theoretical loadings of conjugates 22f-22i 
 
Table 6.5 and Figure 6.11 point out that the higher the theoretical platinum 
loading the higher the effectively loaded. However, only a third of the 
theoretical amount was bound to chitosan. Therefore, the Pt/amino groups ratio 
was fixed at 2% in order to avoid any waste of complex (the unreacted platinum 
cannot be recovered): for this reason, the conjugate employed in the further 
coupling reactions was 22b. 
 
6.7.2 Size and Stability Investigations 
 
The DLS and ζ potential analyses of 22b were carried out in order to evaluate its 
dimension and the suspension stability in ultrapure water at 25 °C. 
Also in this case, the conjugate exceeds the threshold of stability: the ζ potential 
value (37.5 ± 0.6 mV) is higher than +30 mV. 
The dimensional analysis (DLS diameter = 215 ± 12 nm) demonstrates that the 
presence of another species on the chitosan surface causes an increase in size: in 
y = 0.24x + 0.21 
Radj
2
 = 0.999 
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fact, it passes from about 180 nm, when only the (3-
carboxypopyl)trimethylammonium functionality decorates the surface, to about 
215 nm after the coupling with also the Pt(IV) complex. Also in this case, the 
presence of a solvation shell must be considered. 
 
6.8 Synthesis of the Activated N-hydroxysuccinimidyl Ester of 4-
(methylsulphonyl)benzoic Acid (23) 
 
After establishing the “reaction time” (4 hours) and the “Pt/-NH2 groups ratio” 
(2% of complex respect to the total available amino groups mmol), the 
remaining suspension aliquot of conjugate 22b was further functionalized with 
other compounds containing a carboxylic group in order to evaluate the 
possibility of loading several species on chitosan. At first, the conjugate was 
coupled with the 4-(methylsulphonyl)benzoic acid: it was chosen because sulfur 
can be detected (by selecting the S 180.731 nm line) and quantified by ICP-
OES. 
As seen for other compounds having free carboxylic groups, the activation by 
DCC (N,N’-dicyclohexylcarbodiimmide) and NHS (N-hydroxysuccinimide) was 
necessary. 
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In particular, 4-(methylsulphonyl)benzoic acid (100 mg, 0.499 mmol) was 
dissolved in 2 mL of anhydrous DMF and, to the solution, DCC (124 mg, 0.599 
mmol) and NHS (69.0 mg, 0.599 mmol) were added and the mixture was stirred 
at 0 °C for 1 hour and at room temperature overnight. After the established time, 
the solution was cooled to -18 °C and dicyclohexylurea was removed by 
filtration (porosity 0.45 μm). DMF was removed under reduced pressure to 
obtain a colorless oil. A white powder was precipitated by acetone/diethyl ether, 
washed with diethyl ether and then dried in vacuo. 
Yield: 111 mg, 0.372 mmol, 74.5%. 
 
6.8.1 Characterization of the Compound 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
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composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature of 
37 °C and the UV-Visible detector set at 210 nm. Complex 23 showed a 
retention time of 7.17 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 6.12). 
 
 
Figure 6.12: ESI-MS spectrum of complex 23, prepared in a 50:50 ultrapure water and methanol 
mixture 
 
The ESI-MS spectrum, registered in positive ion mode with a cone voltage of 
30V, shows a value at 298.1 m/z, corresponding to the pseudo-molecular ion 
[M+H]
+
 peak, and another one at 320.1 m/z which represents the adduct with 
sodium ion [M+Na]
+
. Moreover, it is possible to observe the typical isotopic 
pattern of sulfur compounds: the m/z values are confirmed by the comparison 
with the simulated ESI-MS spectra (Figure 6.13). 
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Figure 6.13: Simulated ESI-MS spectra of a) the pseudo-molecular ion [M+H]
+
 and b) the 
sodium adduct [M+Na]
+
 peaks of the compound 23 
 
1
H-NMR 
 
Figure 6.14: 
1
H-NMR spectrum of complex 23, registered in DMSO-d6 
a) 
b) 
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The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of compound 23 (Figure 6.14) 
shows the following signals, δ: 2.92 (s, 4H, -CH2CON), 3.33 (s, 3H, -CH3), 8.21 
(d, 2H, -CH=CS, 
3
J = 8.55 Hz), 8.35 (d, 2H, -CH=CCO, 
3
J = 8.55 Hz) ppm. 
 
13
C-NMR 
 
Figure 6.15: 
13
C-NMR spectrum of complex 23, registered in DMSO-d6 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of complex 23 (Figure 6.15) 
shows the following signals, δ: 25.6 (-CH2CON), 43.0 (-CH3), 128.1 (-CH=CS), 
128.8 (-CH=CCO), 131.0 (-CH=CCO), 146.4 (-CH=CS), 160.9 (-CH=CCO), 
170.1 (-CH2CON) ppm. 
 
After the characterization, complex 23 was coupled to the chitosan previously 
functionalized with the ammonium derivative and the Pt(IV) complex (22b). 
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6.9 Further Coupling of the Modified Chitosan Conjugate 22b with 
Compound 23 (24) 
 
To the DMF suspension 22b, containing chitosan coupled with both the 
ammonium derivative and complex 8, compound 23 (14.0 mg, 0.0471 mmol, 
4% respect to the total chitosan amino groups mmol) was added and the mixture 
was stirred at room temperature for 24 hours (to allow a large quantity to be 
coupled). DMF was then removed under reduced pressure and the conjugate was 
dialyzed in ultrapure water for 2 days, obtaining completely water soluble 
conjugates. An aliquot was frozen by means of liquid nitrogen and lyophilized. 
The lyophilized samples (4-5 mg) were mineralized by using the previously 
described procedure (paragraph 6.5), diluted with 1% v/v HNO3 and analyzed 
by ICP-OES. 
The data (effective percentage of S loading = 0.40 ± 0.15 %, corresponding to 
0.0207 ± 0.0075 mmol S complex/g chitosan) allows to evaluate that the loaded 
amount is about a tenth of the desired loading: probably, the activated species 
(23) is not very reactive and its coupling with the chitosan amino groups results 
to be difficult. 
 
6.9.1 Size and Stability Investigations 
 
The DLS and ζ potential analyses were carried out in order to evaluate the 
dimensions and the suspension stability of conjugate 24 in ultrapure water at 25 
°C. 
The ζ potential data (36.9 ± 1.0 mV) are higher than +30 mV: the threshold 
value is exceeded also in this case and, therefore, a high suspension stability is 
ensured. 
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The dimensional analysis (DLS diameter = 202 ± 22 nm) demonstrates that, 
after the coupling with a third species (23), the size is not much larger than the 
one of conjugate 22b: by considering the standard deviations, the results 
obtained for 22b (215 ± 12 nm) are very similar to the 24 data. Probably, it is 
due to the fact that 23 does not give a high hindrance to chitosan and, moreover, 
the loaded amount is quite low. 
After having studied the size and ζ potential parameters, the subsequent phase 
consisted of verifying the behavior of another species: the 4-(bis(quinolin-2-
ylmethyl)amino)butanoic acid (Figure 6.16). The tricarbonyl Re and Tc 
compounds are stabilized by many kinds of ligand and this allows to modulate 
the physicochemical features of the drug. As regards the nature of the ligand, 
some studies focused the attention on the importance of the choice of mono- bi- 
and tridentate ones [10] and a tridentate chelator resulted to be the most efficient 
[10, 11]: in fact, it occupies the three free coordination sites of the tricarbonyl 
metal (Re or Tc). 
 
6.10 Coupling of the Modified Chitosan Conjugate 22b with the 4-
(bis(quinolin-2-ylmethyl)amino)butanoic Acid (25) 
 
The conjugate 25 was prepared by employing the same procedure described to 
synthesize the system 24 but, in this case, chitosan was decorated with the 
ammonium derivative, the Pt(IV) complex and the ligand reported in Figure 
6.16. 
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Figure 6.16: Tridentate ligand useful to chelate Re and Tc 
 
In particular, a solution of ammonium derivative (256 mg, 1.41 mmol), HBTU 
(803 mg, 2.12 mmol) and DIPEA (738 μL, 4.24 mmol) in 4 mL of anhydrous 
DMF were magnetically stirred for 30 minutes. Then the protonated chitosan 
(228 mg, 1.18 mmol) and DIPEA (615 μL, 3.53 mmol) were added to the 
mixture and the reaction was carried out at room temperature for 24 hours. After 
this time, a small aliquot was processed (removal of the DMF, dialysis and 
lyophilization) in order to quantify the content of the (3-
carboxypropyl)trimethylammonium chloride, by means of a conductometric 
titration: 29.5% respect to the total amino groups mmol, 1.52 mmol/g chitosan. 
Then, complex 8 (13.2 mg, 0.0235 mmol, corresponding to 2% respect to the 
total amino groups mmol) was added to the mixture, which was stirred for 4 
hours. An anhydrous DMF solution (1 mL) of tridentate ligand (9.1 mg, 0.0235 
mmol), HBTU (13.4 mg, 0.0353 mmol) and DIPEA (8.20 μL, 0.0471 mmol) 
was stirred for 30 minutes and then it was added to the previously prepared 
mixture and the reaction was carried out at room temperature for 24 hours. 
Then, DMF was removed under reduced pressure and the sample was recovered 
with ultrapure water, in order to be dialyzed. However, by adding water, a dark 
brown powder precipitated: it was the tridentate ligand which, being very 
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lipophilic, was not soluble in water. For this reason, dichloromethane (DCM) 
was added to the obtained water suspension because it can dissolve the ligand 
(in fact, it became brown): the result was a biphasic solution in which a powder 
was still present. The brown organic fraction was separated by means of a 
separating funnel and this procedure was repeated several times till the 
excludable dichloromethane fraction resulted to be colorless. Then, the eventual 
remained DCM was removed under reduced pressure and the light brown 
solution was dialyzed (MW cut-off membrane of 14 kDa) in ultrapure water for 
2 days: the conjugate resulted to be completely soluble in water. 
The water solution (about 20 mL) was divided into two aliquots: the first was 
maintained with the free chelator (in order to further react with a 
99m
Tc 
derivative), whereas the other one was employed to chelate a rhenium(I) 
complex. This latter, the fac-[ReBr3(CO)3][Net4]2, was used as a model of the 
technetium species because they had the same structure: in fact, they showed 
three hydrolizable groups (Br) and three carbonyls. The Re(I) compound was 
not synthesized in this work (its synthetic procedure was reported by Alberto et 
al. [12]) but it was used as such and its structure and characterization are shown 
in paragraph 6.11.1. 
 
6.10.1 Size and Stability Investigations 
 
The DLS and ζ potential analyses, performed in ultrapure water at 25 °C, were 
carried out in order to evaluate the dimension and the suspension stability of 
conjugate 25. 
Also in this case, the threshold of stability is exceeded since the ζ potential value 
is higher than +30 mV: 45.9 ± 1.1 mV. 
From a dimensional point of view, it is possible to observe that the size (DLS 
diameter = 298 ± 21 nm) results to be increased respect to the previous cases (in 
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which the DLS diameters were about 200 nm): probably, this is due to the fact 
that the ligand is sterically hindered and this may cause an increase in size. 
Moreover, the analysis is performed in ultrapure water and, therefore, the 
solvation sphere must be considered. Although the size is about 300 nm, the 
conjugates can be used for passive DTD strategies by exploiting the EPR effect 
because the fenestrations of the vascular system still have compatible 
dimensions. 
 
6.11 Chelation Reaction of the Re(I) Complex with 
Diethylenetriamine (26) 
 
In order to set up the reaction condition for the coordination of a 
99m
Tc complex 
to chitosan derivatives, the “cold” Re complex fac-[ReBr3(CO)3][NEt4]2, 
synthesized by Alberto [12], was used with the model triamine DIEN 
(diethylenetriamine). 
 
 
 
In particular, the fac-[ReBr3(CO)3][NEt4]2 (100 mg, 0.130 mmol) and 
diethylenetriamine (DIEN, 14.0 μL, 0.130 mmol) were dissolved in 12 mL of 
methanol and the mixture was heated at reflux (about 70 °C) overnight. The 
solvent was then removed under reduced pressure and the product was dried in 
vacuo. 
Yield: 56.0 mg, 0.124 mmol, 95.2%. 
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6.11.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
methanol (isocratic elution), a flow rate of 0.500 mL/min, a temperature of 37 
°C and the UV-Visible detector set at 210 nm. Complex 26 showed a retention 
time of 4.08 minutes and its identity was attributed by the corresponding ESI-
MS spectrum (Figure 6.17a). 
 
 
 
a) 
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Figures 6.17: a) ESI-MS spectrum of the complex 26, prepared in a 50:50 mixture of ultrapure 
water and methanol, b) simulated ESI-MS spectrum of the molecular ion [M-Br]
+
 of complex 26 
 
The ESI-MS spectrum (Figure 6.17a), registered in positive ion mode with a 
cone voltage of 30V, allows to observe a value at 374.3 m/z which verifies the 
presence of the species [M-Br]
+
 as confirmed by the simulation of this spectrum 
(Figure 6.17b). 
 
Infrared Spectroscopy 
 
Complex 26 and its precursor were analyzed by IR spectroscopy. 
 
A dry KBr plate of the sample was prepared and the spectrum (Figure 6.18), 
with a 2 cm
−1
 resolution, was registered on a Bruker FTIR Equinox 55 
spectrometer in the range 4000-400 cm
−1
. 
 
b) 
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Figure 6.18: IR spectrum of the rhenium(I) complex, synthesized by Alberto et al. [12], 
prepared in KBr 
 
The IR spectrum of fac-[ReBr3(CO)3][NEt4]2 shows several signals 
corresponding to the vibrational modes (i.e. stretching, bending, etc.) of the 
functional groups present on the considered compound. In particular, the 
attention is focused on the two signals at 1868 and 1999 cm
-1
 which represent 
the typical pattern of tricarbonyl compound and the values are consistent with 
the ones reported by Alberto et al. [12] (i.e. 1870 and 2001 cm
-1
). 
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Figure 6.19: IR spectrum of the complex 26, prepared in KBr 
 
The IR spectrum of complex 26 (Figure 6.19) shows, in particular, two signals 
(typical of the presence of three carbonyl groups) at 1876 and 2011 cm
-1
 which 
result to be shifted respect to the values reported in Figure 6.18 (i.e. 1868 and 
1999 cm
-1
), probably due to the coordination of the diethylenetriamine. 
 
The reaction occurred successfully and, therefore, this method was applied to 
the ligand chosen to be bound to the chitosan surface. 
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6.12 Chelation Reaction of the Re(I) Complex with the 4-
(bis(quinolin-2-ylmethyl)amino)butanoic Acid (27) 
 
 
 
fac-[ReBr3(CO)3][NEt4]2 (25.0 mg, 0.0324 mmol) was reacted with 4-
(bis(quinolin-2-ylmethyl)amino)butanoic acid (12.5 mg, 0.0324 mmol) in 4 mL 
of methanol, by using a reflux condenser, at 70 °C overnight. The solvent was 
then removed under reduced pressure and then the product obtained was dried in 
vacuo. 
Yield: 22.8 mg, 0.0310 mmol, 95.5%. 
 
6.12.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Complex 27, identified by 
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the corresponding ESI-MS spectrum (Figure 6.20), showed a retention time of 
13.3 minutes. 
 
 
Figure 6.20: ESI-MS spectrum of the complex 27, prepared in a 50:50 mixture of ultrapure 
water and methanol 
 
In the ESI-MS spectrum, registered in positive ion mode with a cone voltage of 
30V, it is possible to observe a m/z value at 656.3 which corresponds to the 
species [M-Br]
+
 and it is confirmed also by the simulated ESI-MS spectrum 
(Figure 6.21). 
 
 
Figure 6.21: Simulated ESI-MS spectrum of the species [M-Br]
+
 of complex 27 
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Infrared Spectroscopy 
 
The sample was prepared as described in paragraph 6.11.1 and the 
corresponding IR spectrum shows, in particular, two signals at 1902 and 2016 
cm
-1
 which result to be shifted respect to the values reported for the free Re(I) 
complex (i.e. 1868 and 1999 cm
-1
) and for the complex chelated by DIEN (i.e. 
1876 and 2011 cm
-1
): this is probably due to the coordination of the hindered 
ligand. 
 
Also this chelation reaction successfully occurred and, for this reason, the 
procedure was applied to the case of conjugate 25 with the rhenium(I) species. 
 
6.13 Chelation Reaction of Conjugate 25 with the Re(I) Complex 
(28) 
 
One of the two aliquots of the previously prepared conjugate 25 (about 10 mL, 
containing half of the tridentate ligand mmol, i.e. 0.0118 mmol) was reacted 
with the rhenium(I) complex. In particular, the fac-[ReBr3(CO)3][NEt4]2 (18.1 
mg, 0.0235 mmol) was added to the water solution of 25 and the reaction was 
performed at 70 °C overnight. The solution was then dialyzed in ultrapure water 
for 2 days and an aliquot of the final solution was frozen by liquid nitrogen and 
lyophilized. 
Conjugate 28 (4-5 mg) was mineralized by using the previously described 
procedure (paragraph 6.5), diluted with 1% v/v HNO3 and analyzed by means 
of ICP-OES in order to quantify the Pt and Re contents. 
The coupling results (effective percentage of Pt loading = 0.68 ± 0.19 %, 
corresponding to 0.0348 ± 0.0098 mmol Pt/g chitosan, effective percentage of 
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Re loading = 1.28 ± 0.62 %, corresponding to 0.0659 ± 0.0321 mmol Re (= 
ligand)/g chitosan) are expressed as a mean of at least three independent 
replicates and allow to evaluate that the Re content is higher than the Pt one. 
Moreover, it is possible to determine the ligand amount bound to the chitosan 
from the Re content: in fact, 1 mmol of ligand = 1 mmol of rhenium(I) complex. 
The radiopharmaceutical drugs are generally used at very low concentrations. In 
this case, the ligand concentration is much higher: this can allow to modulate the 
99m
Tc complex quantity to be chelated, depending on the requirements. 
 
6.13.1 Size and Stability Investigations 
 
The DLS and ζ potential analyses of conjugate 28 were performed in ultrapure 
water at 25 °C and the results are shown and compared to the previous 
conjugates data in Table 6.6. 
 
Conjugate DLS diameter ζ potential 
22 180 ± 10 nm 41.5 ± 3.1 mV 
22b 215 ± 12 nm 37.5 ± 0.6 mV 
25 298 ± 21 nm 45.9 ± 1.1 mV 
28 300 ± 24 nm 39.0 ± 2.4 mV 
Table 6.6: Size and suspension stability results of conjugate 28 in ultrapure water 
 
The ζ potential value of conjugate 28 is higher than +30 mV and this indicates 
that the suspension is highly stable. 
As regards the size, also in this case (as described for conjugate 25), it results to 
be increased with respect to the cases in which the chitosan surface was 
functionalized with (3-carboxypropyl)trimethylammonium derivative and the 
Pt(IV) complex. 
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6.13.2 Characterization of Conjugate 28 
 
Infrared Spectroscopy 
 
The sample was prepared as described in paragraph 6.11.1 and the 
corresponding IR spectrum is reported in Figure 6.22. 
 
 
Figure 6.22: IR spectrum of the conjugate 28, prepared in KBr 
 
Two signals (typical of the presence of three carbonyl groups) can be observed 
at 1895 and 2017 cm
-1
 and they are similar to those obtained for complex 27 (i.e. 
1902 and 2016 cm
-1
): in fact, the species involved in the chelation are the same 
of the previous case. 
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The analysis of all the results allows to verify the occurred chelation and, 
therefore, that the system can be effectively used for chelating a technetium 
compound, exploitable for diagnostic purposes. 
 
6.14 Conclusions 
 
In this chapter, the very low soluble chitosan from shrimp shell was coupled to 
the activated form of (OC-6-44)-diammine(4-
carboxypropanoato)dichloridoethanolatoplatinum(IV) (8). A protonation 
procedure was carried out before each coupling in order to allow the 
polysaccharide to be soluble in aqueous solutions. However, during the dialysis 
of the conjugates (to remove the unreacted species), portions of them 
precipitated and could not be resuspended again. Therefore, a chemical 
modification was performed in order to make chitosan soluble in aqueous 
solutions independently of the pH: in particular, the (3-
carboxypropyl)trimethylammonium chloride was used. 
The modified chitosan was coupled to the platinum complex at different 
coupling times and by using different amounts of the prodrug, in order to choose 
the best reaction conditions. These new conjugates were completely soluble in 
water. 
The subsequent phase consisted of the introduction of a ligand able to chelate 
the 
99m
Tc(I) species, i.e. (4-(bis(quinolin-2-ylmethyl)amino)butanoic acid). 
Before the reactions with the radioactive 
99m
Tc, the cold Re analogous 
compound was used. In particular, the ability in the chelation of the rhenium(I) 
compound (fac-[ReBr3(CO)3][NEt4]2) was verified by using a tridentate ligand 
as a model (diethylenetriamine), the free quinolin ligand and then the complete 
conjugate containing the charged species, the platinum complex and the ligand 
itself. 
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The final conjugate was soluble independently of the pH, was functionalized 
with a Pt(IV) prodrug and contained a ligand able to chelate a Tc derivative with 
a similar structure to the fac-[ReBr3(CO)3][NEt4]2 one: it can represent a system 
suitable for theranostics purposes. 
The perspectives of this work are the further reaction with a 
99m
Tc complex in 
collaboration with Dr. A. Paulo (Centro de Ciências e Tecnologias Nucleares 
(C
2
TN), Instituto Superior Técnico, Universidade de Lisboa, Portugal) and the 
in vivo evaluation of the conjugate. 
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Capitolo 7  
Chapter VII 
 
 
 
 
 
 
 
 
 
 
Coupling Reaction with Iron Oxide 
Nanoparticles (IONPs) 
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7.1 Introduction 
 
Since early diagnosis is fundamental for a successful eradication of tumors, the 
research is moving towards the development of systems which can be exploited 
both for diagnosis and therapy purposes. In this work the attention was focused 
on magnetic iron oxide nanoparticles which can ensure the delivery of a 
platinum prodrug into the cells and can be employed in many fields (Figure 
7.1), such as cancer therapy hyperthermia and Magnetic Resonance Imaging 
(MRI), due to their superparamagnetism. 
 
 
Figure 7.1: Possible cancer treatments based on the use of magnetic nanoparticles. 
The picture was obtained after a slight modification of that reported in literature [1] 
 
These NPs, since 1987, have been clinically administered to detect spleen and 
liver diseases by means of MRI. They are composed of magnetite (Fe3O4) and 
maghemite (γ-Fe2O3), are considered superparamagnetic because they can be 
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oriented in the direction of a magnetic field and, after its removal, they restore 
their initial state, and they are biocompatible. Their biocompatibility is due to 
the fact that the uptake, excretion and storage of iron are efficiently regulated 
and the clearance of the excess occurs without serious side effects. 
Furthermore, they can be classified into different categories depending on their 
size. The size role is crucial because the nanoparticles dimensions affect their 
biodistribution and accumulation into the tumor site: 
 size higher than 100 nm may induce embolization and non-specific 
uptake by the reticuloendothelial system [2], 
 diameters higher than 30 nm (SPIO, i.e. small paramagnetic iron oxide), 
often, have a short blood half-life because they are phagocytosed in liver 
and spleen and this causes a loss of the signal exploitable for MRI [3], 
 dimensions between 1 and 30 nm (USPIO, i.e. ultrasmall paramagnetic 
iron oxide) avoid early phagocytosis and, therefore, allow to be used as 
contrast agents and monitoring tool [3]. 
Feridex, Endorem and Resovist are some examples of clinically administered 
superparamagnetic iron oxide nanoparticles and, in particular, they are 
employed in USA (Feridex), Europe (Endorem and Resovist) and Japan 
(Resovist). 
As regards the imaging methods, the MRI is a noninvasive scan of the body and 
exploits the water molecules hydrogen atoms which, in the presence of an 
appropriate magnetic field, are excited. After this process, their relaxation 
occurs and different tissues can be distinguished by different relaxation times T1 
and T2. Some contrast agents (based on gadolinium or manganese) act on T1 by 
shortening it and, therefore, giving rise to a brighter picture (positive contrast). 
On the contrary, superparamagnetic iron oxide nanoparticles reduce T2 
(negative contrast). Therefore, the use of superparamagnetic iron oxide 
nanoparticles allows to improve the sensitivity of MRI. 
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In the case of magnetic NPs, a possible exploitable therapy is the hyperthermia, 
i.e. a locally increase of a tissue temperature. It is known that the physiological 
temperature is 37 °C and, therefore, higher values can lead the cell to lose its 
functions and also to its death. In fact, the heat generated by the nanoparticles 
when placed in an alternative magnetic field can be exploited as an antitumoral 
treatment. The accumulation of the NPs into the diseased site can be ensured by 
exploiting an external magnetic field or by ligand-receptor interactions [4], even 
though in the first case the specific delivery is problematic and side effects may 
occur (such as the heating of the healthy tissues). 
In this work, Iron Oxide Magnetic Nanoparticles (IONPs) functionalized with 
furan groups were employed in collaboration with Dr. Jérôme Fresnais 
(Laboratoire de Physico-Chimie des Electrolytes, Colloïdes et Sciences 
Analytiques, Paris (France)). Furan can be exploited for Diels-Alder 
cycloaddition. Therefore, in the first synthetic phase of this work, some Pt(IV) 
complexes bearing a dienophile functionality were prepared. In particular, 
glycine and maleic anhydride reacted in order to obtain the (Z)-4-
((carboxymethyl)amino)-4-oxobut-2-enoic acid (29). Then, a cyclization 
reaction allowed to synthesize the 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)acetic acid (30), which represents the ligand that will be coordinated to the 
platinum core, in axial or equatorial position (in this latter case, by substitution 
of a chloride ion of cisplatin), and the dienophile suitable for a Diels-Alder 
cycloaddition. In particular, four Pt(IV) compounds were prepared: three show 
the maleimide derivative in equatorial position (32, 33, 34) and one in axial 
position (35). However, only one of them was chosen for further couplings, due 
to its high purity and ease of synthesis. Therefore, its cycloaddition reaction was 
studied in the presence of different dienes, i.e. a furan, a ligand containing a 
furan group (Furan-Functionalized Phosphonic Acid-Terminated POE 
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Monomethyl Ether) and iron oxide nanoparticles containing the same ligand 
(Figure 7.2). 
 
 
Figure 7.2: Schematic representation of the synthesis and applications of the IONPs [5]. 
PMDETA = N,N,N′,N′′,N′′-pentamethyldiethylenetriamine and TMSBr = trimethylsilyl bromide 
 
Then, the in vitro and in vivo biological activity of the Diels-Alder product must 
be evaluated and, in particular, the hyperthermia treatment. 
The synthesized platinum complexes and conjugates are reported here in order 
of discussion: 
 (Z)-4-((carboxymethyl)amino)-4-oxobut-2-enoic acid (29), 
 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid (30), 
 (SP-4-3)-diamminechlorido(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) 
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      acetate)platinum(II) (31), 
 (OC-6-44)-diamminechloridodihydroxido(2-(2,5-dioxo-2,5-dihydro-1H-
pyrrol-1-yl)acetate)platinum(IV) (32), 
 (OC-6-44)-diamminedichlorido(2-hydroxyethanolato)(2-(2,5-dioxo-2,5-
dihydro-1H-pyrrol-1-yl)acetate)platinum(IV) (33), 
 (OC-6-44)-diammine(4-carboxypropanoato)dichlorido(2-(2,5-dioxo-2,5-
dihydro-1H-pyrrol-1-yl)acetate)platinum(IV) (34), 
 (OC-6-44)-diamminedichloridoethanolato(2-(2,5-dioxo-2,5-dihydro-1H-
pyrrol-1-yl)acetate)platinum(IV) (35), 
 (OC-6-44)-diamminedichloridoethanolato(2-(1,3-dioxo-3a,4,7,7a-
tetrahydro-1H-4,7-epoxyisoindol-2(3H)-yl)acetate)platinum(IV) (36), 
 Product of the Diels-Alder cyclization between complex 35 and the 
furan-functionalized ligand (37), 
 Product of the Diels-Alder cyclization between complex 35 and IONPs 
(38). 
 
7.2 Synthesis of the (Z)-4-((carboxymethyl)amino)-4-oxobut-2-
enoic Acid (29) 
 
 
 
Complex 29 was synthesized according to a previously published procedure [6]. 
In particular, to a solution of maleic anhydride (1.08 g, 11.1 mmol) in glacial 
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acetic acid (14 mL), glycine (0.830 g, 11.1 mmol) was added. The suspension 
was magnetically stirred for 5 hours at room temperature. Then, the product was 
separated by centrifugation, washed twice with cold ultrapure water and twice 
with methanol, and dried in vacuo. 
Yield: 1.76 g, 10.2 mmol, 91.8%. 
 
7.2.1 Characterization of the Compound 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 20:80 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 29 showed a 
retention time of 8.65 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 7.3). 
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Figure 7.3: ESI-MS spectrum of compound 29, prepared in methanol 
 
The ESI-MS spectrum of compound 29 (Figure 7.3), registered in positive ion 
mode with a cone voltage of 30V, shows the pseudo-molecular ion [M+H]
+
 peak 
at 174.2 m/z and the [M-OH]
+
 and [M+Na]
+
 species at 156.2 and 196.2 m/z, 
respectively. 
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1
H-NMR 
 
Figure 7.4: 
1
H-NMR spectrum of compound 29, registered in DMSO-d6 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of 29 (Figure 7.4) shows the 
following signals, : 3.91 (d, 2H, -CH2, 
3
J = 5.85 Hz), 6.31 (d, 1H, -CHCO2H, 
3
J 
= 12.4 Hz), 6.43 (d, 1H, -CHCONH, 
3
J = 12.4 Hz), 9.19 (t, 1H, -NH, 
3
J = 5.35 
Hz) ppm. 
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13
C-NMR 
 
Figure 7.5: 
13
C-NMR spectrum of compound 29, registered in DMSO-d6 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of 29 (Figure 7.5) shows the 
following signals, δ: 40.97 (-CH2), 130.0 (-CHCONH), 133.0 (-CHCO2H), 
165.2 (-CHCO2H, 165.98 (-CHCONH), 170.4 (-CH2CO2H) ppm. 
 
The product was synthesized in high purity and, therefore, was employed for the 
preparation of the ligand, which must be coordinated to the Pt in equatorial or 
axial position. 
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7.3 Synthesis of the 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic 
Acid (30) 
 
 
 
The synthetic procedure was reported in literature [7]. Compound 29 (500 mg, 
2.89 mmol) was suspended in 75 mL of toluene. Then, after the addition of 1.4 
mL of triethylamine (TEA), the suspension was left under vigorous stirring at 80 
°C in an oil bath till the reagent was completely dissolved (about 2 hours): the 
solution became pale yellow and, on the flask bottom, a brownish oil was 
formed. It was eliminated by centrifugation. Toluene was removed under 
reduced pressure. Then, the colorless residue was dissolved with ultrapure water 
(about 50 mL) and the pH was adjusted to 2.0 ± 0.1 with few drops of 
concentrated HCl. Two extractions with of ethyl acetate were carried out and the 
organic phase was made anhydrous with anhydrous sodium sulfate and 
evaporated to dryness by a rotary evaporator. 
The product was collected and dried in vacuo (it was very hygroscopic). 
Yield: 0.322 g, 2.07 mmol, 71.9%. 
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7.3.1 Characterization of the Compound 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 20:80 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 30 showed a 
retention time of 8.71 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 7.6). 
 
 
Figure 7.6: ESI-MS spectrum of compound 30, dissolved in methanol 
 
Figure 7.6 shows the ESI-MS spectrum of compound 30, registered in negative 
ion mode with a cone voltage of 30V, and it allows to confirm the presence of 
the pseudo-molecular ion [M-H]
-
 at 154.0 m/z. 
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1
H-NMR 
 
Figure 7.7: 
1
H-NMR spectrum of compound 30, registered in DMSO-d6 
 
The 
1
H-NMR (500 MHz, DMSO-d6) spectrum of 30 (Figure 7.7) shows the 
following signals, δ: 4.14 (s, 2H, -OCOCH2), 7.13 (s, 1H, -NCOCH) ppm. 
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13
C-NMR 
 
Figure 7.8: 
13
C-NMR spectrum of compound 30, registered in DMSO-d6 
 
The 
13
C-NMR (125.7 MHz, DMSO-d6) spectrum of 30 (Figure 7.8) shows the 
following signals, δ: 38.5 (-OCOCH2), 134.9 (-NCOCH=CH), 168.9 (-
OCOCH2), 170.4 (-NCOCH=CH) ppm. 
 
The synthesized ligand, obtained in high purity, was used to substitute one of the 
two leaving groups of cisplatin in order to exploit also the equatorial position for 
the coupling with another drug or a vector. In particular, the reaction of cisplatin 
with an almost stoichiometric amount of silver nitrate allows to replace a 
chloride with a water molecule. Then, this intermediate reacts with a solution 
containing the salt of the previously prepared ligand (30), obtaining as a result a 
Pt(II) complex which can be functionalized also in equatorial position (31). Its 
synthesis and characterization are reported in the following paragraph. 
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7.4 Synthesis of the (SP-4-3)-diamminechlorido(2-(2,5-dioxo-2,5-
dihydro-1H-pyrrol-1-yl)acetate)platinum(II) (31) 
 
 
The replacement reaction of one of the two cisplatin chlorides was carried out 
according to a procedure [8]. In particular, to a suspension of cisplatin (100 mg, 
0.333 mmol) in 5 mL of anhydrous DMF, silver nitrate (53.7 mg, 0.317 mmol) 
was added dropwise and the mixture was magnetically stirred at room 
temperature for 24 hours in the dark. The suspension was then filtered (PTFE 
filter with a porosity of 0.45 μm) in order to remove AgCl (precipitated during 
the displacement of the chloride ligand). The solution was added to a solution of 
potassium 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetate in anhydrous DMF. 
This latter was previously prepared by dissolving compound 30 (57.3 mg, 0.369 
mmol) and KOH (20.7 mg, 0.369 mmol) in ultrapure water, by correcting the 
pH value to about 5-6, by removing water under reduced pressure and by 
suspending the obtained species in anhydrous DMF. The reaction was carried 
out at 50 °C for 24 hours in the dark. The mixture was then filtered (0.45 μm 
porosity) and DMF was removed under reduced pressure. The yellow product 
was precipitated by adding ethanol/diethyl ether, washed with ethanol and 
methanol and finally dried in vacuo. 
Yield: 59.1 mg of not completely pure compound. 
 
286 
 
7.4.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. The chromatogram of the 
reaction product is reported in Figure 7.9. 
 
 
Figure 7.9: Chromatogram of complex 31, prepared in ultrapure water 
 
The chromatogram shows three main peaks at 5.31, 5.82 and 8.15 minutes, the 
identity of which is verified by the corresponding ESI-MS spectra (Figures 
7.10-7.12). 
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Figure 7.10: ESI-MS spectrum of the species eluted at 5.31 minutes 
 
The ESI-MS spectrum (Figure 7.10), registered in positive ion mode with a 
cone voltage of 30V, shows a value at 420.3 m/z, corresponding to the pseudo-
molecular ion [M+H]
+
 peak of complex 31. 
 
 
Figure 7.11: ESI-MS spectrum of the species eluted at 5.82 minutes 
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The ESI-MS spectrum (Figure 7.11), registered in positive ion mode with a 
cone voltage of 30V, shows a value at 560.3 m/z, corresponding to the [M+Na]
+
 
adduct of a Pt(II) complex in which also the second chloride ligand is replaced 
by another 30 molecule, byproduct. 
 
 
Figure 7.12: ESI-MS spectrum of the species eluted at 8.15 minutes 
 
The ESI-MS spectrum (Figure 7.12), registered in negative ion mode with a 
cone voltage of 30V, shows a value at 154.0 m/z, corresponding to the pseudo-
molecular ion [M-H]
-
 peak of the unreacted 2-(2,5-dioxo-2,5-dihydro-1H-
pyrrol-1-yl)acetic acid (30). 
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Figure 7.13: 
1
H-NMR spectrum of complex 31, registered in DMF-d7 
 
The 
1
H-NMR (500 MHz, DMF-d7) spectrum of 31 (Figure 7.13) shows the 
following signals, δ: 3.97 (s, 2H, -OCOCH2), 4.16 (m, 3H, -NH3 in trans to the 
carboxylate ligand), 4.70 (m, 3H, -NH3 in trans to the chloride ligand), 7.02 (s, 
2H, -CH=CHCON) ppm. 
It is possible to attribute the signals at 4.16 and 4.70 ppm to the protons of the 
carrier groups in trans to the carboxylate and to the chloride ligands, 
respectively, since literature [9] reports that protons in trans to a chloride show a 
higher chemical shift than the ones of a species in trans to a carboxylato group. 
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Figure 7.14: 
13
C-NMR spectrum of complex 31, registered in DMF-d7 
 
The 
13
C-NMR (125.7 MHz, DMF-d7) spectrum of 31 (Figure 7.14) shows the 
following signals, δ: 40.1 (-OCOCH2), 135.1 (-NCOCH=CH), 171.2 (-
NCOCH=CH), 174.1 (-OCOCH2) ppm. 
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Figure 7.15: 
195
Pt-NMR spectrum of complex 31, registered in DMF-d7 
 
The 
195
Pt-NMR spectrum of complex 31 (Figure 7.15) was registered in DMF-
d7 (at a 107.2 MHz NMR frequency) and shows a signal with a chemical shift 
value of -1749 ppm, which is consistent with a Pt(II) complex containing a 
chloride, a carboxylato and two amines. 
 
After a further step of purification, complex 31 was employed as the basis for 
the synthesis of three Pt(IV) compounds, the axial ligands of which must be 
exploited for further couplings to other drugs or active species. 
In one case, the oxidation reaction was carried out by using hydrogen peroxide 
in water in order to prepare a symmetrical complex (32) with two hydroxido 
groups in axial position (the first deriving from the H2O2 and the second from 
the solvent). 
In the other cases, the N-chlorosuccinimide (NCS) was the oxidizing agent: this 
is a source of “positive chloride ions”, which remove two electrons to the Pt(II) 
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that is then oxidized to Pt(IV) [10]. The second axial ligand is 2-
hydroxoethanolato (complex 29), which derives from the reaction solvent (i.e. 
ethylene glycol), or 4-carboxypropanoato (compound 30), deriving from the 
nucleophile (i.e. succinic anhydride) dissolved in a non-coordinating solvent 
(acetone). This latter is not completely anhydrous and it is hypothesized that the 
water present in the solvent has an important role in the reaction mechanism: 
probably, an hydroxido is at first coordinated to platinum in axial position, by 
forming an intermediate which then reacts with the anhydride to obtain the final 
product. 
 
7.5 Synthesis of the (OC-6-44)-diamminechloridodihydroxido(2-
(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetate)platinum(IV) (32) 
 
 
 
Complex 31 (35.0 mg, 0.0836 mmol) was suspended in 1 mL of a 50% w/w 
aqueous solution of hydrogen peroxide and the mixture was magnetically stirred 
in an ice bath for 2 hours. Then the water was removed under reduced pressure 
and the product was precipitated by acetone/diethyl ether, washed with diethyl 
ether and dried in vacuo. 
Yield: 19.7 mg of crude product (see RP-HPLC-ESI-MS results). 
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7.5.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. 
The RP-HPLC-ESI-MS characterization allows to verify that the oxidation 
reaction of complex 31, in these conditions, was not successful: in fact, the 
Pt(II) complex is not formed (not even in small amounts). For this reason, this 
oxidation method was abandoned and other strategies, based on the use of the N-
chlorosuccinimide, were carried out to obtain an oxidized product. 
 
7.6 Synthesis of the (OC-6-44)-diamminedichlorido(2-
hydroxyethanolato)(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) 
acetate)platinum(IV) (33) 
 
 
294 
 
 
Complex 31 (46.0 mg, 0.110 mmol) was suspended in 1.5 mL of ethylene glycol 
and was magnetically stirred for 30 minutes. Then a slight excess of N-
chlorosuccinimide (14.8 mg, 0.111 mmol) was added to the mixture and the 
reaction was carried out at room temperature for 4 hours in the dark. After the 
established time, the mixture was filtered and a yellow product was precipitated 
by adding acetone/diethyl ether, washed with diethyl ether and dried in vacuo. 
Yield: 35.8 mg of crude product (see RP-HPLC-ESI-MS results). 
 
7.6.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. 
Also in this case, the RP-HPLC-ESI-MS characterization allows to verify that 
complex 31 was not oxidized and, for this reason, this oxidation method was 
modified: in fact, the ethylene glycol was replaced by the use of a non-
coordinating solvent (acetone) and of a nucleophile (succinic anhydride) in 
order to study this oxidation method again but allowing the coordination of 
another type of second axial ligand. 
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7.7 Synthesis of the (OC-6-44)-diammine(4-
carboxypropanoato)dichlorido(2-(2,5-dioxo-2,5-dihydro-1H-
pyrrol-1-yl)acetate)platinum(IV) (34) 
 
 
 
Complex 31 (92.1 mg, 0.220 mmol) and N-chlorosuccinimide (29.7 mg, 0.222 
mmol) were suspended in 2 mL of anhydrous acetone. Then succinic anhydride 
(440 mg, 4.40 mmol), dissolved in 14 mL of anhydrous acetone, was added to 
the mixture and the reaction was carried out at room temperature for 4 hours in 
the dark. Subsequently, the solid was removed by filtration and the acetone was 
removed under reduced pressure. The solid was collected and washed several 
times with diethyl ether and then dried in vacuo. 
Yield: 42.6 mg of not completely pure compound. 
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7.7.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 50:50 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Complex 34, the 
chromatogram of which is reported in Figure 7.16, shows a retention time of 
5.75 minutes and its identity is attributed by the corresponding ESI-MS 
spectrum (Figure 7.17). However, the chromatogram allows to evaluate the 
presence of other species, the identity of which is not attributed, except for the 
compound eluted at 8.15 minutes which is a residue of 30. 
 
 
Figure 7.16: Chromatogram of the reaction product, dissolved in a 50:50 mixture of ultrapure 
water and methanol 
 
297 
 
 
Figure 7.17: ESI-MS spectrum of complex 34, dissolved in a 50:50 mixture of ultrapure water 
and methanol 
 
The ESI-MS spectrum reported in Figure 7.17, registered in positive ion mode 
with a cone voltage of 30V, confirms the identity of the product eluted at 5.75 
minutes (complex 34): in fact, it is possible to observe the pseudo-molecular ion 
[M+H]
+
 peak at 572.3 m/z, the [M+Na]
+
 adduct at 594.3 m/z and the fragment 
[M-succinate]
+
 at 454.2 m/z. 
 
The synthesized complex was not pure enough to proceed with its activation and 
subsequent coupling with a primary amine (model of an amino-functionalized 
vector). For this reason, the project to prepare a Pt(IV) compound with a 2-(2,5-
dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid (30) coordinated in equatorial 
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position was abandoned and the axial position of complex 6 (i.e. (OC-6-
44)diamminedichloridoethanolatohydroxidoplatinum(IV)) was exploited. 
 
7.8 Synthesis of the (OC-6-44)-diamminedichloridoethanolato(2-
(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetate)platinum(IV) (35) 
 
 
 
The carboxylic acid of the compound 30 was activated by employing a 
procedure reported in literature [11]. In particular, a solution of 30 (48.0 mg, 
0.309 mmol) and DCC (63.8 mg, 0.309 mmol), dissolved in 1 mL of anhydrous 
DMF, was sonicated in an ultrasonic bath for 15 minutes at room temperature: 
the colorless solution became dark red and a white solid (DCU) precipitated. 
Then the precipitate was separated by centrifugation and the supernatant was 
added very slowly (dropwise for 30 minutes) to a suspension of 6 (100 mg, 
0.276 mmol) in 5 mL of anhydrous DMF. The reaction was carried out 
overnight at room temperature. The mixture was then cooled, filtered (PTFE 
filter with a porosity 0.45 μm) and the DMF was evaporated by a rotary 
evaporator (bath temperature set at < 60 °C). The yellow oil obtained was 
dissolved in ultrapure water, in order to allow the precipitation of the remained 
DCU. The yellow solution was filtered (0.45 μm porosity), the water was 
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removed under reduced pressure and the reaction product was precipitated with 
acetone/diethyl ether and then dried in vacuo. 
Yield: 83.2 mg, 0.167 mmol, 60.4%. 
 
7.8.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 70:30 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (by isocratic elution), a flow rate of 0.500 mL/min, a temperature 
of 37 °C and the UV-Visible detector set at 210 nm. Compound 35, the 
chromatogram of which is shown in Figure 7.18, is eluted at 9.20 minutes and 
its identity is attributed by means of the corresponding ESI-MS spectrum 
(Figure 7.19). However, other two species are eluted at 5.20 and 10.03 minutes 
and they correspond to cisplatin and compound 30, respectively. 
 
 
Figure 7.18: Chromatogram of complex 35, dissolved in ultrapure water 
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Figure 7.19: ESI-MS spectrum of complex 35, prepared in ultrapure water 
 
In the ESI-MS spectrum reported in Figure 7.19, registered in positive ion mode 
with a cone voltage of 30V, complex 35 is confirmed by the presence of the 
pseudo-molecular ion [M+H]
+
 peak at 500.4 m/z, the adduct [M+Na]
+
 at 522.4 
m/z and the fragment [M-OCH2CH3]
+
 at 454.4 m/z. 
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Figure 7.20: 
1
H-NMR spectrum of complex 35, registered in D2O 
 
The 
1
H-NMR (500 MHz, D2O) spectrum of 35 (Figure 7.20) shows the 
following signals, δ: 1.19 (t, 3H, -OCH2CH3, 
3
J = 6.95 Hz), 3.43 (q, 2H, -
OCH2CH3, 
3
J = 6.95 Hz), 4.39 (s, 2H, -OCOCH2), 6.97 (s, 2H, -NCOCH=CH) 
ppm. 
The δ signals at 2.85 and 3.01 ppm correspond to –(CH3)2 of DMF, employed 
during the synthetic phase and not completely removed. 
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Figure 7.21: 
13
C-NMR spectrum of complex 35, registered in D2O 
 
The 
13
C-NMR (500 MHz, D2O) spectrum of 35 (Figure 7.21) shows the 
following signals, δ: 16.11 (-OCH2CH3), 39.95 (-OCOCH2), 67.66 (-OCH2CH3), 
134.74 (-NCOCH=CH), 172.37 (-NCOCH=CH), 176.34 (-OCOCH2) ppm. 
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Figure 7.22: 
195
Pt-NMR spectrum of complex 35, registered in D2O 
 
In the 
195
Pt-NMR spectrum (Figure 7.22), registered in D2O (at a 107.2 MHz 
NMR frequency), it is possible to observe the presence of an intense signal (in 
the form of a defined quintuplet, 
1
J = 197.4 Hz) at 904 ppm which is attributed 
to complex 35: in fact, it is consistent with a Pt(IV) complex having coordinated 
an alkoxido, two chlorides, two amines and a carboxylato. 
The signals multiplicity is typical of the coupling of 
195
Pt (whose spin quantum 
number I is ½) with two 
14
N atoms (I = 1) and it is quite broad, due to the 
coupling with the quadrupolar nucleus 
14
N. 
 
7.8.2 Stability in Aqueous Solution of Complex 35 
 
In order to evaluate the behavior of 35 in solution (at 25 °C, in the dark), the 
complex (12.0 mg, 0.0240 mmol) was dissolved in 600 μL of D2O, transferred 
in a NMR tube and its stability was followed by means of 
1
H-NMR 
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spectroscopy. The spectra, registered at the initial time (t = 0), after 12 and 60 
hours, were compared in Figure 7.23. 
 
1
H-NMR 
 
Figure 7.23: 
1
H-NMR spectra of 35, registered in D2O, at a) t = 0, b) t = 12h, and c) t = 60h 
 
In the spectrum, registered at the initial time (Figure 7.23a), it is possible to 
observe the presence of some impurities at about 2.1, 3.6, 4.1 and 4.3 ppm 
(green indicators). However, after already 12 hours (Figure 7.23b), these species 
grow and the signal at 4.1 ppm (red indicator), in particular, begins to shift at 
higher values. After 60 hours (Figure 7.23c) the δ signals are much higher (light 
blue indicators) and the species that at first was at about 4.1 ppm underwent a 
shift of about 0.1 ppm. Therefore, the results show that a degradation of the 
Pt(IV) complex begins within 12 hours and this suggests that, consequently, the 
Diels-Alder reaction must be performed within one day, in order to limit the 
formation of byproducts. 
 
 
c) 
b) 
a) 
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7.9 Diels-Alder Reaction with Furan 
 
In a cycloaddition reaction, two species containing π bonds react to synthesize a 
cyclic molecule, obtained after the rearrangement of the π electrons and the 
formation of two new π bonds. The Diels-Alder is one of the most known 
examples of cycloaddition reaction. Moreover, this latter can be classified by 
considering the number of π electrons that take part in the process. The Diels-
Alder reaction is a cycloaddition [4 + 2] because one compound takes part with 
its four π electrons and the other one with two π electrons. 
In this case, the reaction involved the π electrons of the maleimide derivative 
present in complex 35 (dienophile) and the ones of furan (conjugated diene). 
This latter was employed as a model in order to set up the reaction conditions 
for the cycloaddition. In particular, two different temperatures were compared, 
i.e. 40 °C and 25 °C, because the first was the same reported in literature [5] and 
the second was chosen in order to verify the cyclization in the absence of 
heating. The reaction time was fixed at 5 days [5]. 
 
7.9.1 Characterization of Furan 
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Figure 7.24: 
1
H-NMR spectrum of furan, registered in D2O 
 
The 
1
H-NMR (500 MHz, D2O) spectrum of furan (Figure 7.24) was acquired 
for comparison purposes and shows the following signals, δ: 6.53 (s, 1H, -
OCH=CH), 7.59 (s, 1H, -OCH=CH) ppm. 
 
7.9.2 Synthesis of the (OC-6-44)-diamminedichloridoethanolato(2-
(1,3-dioxo-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindol-2(3H)-yl) 
acetate)platinum(IV) (36): I Method 
 
In a NMR tube, furan (1.75 μL, 0.0240 mmol) and 35 (12.0 mg, 0.0240 mmol) 
were dissolved in 0.6 mL of D2O and immersed in an oil bath preset at 40 °C. 
The reaction was followed by 
1
H-NMR spectroscopy for 5 days. 
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At first, when both compounds were dissolved, the t = 0 (initial reaction time) 
spectrum was registered and compared to the 
1
H-NMR spectra of free furan and 
complex 35 (Figure 7.25). 
 
1
H-NMR 
 
Figure 7.25: 
1
H-NMR spectrum of the reaction at t = 0 (c)) compared to a) furan and b) complex 
35 
1
H-NMR spectra. All the spectra were registered in D2O 
 
Then, the tube was immersed in the oil bath (40 °C) and the reaction started in 
order to obtain the compound 36 (Figure 7.26). The 
1
H-NMR spectra were 
registered almost every 12 hours for 5 days; Figure 7.27 shows the most 
relevant spectra. 
 
a) 
b) 
c) 
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Figure 7.26: Structural formula of the Diels-Alder reaction product (36) 
 
 
Figure 7.27: 
1
H-NMR spectra of the Diels-Alder reaction (at 40 °C) 
at a) t  = 0, b) t = 17 h, c) t = 23 h, d) t = 41 h, e) t = 50 h 
 
The 
1
H-NMR spectra allowed to verify that the Diels-Alder reaction happened: 
in fact, the signal of maleimide-CH (red indicator in Figure 7.27a) and furan-
CH (green indicators) gradually disappeared, even though not completely. 
Probably, a little amount of the two reactants did not react but this does not 
represent a disadvantage when using IONPs [5], since they can be removed by 
dialysis in ultrapure water. 
a) 
b) 
c) 
d) 
e) 
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Moreover, in the δ range between 5.4 and 5.6 ppm, the two characteristic signals 
of the bound furan [5] were formed: it is possible to evaluate the progress of the 
reaction already in the Figure 7.27a, after the addition of the furan to the 
platinum solution. However, in the δ region between 3.5 and 4.5 ppm many new 
signals can be observed and they have been already seen as regards the study of 
the stability in solution of complex 35 (Figures 7.23). 
The right assignment is indicated in paragraph 7.9.3. 
Furthermore, the solution color changed from yellow at t = 0 (almost unchanged 
within 24 hours) to the very dark orange of the 5
th
 day. In particular, after the 
first 24 hours the color became darker and darker: this indicated a degradation of 
the species present in the mixture. For this reason, it was decided to perform the 
reaction at 25 °C (II method) to avoid or limit the degradation process. 
 
7.9.3 Synthesis of the (OC-6-44)-diamminedichloridoethanolato(2-
(1,3-dioxo-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindol-2(3H)-yl) 
acetate)platinum(IV) (36): II Method 
 
In a NMR tube, furan (1.75 μL, 0.0240 mmol) and complex 31 (12.0 mg, 0.0240 
mmol) were dissolved in 0.6 mL of D2O and the reaction was carried out at 25 
°C and followed by 
1
H-NMR spectroscopy for 5 days. 
Also in this case, when both compounds were dissolved in D2O, the t = 0 
1
H-
NMR spectrum was registered and compared to the 
1
H-NMR spectra of furan 
and of the Pt(IV) complex (Figure 7.28). 
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Figure 7.28: 
1
H-NMR spectrum of the reaction at t = 0 (c)), compared to a) furan and b) 
complex 31 
1
H-NMR spectra. All the spectra were registered in D2O 
 
Then, the reaction started in order to obtain the compound 36. 
1
H-NMR spectra 
were registered almost every 12 hours for 5 days and compared (Figures 7.29 
and 7.30). 
 
 
Figure 7.29: 
1
H-NMR spectra of the Diels-Alder reaction (at 25 °C) at a) t  = 0, b) t = 17h, 
c) t = 23 h, d) t = 41h, e) t = 50h 
c) 
b) 
a) 
a) 
 
b) 
 
c) 
 
d) 
 
e) 
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Figure 7.30: 
1
H-NMR spectra of the Diels-Alder reaction (at 25 °C) at a) t = 0, b) t = 136h 
 
Also in this case, the 
1
H-NMR spectra show that the Diels-Alder reaction 
happened: the free furan signals gradually disappeared and, in the δ range 
between 5.4 and 5.6 ppm, it is possible to find the two characteristic signals of 
the bonded furan. However, in δ region between 3.5 and 4.5 ppm, many new 
signals can be observed (they have been already seen in Figure 7.29b) and the 
maleimide-CH signal does not completely disappear. 
In this case, the solution color (yellow) remained unchanged during the whole 
reaction period (5 days). 
Furthermore, in Figure 7.31 the 
195
Pt-NMR spectrum of the Diels-Alder product 
(36) is reported: it was registered in D2O (at a 107.2 MHz NMR frequency) after 
100 hours from the beginning of the reaction and shows a well-defined signal (
1
J 
= 197.7 Hz) at 906 ppm, consistent with a Pt(IV) complex containing an 
alkoxido, two chlorides, two amines and a carboxylato. 
 
a) 
 
b) 
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Figure 7.31: 
195
Pt-NMR spectrum of the Diels-Alder reaction product (36) after 100h from the 
beginning of the reaction, registered in D2O 
 
The typical signal multiplicity is due to the coupling of 
195
Pt (I = ½) with two 
14
N atoms (I = 1) and it is quite broad was caused by the coupling with the 
quadrupolar nucleus 
14
N. 
The right assignment is allowed by the Heteronuclear Single Quantum 
Correlation-NMR spectrum (Figure 7.32) of the Diels-Alder reaction (at 25 °C), 
registered after 50 hours from the beginning of the reaction. 
The series of double signals is justified by the formation of exo/endo products 
and their attribution is carried out according to the literature [12]. 
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Figure 7.32: HSQC-NMR spectrum of the Diels-Alder reaction at t = 50h, registered in D2O 
 
The 
1
H-NMR (500 MHz, D2O) spectrum of the Diels-Alder reaction, shows the 
following signals, δ: 1.19 (t, 3H, H1’, 3J = 6.95 Hz), 3.23 (m, 1H, H4’exo), 3.43 
(q, 2H, H2’, 3J = 6.95 Hz), 3.83 (m, 1H, H4’endo), 5.48 (s, 2H, Hb’), 6.63 (s, 
2H, Ha’) ppm. 
The assignment of H3’ is in the δ region between 3.98 and 4.34 ppm. The 
signals at 4.39 (H3) and 6.97 (H4) ppm are due to the unreacted 35. 
In addition, the red indicators are employed to point out the signals that are 
formed from the free Pt(IV) complex itself. 
 
The portion of the 
13
C-NMR (125.7 MHz, D2O) spectrum of 36 reported in 
Figure 7.32 shows the following signals, δ: 16.1 (C1’), 36.9 or 39.9 (C3’), 45.8 
(C4’), 67.6 (C2’), 79.3 (Cb’), 134.4 (Ca’) ppm. 
The signals at 36.9 or 39.9 (C3) and 134.7 (C4) ppm are due to the unreacted 
35. 
 
  
1’ 
4’ 
2’ DMF 
3 and 3’ 
4’ 4 b’ a’ 
3 and 3’ 
4’ 
1’ 
4 
a’ 
b’ 
2’ 
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The results obtained in paragraphs 7.9.2 and 7.9.3 allow to verify the 
occurrence of the Diels-Alder reaction by using furan as a model and to evaluate 
that the best condition is 25 °C (a higher temperature leads to further 
degradations). 
The presence of unreacted 35 can be solved: in fact, when using IONPs, dialysis 
can be exploited to removed all the unreacted low MW species. 
 
7.10 Diels-Alder Reaction with the Furan-Functionalized 
Phosphonic Acid-Terminated POE Monomethyl Ether 
 
The reaction conditions (i.e. 40 °C and 25 °C) used with the maleimide 
derivative and furan were applied to the case of a ligand containing a furan 
group: in particular, this ligand was exposed on the surface of the Iron Oxide 
NanoParticles (IONPs) synthesized by N’Guyen et al. [5]. 
 
7.10.1 Characterization of the Ligand 
 
1
H-NMR spectrum (registered in D2O) of the furan-functionalized phosphonic 
acid-terminated PEO (polyethyleneoxide) monomethyl ether (Figure 7.33), was 
registered for comparison purposes. 
 
 
Figure 7.33: Structural formula of the ligand exposed from the IONPs surface 
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1
H-NMR 
 
Figure 7.34: 
1
H-NMR spectrum of the ligand, registered in D2O 
 
The signal at 3.41 ppm corresponds to PEO-OCH3, the protons of POE-
OCH2 resonate in the δ region between 3.5 and 3.9 ppm, the proton of -CHP 
shows a signal at 4.28 ppm, the PEO methylene -NCH2 has a signal at 4.64 ppm, 
and the protons of furan and triazole resonate in the δ region between 6.5 and 8 
ppm [5]. 
 
7.10.2 Diels-Alder Reaction: I Method 
 
In a NMR tube, furan-functionalized phosphonic acid-terminated POE 
monomethyl ether (54.7 mg, 0.0240 mmol) and complex 35 (12.0 mg, 0.0240 
mmol) were dissolved in 0.6 mL of D2O and immersed in an oil bath preset at 
40 °C. The reaction was followed by 
1
H-NMR for 5 days. 
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When both compounds were dissolved in D2O, the t = 0 
1
H-NMR spectrum was 
registered and compared to the free ligand spectrum (Figure 7.35). 
 
 
Figure 7.35: a) 
1
H-NMR spectrum of the ligand, b) 
1
H-NMR spectrum at t = 0 (initial time 
reaction) 
 
In Figure 7.35b (t = 0) it is possible to observe the signals of the Pt complex 
together with some changes in the original signals of the ligand (Figure 7.35a). 
Then, the tube was immersed in the oil bath (40 °C) and the reaction started in 
order to obtain the compound 37 (Figure 7.36). The 
1
H-NMR spectra were 
registered at t = 1d, t = 2d and t = 5d of reaction (where d = day) and were 
compared in Figure 7.37. 
 
a) 
b) 
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Figure 7.36: Structural formula of the Diels-Alder reaction product (37) 
 
 
Figure 7.37: 
1
H-NMR spectra at a) t = 0, b) t = 1d, c) t = 2d, d) t = 5d of reaction 
 
The 
1
H-NMR (500 MHz, D2O) spectra indicate that the Diels-Alder reaction 
happened and, after 2 days, the signals of maleimide-CH disappeared. However, 
instead of few well-defined signals of the product, a multitude of little signals 
(in particular, in the δ area between 5 and 8 ppm) can be observed. This is 
particularly evident in the spectrum of the 5
th
 day (Figure 7.37d), together with 
an overlap in the δ region 3.5-4.5 ppm. 
a) 
b) 
c) 
d) 
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195
Pt-NMR 
 
Figure 7.38: 
195
Pt-NMR spectrum of the Diels-Alder product, registered in D2O 
 
The 
195
Pt-NMR spectrum (Figure 7.38) of the reaction product, registered in 
D2O (at a 107.2 MHz NMR frequency) after five days, shows a signal at 908 
ppm, in the form of a not-well defined multiplet. It is consistent with a Pt(IV) 
complex containing an alkoxido, two chlorides, two amines and a carboxylato, 
and it is comparable to the results obtained in the case of the Diels-Alder 
reaction with furan (Figure 7.31). 
Moreover, the solution color changed from yellow at t = 0 (almost unchanged 
within 2 days) to the dark orange of the 5
th
 day: probably a degradation was in 
progress, as observed in paragraph 7.9.2. 
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7.10.3 Diels-Alder Reaction: II Method 
 
In a NMR tube, furan-functionalized phosphonic acid-terminated POE 
monomethyl ether (54.7 mg, 0.0240 mmol) and complex 35 (12.0 mg, 0.0240 
mmol) were dissolved in 0.6 mL of D2O. The reaction was carried out at 25 °C, 
to avoid the Pt(IV) complex degradation, and it was followed by 
1
H-NMR for 7 
days. 
Also in this case, the t = 0 (initial reaction time) 
1
H-NMR spectrum was 
registered and was compared to the spectra of the free ligand and 35 (Figure 
7.39). 
 
 
Figure 7.39: a) 
1
H-NMR spectrum of the ligand, b) 
1
H-NMR spectrum of the Pt(IV) complex, 
c) 
1
H-NMR spectrum at t = 0 (initial time reaction) 
 
In Figure 7.39c it is possible to observe the signals of the Pt complex together 
with some changes in the original signals of the ligand (Figure 7.39a). 
The reaction started in order to obtain compound 37. 
1
H-NMR spectra were 
registered almost every 12 hours for seven days. 
a) 
b) 
c) 
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Figure 7.40: 
1
H-NMR spectra at a) t = 0 and of the reaction after b) 18h, c) 24h, d) 46h, e) 72h 
 
 
Figure 7.41: 
1
H-NMR spectra at a) t = 0 and of the reaction after b) 72h, c) 103h, d) 143h, 
e) 163h 
 
The 
1
H-NMR (500 MHz, D2O) spectra (Figures 7.40-7.41) allow to evaluate 
that the Diels-Alder reaction was in progress because the signals of maleimide-
CH disappeared, even though slowlier than in the previous case. However, 
a) 
b) 
c) 
d) 
e) 
a) 
b) 
c) 
d) 
e) 
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instead of few well-defined signals of the product, a multitude of little signals is 
visible (in particular, in the δ region between 7 and 8 ppm). In addition, in the δ 
region between 5 and 6 ppm some new signals appeared but it is not possible to 
make a correct attribution. 
 
195
Pt-NMR 
 
Figure 7.42: 
195
Pt-NMR spectrum of the Diels-Alder product, registered in D2O 
 
The 
195
Pt-NMR spectrum of the reaction product after five days (Figure 7.42), 
registered in D2O (at a 107.2 MHz NMR frequency) shows a signal at 908 ppm, 
in the form of a not-well defined multiplet, which is consistent with a Pt(IV) 
complex having coordinated two chlorides, two amines, an alkoxido and a 
carboxylato. 
Moreover, as verified in paragraph 7.9.3, the yellow solution remained 
unchanged during the five days. 
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The results reported in paragraphs 7.10.2 and 7.10.3 allow to verify that, also in 
this case, the Diels-Alder reaction occurred and, as previously described in 
paragraph 7.9, the best temperature condition is 25 °C. 
 
7.11 Diels-Alder Reaction with IONPs 
 
The results obtained in paragraphs 7.7 and 7.8 point out that the Diels-Alder 
reaction must be performed at 25 °C, in order to avoid degradation (even 
though, in the case of IONPs, not coupled molecules can be removed by 
dialysis). For this reason, complex 35 and IONPs [5], were reacted in the 
previously mentioned conditions, both for 24 hours and 5 days (as a 
comparison). 
 
7.11.1 Main Features of the IONPs 
 
The Iron Oxide NanoParticles, synthesized by Dr. Jérôme Fresnais (Laboratoire 
de Physico-Chimie des Electrolytes, Colloïdes et Sciences Analytiques, Paris 
(France)), were provided as water solution with the following features: 
 0.528 % w/w (i.e. 0.528 g of IONPs in 100 g of sample), 
 1 g/mL solution density, 
 1 × 10-4 mol furan/g IONPs, 
 43.1 mM Fe concentration, 
 9 nm as mean diamenter. 
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7.11.2 Diels-Alder Reaction for 24 Hours 
 
An aliquot of the IONPs (600 μL, 0.317 μmol) was added to complex 35 (7.91 
mg, 15.8 μmol) and the mixture was magnetically stirred at 25 °C for 24 hours. 
Then the sample was collected and dialyzed in ultrapure water for four days by 
using a dialysis tubing cellulose membrane (the molecular weight cut-off was 1 
kDa). An aliquot of the sample (200 μL) was mineralized by acid digestion, with 
37% w/w HCl, in an ultrasonic bath at 60 °C for 1 hour. During the 
mineralization, the color solution changed from the initial brown to a bright 
yellow. Then the solution was diluted with HNO3 1% v/v and the Pt content was 
quantified by means of ICP-OES analysis and, as a consequence, the Pt/furan 
ratio was determined. In particular, the Pt concentration is 1.00 mM, which 
corresponds to a Pt/furan ratio was 1.9. 
 
7.11.3 Diels-Alder Reaction for 5 Days 
 
Another IONPs aliquot (600 μL, 0.317 μmol) was added to complex 35 (7.91 
mg, 15.8 μmol) and the reaction was carried out at 25 °C for 5 days. After the 
established time, the sample was processed as described in paragraph 7.9.2. 
The data show that the Pt concentration is 1.95 mM and the Pt/furan ratio is 3.7. 
 
7.12 Conclusions 
 
In this work, a ligand functionalized with a maleimide derivative (dienophile 
species) was successfully synthesized and, therefore, it was employed for the 
preparation of Pt(IV) complexes having one equatorial or axial position 
occupied by this ligand. The results point out that only complex 35 (in which the 
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maleimide was axially coordinated) is promising. For this reason, its 
functionalizable group (alkene) was exploited for Diels-Alder cycloaddition 
reactions. Furan derivatives were used as a model to set up the reaction 
conditions and the successful results allowed to apply the synthetic procedure to 
magnetic iron oxide nanoparticles (IONPs). 
The two synthesized conjugates are undergoing in vitro biological assays. 
At first, hyperthermia therapies will be exploited (by means of the retro-Diels-
Alder reaction) in order to release the Pt(IV) prodrug, which, after the so-called 
activation by reduction, gives rise to the active Pt(II) species. 
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Capitolo 8  
Chapter VIII 
 
 
 
 
 
 
 
 
 
 
Drugs Encapsulation into Liposomes 
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8.1 Introduction 
 
It is known that malignant pleural mesothelioma (MPM) is a tumor which 
affects the mesothelial cells that line the pleural cavity and it is associated to the 
exposure to asbestos fibers. Many decades may elapse between the exposure and 
the disease diagnosis and, despite its rarity, MPM is very aggressive because the 
median survival goes from 8 to 12 months. In this regard, the Food and Drug 
Administration accepted a treatment which exploits the combination of cisplatin 
and pemetrexed (i.e. an antifolate which acts on some enzymes involved in the 
synthesis of thymidine and purine), which results to partially extend (by a few 
months) the median survival with respect to a cisplatin-based therapy [1]. 
Furthermore, since epigenetic modifications play a significant role in neoplastic 
progression, the research aims to co-administer drugs, which exploit this 
function, with other chemotherapeutics [2]. 
One of the epigenetic modifications is the acetylation of histone (i.e. a protein 
that represents the structural component of chromatin), which is controlled by 
histone acetyltransferases (HAT) and deacetylases (HDAC) (Figure 8.1). These 
latter enzymes, in particular, remove the acetyl groups from the histone lysines 
increasing the association of the histone with DNA and preventing the binding 
of cisplatin to DNA. For this reason, HDAC inhibitors (HDACI) must be 
employed in order to inhibit deacetylation (and, therefore, the DNA interaction 
with histones) and to allow the drug to bind to its target. Moreover, the 
accumulation of acetylated histones activates the transcription of some genes 
and, when they are expressed, the tumor growth is inhibited and apoptosis is 
induced [2]. 
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Figure 8.1: Hystone acetylation and deacetylation, which play important roles in gene 
expression. The picture is adapted from [3] 
 
Hydroxamic acids, such as suberoylanilide hydroxamic acid (SAHA or 
Vorinostat), and anions of aliphatic acids (such as 2-propylpentanoate or 
valproate) can be mentioned among the HDACIs. In particular, valproate 
(clinically employed as an anticonvulsant drug) showed a HDAC inhibition 
activity and its effect positively influenced the results of the co-administration of 
cisplatin with pemetrexed in the case of mesothelioma diseases [2]. Moreover, 
Zanellato et al. [4] evaluated the combination index (CI, i.e. a quantitative 
measure of the efficacy of a drug combination [5, 6]) of valproate and cisplatin: 
 
    
           
             
  
           
             
  
                         
                                 
 
 
 closed chromatin 
 DNA inaccessible 
 transcription repression 
 open chromatin 
 DNA accessible 
 transcription activation 
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(where the drug ICx is the concentration of the single drug to obtain the x% of 
cell viability and the [cisplatin] and [valproate] are the concentrations of these 
drugs within the combination to achieve the same result, i.e. x% viability) on 
some malignant pleural mesothelioma cell lines. The purpose was to verify if 
synergistic (CI < 1), additive (CI = 1) or antagonistic (CI > 1) effects occurred: 
synergy was generally observed. 
In this work [7], three types of cationic liposomes (containing cisplatin, 
valproate sodium salt and the combination of both drugs in an approximative 1:2 
molar ratio) were synthesized in order to evaluate if the co-administration of the 
two drugs encapsulated into the lipid vectors allowed to obtain the same 
antiproliferative effect of a Pt(IV) complex, the axial ligands of which were both 
valproate, i.e. (OC-6-33)-diamminedichloridobis(2-
propylpentanoate)platinum(IV) (39). This latter proved to have a high cytotoxic 
activity on several tumor cell lines, higher than cisplatin [8]. Moreover, complex 
39 was also encapsulated into a forth liposome for comparison. 
Furthermore, the combination index of the two liposomes containing the single 
drugs was evaluated in order to verify if a synergism occurs, as well as in the 
case of free cisplatin and valproate. 
The cellular accumulation of the platinum complexes and liposomes and the 
DNA platination (i.e. the amount of platinum bound to DNA) of complex 39 
were evaluated. 
The synthesized platinum(IV) complex and liposome formulations are reported 
in order of discussion: 
 (OC-6-33)-diamminedichloridobis(2-propylpentanoate)platinum(IV) 
(39), 
 cationic liposomes without any drugs, 
 cationic liposomes encapsulating cisplatin, 
 cationic liposomes encapsulating valproate sodium salt, 
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 cationic liposomes encapsulating both cisplatin and valproate sodium 
salt, 
 cationic liposomes encapsulating complex 39. 
 
8.2 Synthesis of the (OC-6-33)-diamminedichloridobis(2-
propylpentanoate)platinum(IV) (39) 
 
 
 
Complex 39 was prepared according to a previously reported procedure [8]. In 
particular, to a suspension of complex 1 (100 mg, 0.299 mmol) and pyridine 
(1.00 mL, 12.4 mmol) in 3 mL of acetone, a solution of 2-propylpentanoyl 
chloride (1.36 mL, 7.81 mmol) in 5 mL of acetone was added dropwise and the 
reaction was carried out for 4 hours at 70 °C with a reflux condenser. After the 
established time, 10 mL of hexane were added to the mixture, which was 
centrifuged and filtered (0.45 μm porosity). The solvent was then removed 
under reduced pressure. A white solid was precipitated by the addition of diethyl 
ether, washed several times with ultrapure water and diethyl ether and finally 
dried in vacuo. 
Yield: 86.0 mg, 0.147 mmol, 49.0%. 
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8.2.1 Characterization of the Complex 
 
RP-HPLC-ESI-MS 
 
The analysis was performed by employing a stationary phase consisting of a 
C18 Phenosphere-NEXT column 5 μm, 250 × 4.60 mm ID, a mobile phase 
composed by a 20:80 mixture of a 15 mM aqueous solution of formic acid and 
pure methanol (isocratic elution), a flow rate of 0.500 mL/min, a temperature of 
37 °C and the UV-Visible detector set at 210 nm. Compound 39 showed a 
retention time of 12.70 minutes and its identity was attributed by the 
corresponding ESI-MS spectrum (Figure 8.2). 
 
 
Figure 8.2: ESI-MS spectrum of complex 39, prepared in methanol 
 
The ESI-MS spectrum of compound 39 (Figure 8.2), registered in positive ion 
mode with a cone voltage of 30V, confirms the success of the reaction: in fact, it 
shows the pseudo-molecular ion [M+H]
+
 peak at 587.3 m/z. 
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1
H-NMR 
 
Figure 8.3: 
1
H-NMR spectrum of complex 39, registered in MeOD-d4 
 
The 
1
H-NMR (500 MHz, MeOD-d4) spectrum of complex 39 (Figure 8.3) 
shows the following signals, δ: 0.90 (t, -CH3, 12H, 
3
J = 7.2 Hz), 1.35 (m, -
CH2CH3, 8H), 1.56 (m, -CH2CH2CH3, 8H), 2.41 (m, -CH, 2H) ppm. 
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13
C-NMR 
 
Figure 8.4: 
13
C-NMR spectrum of complex 39, registered in MeOD-d4 
 
The 
13
C-NMR (125.7 MHz, MeOD-d4) spectrum of complex 39 (Figure 8.4) 
shows the following signals, δ: 14.5 (-CH3), 21.7 (-CH2CH3), 36.4 (-
CH2CH2CH3), 48.5 (-CH), 187.8 (-CO2) ppm. 
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195
Pt-NMR 
 
Figure 8.5: 
195
Pt-NMR spectrum of complex 39, registered in MeOD-d4 
 
The 
195
Pt-NMR spectrum (Figure 8.5) of complex 39 (with a 107.2 MHz NMR 
frequency) showed a well-defined quintuplet at 1096 ppm (
1
J = 177.7 Hz), 
consistent with a Pt(IV) complex containing two chlorides, two amines and two 
carboxylato ligands. 
 
8.3 Preparation of the Liposomes 
 
The liposomes [7] were prepared by the use of two lipids, i.e. the neutral 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and the cationic 1,2-
dioleoyl-sn-glycero-3-ethylphosphocholine (chloride salt) (DOEPC) (Figure 
8.6), which were dosed to synthesize carriers with a positive charge in order to 
ensure the adhesion to the cell membrane [9, 10, 11] in the case of in vitro 
assays. In particular, the molar fraction (α) of cationic lipid 
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was fixed at 0.3 because it represented the best compromise between size and 
charge of the liposome itself: in fact, when α was 0.2 the diameter was slightly 
larger (323 ± 11 nm for liposomes encapsulating valproate salt, and 282 ± 6 nm 
for liposomes encapsulating both drugs), whereas α = 0.1 made the liposome 
difficult to be suspended in aqueous solution because the too low cationic let the 
lipophilic effect prevail. For this reason, the formulations based on 0.1 and 0.2 
molar fraction of DOEPC were abandoned. 
The synthetic procedure was a modification of a reported method [12]. 
 
 
Figure 8.6: Structural formulas of the two lipids employed for the preparation of the liposomes 
 
A mixture of DOPE (13.4 mg, 18.0 mmol) and DOEPC (6.60 mg, 7.76 mmol), 
representing a 0.3 DOEPC molar fraction (α), was dissolved in 1 mL of 
chloroform and dried under reduced pressure for 1 hour to obtain a 
homogeneous lipid film. Then 1 mL of a 20 mM HEPES/20 mM NaCl (pH 7.4) 
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aqueous solution (as such or containing 1 mM cisplatin and/or 2 mM valproate 
sodium salt) was added to the previously prepared film, vortexed and sonicated 
in an ultrasonic bath for 15 minutes in order to obtain a homogeneous 
suspension. This latter was extruded by means of a 1.5 mL Lipex Extruder 
(Northern Lipids Inc.) at 40 °C and under a 20 atm Argon pressure: in particular, 
15 extrusions were carried out with 400, 200 and 100 nm polycarbonate 
extrusion membranes (NucleporeTM, Whatman International Ltd.), i.e. 5 
extrusions per different membrane size. The prepared liposomes were treated in 
order to remove the not encapsulated drugs: they were filtered four times by 
using Centrifree® ultrafiltration devices (regenerated cellulose membrane, the 
molecular weight cut-off of which was 30 kDa, Merck Millipore) at 2000 g 
relative centrifugal force. After each centrifugation, the filtrate volume was 
quantified and the filter unit was refilled with the same volume (with the 20 mM 
HEPES/20 mM NaCl aqueous solution). The centrifugation of the inverted filter 
unit allowed to collect the purified liposomes, which were maintained at 4 °C. It 
was observed that, in these conditions, the liposomes were stable for one month. 
The preparation of the liposomes containing complex 39 was slightly different 
from the previously mentioned one, because this lipophilic compound cannot be 
dissolved in aqueous solutions. Therefore, a mixture of DOPE, DOEPC and 39 
(1 mM) was dissolved in 1 mL of chloroform, dried under reduced pressure and 
then suspended in 1 mL of HEPES/NaCl solution. The prepared mixture was 
processed as previously described. 
The effective concentrations of the encapsulated Pt complexes and valproate 
were quantified by ICP-OES and an immunoturbidimetric assay, respectively. In 
particular, for the first analysis, 20 μL of the liposome suspension were 
mineralized by adding 200 μL of 70% w/w HNO3 in an ultrasonic bath for 1 
hour at 60 °C. Then the solution was diluted with 1% v/v HNO3 to the final acid 
concentration of 1% v/v and the Pt content was measured by ICP-OES (by 
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selecting the 299.797 nm line). As regards the valproate, after the lysis of 50 μL 
of the liposomes suspension with 5% Triton X-100 at 72 °C [13], its content was 
quantified by employing an immunoturbidimetric assay (code MF010, Delta 
Chemie Biotechnology). This latter is based on the reaction between an antibody 
and latex particles bound to valproic acid and the analysis is based on 
turbidimetry: the solution turbidity was measured by exploiting the absorption 
and reflection at a specific wavelength (i.e. 600 nm). The turbidity produced is 
directly proportional to the valproic acid concentration present in the sample. 
 
8.3.1 Size and Stability Investigations 
 
The dimensional analyses of the liposomes were performed by DLS and TEM 
techniques (paragraphs 4.2 and 5.5). 
The preparation of the sample for the DLS analysis consisted of the dilution of 
20 μL of purified sample with the 20 mM HEPES/20 mM NaCl aqueous 
solution to the final volume of 1 mL. Then, the suspension was transferred into a 
quartz cuvette to perform the analysis (for each sample, five measurements were 
carried out). 
For TEM analysis, 100 μL of the sample were dispersed in 200 μL of 4% low 
melting point agarose and, in order to ensure the polymerization of this latter, 
the suspension was maintained at 4 °C for 1 hour. By employing a single edge 
razor blade, the prepared sample was cut in small cubes of about 1-2 mm
3
. Then 
the sample was divided into two batches: in particular, in one of them 2% of a 
potassium permanganate solution was added and it was incubated for 1 hour at 4 
°C under gentle shaking, whereas the other one was fixed in 2.5% 
glutaraldehyde in HEPES overnight at 4 °C and, subsequently, in 1% osmium 
tetroxide solution for 1 hour. Then, each aliquot was washed several times with 
distilled water and dehydrated in graded ethanol series (from 30 to 100%), 
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embedded in Epon-Araldite resin and ultrathin sections were cut with a diamond 
knife in a Leica Ultracut UCT Ultramicrotome, double-stained with uranyl 
acetate and lead citrate, observed through a Philips CM 10 Transmission 
Electron Microscope, which operated at 60 kV. 
The ζ potential analysis allowed to evaluate the suspension stability of each 
sample and was performed after the dispersion of 20 μL of liposomes in a 20 
mM HEPES aqueous solution (without NaCl) to the final volume of 1 mL. Then 
the suspension was transferred into a cuvette and the analysis was carried out 
(five measurements). 
The results of the analyses are shown in Table 8.1. 
 
Liposome containing DLS diameter ζ potential 
no drugs 166 ± 5 nm 58 ± 4 mV 
cisplatin 163 ± 2 nm 58 ± 6 mV 
sodium valproate 190 ± 9 nm 64 ± 2 mV 
both cisplatin and sodium 
valproate 
192 ± 17 nm 59 ± 4 mV 
39 273 ± 14 nm 56 ± 8 mV 
Table 8.1: Size and suspension stability results of the five types of liposomes 
 
The data show that the encapsulation of cisplatin did not cause an increase in 
size, with respect to empty liposomes: in fact, in both cases, the diameters are 
about 160 nm. However, the inclusion of sodium valproate or complex 39 led to 
an increase to about 190 nm and 270 nm, respectively. 
The ζ potential data (about +60 mV) show that all the liposomes exceed the 
threshold of stability (+30 mV): these results indicated that a very high stability 
was ensured for these systems and this aspect may increase the adhesion to the 
cellular membrane. 
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Figure 8.7: TEM micrographs of a) empty liposome after the treatment with KMnO4, b) empty 
liposome after the treatment with OsO4, c) cisplatin liposome after the treatment with OsO4. 
The bars represent 200 nm in a) and b), whereas 100 nm in c) 
 
The TEM micrographs (Figure 8.7) confirm the DLS analysis data. The results 
reported in Chapters IV and V point out that DLS diameters are larger than the 
TEM ones. However, in this case, the two dimensional analyses allow to obtain 
similar values: probably, the treatments employed for the liposomes led to an 
increase in the vector size. 
 
8.4 Spontaneous Drug Release from Liposomes 
 
The drug release from liposomes containing cisplatin, sodium valproate or 
complex 39 was evaluated in  abiological conditions. In particular, the prepared 
nanosystems were kept at 37 °C for 4 hours in  HEPES/NaCl solution and then 
filtered by means of Centrifree® ultrafiltration devices, centrifuged at 2000 g 
relative centrifugal force. Then, the previously described procedure for the 
liposomes purification was here followed: the filtrate volume was quantified, the 
filter unit was refilled with the same volume and the centrifugation of the 
inverted filter unit allowed to collect the liposomes. 
These latter were employed for the quantification of the Pt or valproate residual 
concentration by ICP-OES and immunoturbidimetric assay, respectively, and 
a) b) c) 
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the released amount was determined by means of the difference between the 
initial and the residual concentrations. 
The test showed that the drug release was 15 ± 5 % from the liposomes 
containing cisplatin, 10 ± 3 % from the liposomes encapsulating sodium 
valproate and 3 ± 1 % from the liposomes containing complex 39. 
 
8.5 Biological In Vitro Studies 
 
After the phase of characterization, liposomes and complex 39 were tested in 
vitro to evaluate their ability in the inhibition of the cellular proliferation, their 
accumulation into the cells, their platination of DNA and, in particular, to 
evaluate the combination index of the different liposomes. 
 
8.5.1 The Antiproliferative Activity (IC50) 
 
The liposomes, cisplatin, valproate sodium salt and complex 39 were tested on 
A2780 human ovarian carcinoma cell line, grown in RPMI 1640 medium, which 
was supplemented with L-glutamine (2 mM), penicillin (100 IU/mL), 
streptomycin (100 mg/L) and 10% fetal bovine serum (FBS). The continuous 
treatments (72 hours) were performed at 37 °C in a 5% CO2 humidified chamber 
and, after treating the cells with the compounds, the resazurin reduction assay 
was employed [14] in order to verify the remaining cells viability. The details 
are reported in paragraph 4.19.1. 
The IC50 values (expressed as means of at least three independent replicates) 
were obtained from the dose-response sigmoids. Moreover, the data were 
normalized to 100% of viability for not-treated cells and the 
fluorescence/absorbance of the medium without cells was used as blank. The 
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results are summarized in Table 8.2 and the curve-response curves are shown in 
Figure 8.8. 
 
Compound 
IC50 (μM) considering 
the Pt concentration 
IC50 (μM) considering the 
valproate concentration 
cisplatin 0.46 ± 0.11 - 
sodium valproate - 1833 ± 434 
39 0.011 ± 0.003 0.022 ± 0.003 
cisplatin liposome 0.13 ± 0.02 - 
sodium valproate 
liposome 
- 6.0 ± 1.2 
cisplatin and 
sodium valproate 
liposome 
0.07 ± 0.01 0.14 ± 0.02 
39 liposome 0.007 ± 0.002 0.014 ± 0.003 
Table 8.2: IC50 values of four liposomes compared to cisplatin, valproate sodium salt and 
complex 39 
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Figure 8.8: Dose-response curves of a) cisplatin, complex 39, liposomes with cisplatin, complex 
39 and both the drugs, and b) valproate sodium salt, complex 39, liposomes with valproate 
sodium salt and both drugs 
 
In almost all the cases (except for the liposomes containing both the drugs), it is 
possible to verify that the use of liposomes led to an increased cytotoxic activity 
with respect to free cisplatin and valproate: this is due to the fact that these 
vectors ensure a more efficient accumulation of the drug into the cells. In fact, 
the comparison between free and encapsulated into liposomes cisplatin show 
that the employment of the lipid carrier led to a 3.5 times higher efficacy. The 
antiproliferative activity of sodium valproate is enhanced by about 300 times 
when it is included into the liposomes. 
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As regards the system encapsulating two drugs, the presence of the HDAC 
inhibitor doubles the cytotoxicity of the cisplatin liposome, whereas the 
presence of cisplatin enhances the one of the valproate of about 40 times. 
Complex 39, however, results to be about six times more active than the 
liposome with the combined drugs, even though both contain the two drugs in 
the same ratio: in fact, complex 39 is a cisplatin-based Pt(IV) with two valproate 
coordinated in the axial positions, and the lipid vehicle contains cisplatin and 
valproate in a 1:2 molar ratio. 
As regards the liposome containing 39, instead, the lipid carrier did not 
significantly increase the antiproliferative activity of the free complex. 
 
Furthermore, in order to verify the type of effect of the combination of the 
liposomes formulations, the Combination Index (CI) was evaluated. It is plotted 
as a function of the Affected Fraction, which represents the amount of residual 
viability after each combined treatment and is expressed as a numerical value 
from 0 (100% residual viability) to 1 (0% residual viability). 
In this experiment the liposomes containing both cisplatin and valproate or the 
combined liposomes containing the single drugs were compared to the 
liposomes containg the single drugs. The resulting CI plot are reported in Figure 
8.9.  
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Figure 8.9: Combination Index vs. Affected Fraction of the liposome containing the drugs 
combination with respect to cisplatin-liposome and valproate-liposome (red balls) and 
combination index of the mixture of the cisplatin-liposome and the valproate-liposome with 
respect to cisplatin-liposome and valproate-liposome (yellow balls) 
 
CI is always lower than 1, pointing out a synergism of the two drugs both in the 
case of a co-administration of the two separate liposomes and also when the two 
drugs are encapsulated in the same carrier, as previously demonstrated for free 
cisplatin and sodium valproate [4]. 
 
8.5.2 The Cellular Accumulation 
 
The cellular accumulation of the synthesized compounds was expressed as 
Accumulation Ratio (AR) [15]. 
In particular, 10 μM cisplatin and complex 39 and 1 μM (expressed as Pt 
concentration) suspensions of liposomes (those containing platinum) were 
employed for the several treatments (4 h CT, 4 h CT + 20 h recovery (R) and 24 
h CT) on A2780 human ovarian carcinoma cell line. After the established time, 
100 μL of culture medium were harvested to measure the neat extracellular 
platinum concentration following adsorption to sterile plasticware. After the 
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treatment, cells were washed three times with PBS, detached from the 25 cm
2
 
flasks using 1 mL of 0.05% Trypsin 1X + 2% EDTA and harvested in fresh 
complete medium. Then, an automatic cell counting device was employed to 
measure the cells number and the mean diameter from every cell count. About 5 
× 10
6
 cells were transferred into a glass tube and spun at 1100 rpm for 5 minutes 
at room temperature. The supernatant was removed by aspiration and, in order 
to limit the cellular loss, about 200 μL of the supernatant were left. Each cell 
pellet was stored at -20 °C and, after defrosting it, 350 μL of HNO3 70% w/w 
were added and mineralized for 1 hour at 60 °C in an ultrasonic bath. Then the 
sample was diluted with a 1% v/v aqueous solution of HNO3 (by adding 5650 
μL) to a final 4 % v/v of acid concentration and the platinum content of each 
solution was quantified by means of ICP-MS. 
The results were expressed as Pt μg/L (ppb) and then divided by the platinum 
atomic mass (195 u) to determine the corresponding μM Pt concentration. 
The data processing, after the normalization of the intracellular platinum content 
upon the cells number and volume (calculated from the actual mean cell 
diameter measured for each sample), allowed to determine the intracellular 
platinum concentration. The ratio between the intra- and extracellular Pt 
concentrations allowed to obtain the AR value of each sample (Figure 8.10). 
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Figure 8.10: Bars graphs of the AR values of a) cisplatin, complex 39 and liposomes containing 
cisplatin, both the drugs and complex 39, and b) complex 39 and cisplatin liposome as a function 
of time 
 
The bars graph in Figure 8.10a shows that, after 4 hours of continuous treatment 
(CT), the liposomes containing only cisplatin and both cisplatin and valproate 
have AR values similar to those of complex 39 but about 15 times higher than 
cisplatin. On the contrary, the liposome containing 39 gives the highest cellular 
accumulation results, even though there are no remarkable improvements on the 
efficacy, probably due to an incomplete drug release in the cell cytosol. 
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The Figure 8.10b points out that the AR of complex 39 results increased by 
passing from a 4 hours to a 24 hours CT (as expected for a lipophilic compound) 
and slightly decreased after 4 hours of treatment, followed by 20 hours of 
recovery (R) in fresh medium. This latter study, in particular, aimed to evaluate 
the efficiency of the drug efflux: in fact, the lipophilicity of some platinum(IV) 
species allows them to remain into the cells and to continue to bind DNA [16]. 
Cisplatin (released by the cisplatin liposome), instead, was rapidly removed 
from the cells by efficient detoxification pathways, being a hydrophilic 
compound. 
Furthermore, it was possible to observe a decrease of the accumulation ratio 
values of the cisplatin liposome by passing from a 4 hours to a 24 hours CT and, 
as expected, after a recovery period in fresh medium. 
 
8.5.3 The DNA Platination 
 
The measurements of DNA platination is the phase that follows the cellular 
accumulation and consists of the binding of the considered drug to the DNA. 
This parameter must be normalized for the extracted amount of DNA because 
the extraction efficiency is not constant and can be expressed as Pt pg/DNA μg 
or Pt pg/(1 × 10
6
) cells. This latter can be obtained multiplying the DNA 
platination by 6.550 (in fact, female cells, such as A2780 cells, contain 6.550 μg 
DNA/10
6
 cells; on the contrary, male cells contain 6.436 μg DNA/106 cells). 
In particular, a 10 μM ethanol solution of complex 39 was employed for three 
different treatments of A2780 cells: 4 hours of continuous treatment (CT), 24 
hours of CT, or 4 hours of CT followed by 20 hours recovery (R, i.e. suspension 
of the cells in fresh medium). About 5 × 10
6
 cells, from each experiments, were 
collected for cellular accumulation quantification, whereas about 20 × 10
6
 cells 
were used to quantify the DNA platination. 
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After the fixed time, the cells were transferred into a plastic microcentrifuge 
tube and centrifuged at 1100 rpm for 5 minutes at room temperature: the 
supernatant was removed by aspiration, and the total genomic DNA was 
extracted from the cell pellet. In particular, during cell lysis, DNA was purified 
by RNAse A and proteinase K treatment, then extracted on silica-based 
centrifugation columns and eluted in 300 μL of elution buffer. 8 μL of sample or 
elution buffer (used as blank) were diluted in TE buffer (10 mM Tris-HCl, 1 
mM EDTA, pH 8.0) to the final volume of 80 μL. The absorbance values at 260 
nm (A260, relative to nucleic acids) and at 280 nm (A280, relative to proteins) 
were recorded from triplicate wells. Then, the two previously mentioned values 
(i.e. A260 and A280) were corrected by subtraction of the background absorbance 
(A340), and subsequently the samples purity was verified by means of the 
A260/A280 ratio. In all the cases, this ratio resulted to be higher than 2: this 
indicated that only nucleic acids were present and this avoided the occurrence of 
complexes-proteins interactions, which can modify the results. After the 
subtraction of mean A260 of blank wells, the DNA concentration was calculated 
from the corrected A260 by means of a calibration curve obtained with calf 
thymus DNA. Under these conditions, an absorbance = 1 at 260 nm corresponds 
to 100 μg of DNA per mL. The remaining amount of DNA elution buffer was 
transferred into a borosilicate glass tube, its precise volume was obtained by 
weight in order to determine the total amount of DNA, and the sample was 
stored at -20 °C. After defrosting, the samples were mineralized according to the 
procedure described in paragraph 8.4.2 but, in this case, 100 μL of HNO3 70% 
w/w were added and, after the mineralization, the sample was diluted with a 1% 
v/v aqueous solution of HNO3 (by adding 1800 μL) to a final 3.7 % v/v of acid 
concentration and the platinum content of each solution was quantified by 
means of ICP-MS. 
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The platination data (expressed as Pt pg/ DNA μg of a mean of at least three 
independent replicates) are reported in Figure 8.11. 
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Figure 8.11: Bars graph of the DNA platination of complex 39 after 4 h of continuous treatment 
(CT), 4 h of CT summed to 20 h of recovery, and 24 h of CT 
 
Complex 39 shows an increasing time-related platination: the lipophilicity of the 
compound ensured its permanence into the cells and the platination occurred 
because the Pt(IV) was activated to the Pt(II) metabolite, which continued to 
bind DNA [7, 16]. 
 
8.6 Conclusions 
 
In this work, cationic liposomes containing cisplatin, sodium valproate, their 
combination or complex 39 (i.e. a cisplatin-based Pt(IV) with two valproate 
ligands coordinated in axial position) were successfully prepared. By the 
determination of the Combination Index (CI), it was verified that both the 
liposome formulation of the two free drugs and the co-administration of the two 
separate liposomes (in both cases with 1:2 cisplatin/valproate molar ratio) 
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resulted to be synergic. Moreover, the antiproliferative activity of all the 
liposomes was evaluated on A2780 cell line and compared with free cisplatin, 
valproate and complex 39. The results pointed out that the use of liposomes 
enhances the cytotoxicity of the drugs, except when cisplatin and sodium 
valproate are combined: in fact, in this case, this formulation resulted to be less 
active than complex 39. 
The encapsulation of complex 39, instead, increased its cellular accumulation 
but the corresponding antiproliferative activity was not significantly improved, 
probably because the drug was not completely released at cellular level. 
Complex 39 increased its accumulation ratio passing from 4 hours to 24 hours of 
treatment, whereas the liposome encapsulating cisplatin showed the opposite 
behavior. 
Furthermore, the DNA platination of complex 39 resulted to be increased by 
three times after 24 hours of treatment, with respect to the results obtained after 
4 hours: in fact, being 39 a lipophilic compound, it was not removed by the cells 
(unlike cisplatin) and, therefore, after its reduction to the active species, it 
continued to bind DNA. 
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Conclusions and Perspectives 
 
During the Ph.D. thesis, most attention was focused on the synthesis and 
characterization of several Pt(IV) complexes, containing suitable functionalities 
to be exploited in coupling reactions with vectors (Figure 1) useful for passive 
Drug Targeting and Delivery strategies, in order to improve the selective 
accumulation of such antitumor prodrugs. 
 
 
Figure 1: Schematic representation of different types of platinum drug targeting methods, which 
ensure a more selective accumulation of the drugs into the cells 
 
Some of the employed nanosystems (i.e. silica nanoparticles, modified chitosan 
and liposomes) were synthesized as part of this work, whereas other vectors (i.e. 
fluorescent silica nanoparticles and iron oxide nanoparticles) were provided 
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thanks to the collaboration with the research groups of Prof. M. Laus (Università 
del Piemonte Orientale, DiSIT) and Dr. J. Fresnais (Sorbonne-Université, Paris). 
The synthesized Pt-nanoparticle conjugates were characterized from a chemical 
point of view by SEM, TEM, DLS and ζ potential techniques, and by ICP-MS 
and ICP-OES analyses to determine the amount of the loaded species. The 
biological in vitro experiments, instead, were performed in cell culture 
laboratory at DiSIT (Università del Piemonte Orientale). 
In particular, the coupling reactions with different kinds of amino-functionalized 
silica nanoparticles allowed to prepare conjugates with significant in vitro 
efficacy against A2780 human ovarian carcinoma cell line. The employed 
nanoparticles proved to be suitable vectors for Pt(IV) antitumors prodrugs and, 
as a future perspective, the synthesized nanosized system should be tested in 
vivo, in order to verify the exploitation of the EPR effect. Moreover, other 
platinum complexes could be loaded on the nanoparticles in order to study the 
effect of the modification of the employed prodrugs, trying to avoid the 
occurrence of side effects. 
The conjugates obtained with the couplings of the previously prepared Pt(IV) 
complexes with chitosan and chitosan derivatives were completely characterized 
from a chemical point of view and the in vitro tests are now in progress, in 
collaboration with the Radiopharmaceutical Sciences Group of Dr. A. Paulo 
(Instituto Superior Técnico, Sacavém, Portugal). 
The synthesis and characterization of Pt(IV) prodrugs able to link magnetic iron 
oxide nanoparticles and their coupling reactions with such vectors were 
successful. Moreover the prepared conjugates are now undergoing in vitro 
experiments. Based on the results of these experiments new complexes could be 
synthesized and tested as prodrugs to be linked to such nanoparticles. 
Finally, the synthesis of cationic liposomes and the following encapsulation of 
antitumor drugs were carried out and their in vitro studies were performed. 
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Future perspectives of this work can include the encapsulation of other drugs 
and/or the setting up and following exploitation of different liposome 
formulations. 
In almost all the carried out projects, the results confirmed that these nanosized 
systems are vectors able to ensure a more enhanced in vitro cellular 
accumulation and antiproliferative activity than the corresponding free Pt 
complex. 
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